UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

WASHINGTON, D.C. 20549

 

 

FORM 8-K

  

CURRENT REPORT 

 

Pursuant to Section 13 or 15(d) of the 

Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported): July 1, 2016

 

 

International Packaging and Logistics Group, Inc.

(Exact Name of Registrant as Specified in Charter)

 

Nevada 0-21384 13-3367421
(State or Other Jurisdiction of Incorporation) (Commission File No.) (I.R.S. Employer Identification No.)
     

7700 Irvine Center Drive, Suite 870,

Irvine, California

  92608
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (949) 861-3560

 

_________________________________________________

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Forward Looking Statements

This Current Report on Form 8-K, including the sections entitled “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business,” contains “forward-looking statements” that include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation and availability of resources. These forward-looking statements include, without limitation: statements regarding proposed new services; statements concerning litigation or other matters; statements concerning projections, predictions, expectations, estimates or forecasts for our business, financial and operating results and future economic performance; statements of management’s goals and objectives; and other similar expressions concerning matters that are not historical facts. Words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes” and “estimates,” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to:

  - our failure to implement our business plan within the time period we originally planned to accomplish; and
  - other factors discussed under the headings “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Description of Business.”

Forward-looking statements speak only as of the date they are made. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Item 1.01 Entry into a Material Definitive Agreement.
Item 2.01 Completion of Acquisition or Disposition of Assets.
Item 3.02 Unregistered Sales of Equity Securities.
Item 5.01 Changes in Control of Registrant.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

 

 

  2  
 

Item 1.01 Entry into a Material Definitive Agreement.

 

As more fully described in Item 2.01 below, on May 15, 2016, International Packaging and Logistics Group, Inc. (“IPLO” or “Company”), and Xiuhua Song (the “Purchaser”) entered into a Stock Purchase Agreement (the “Purchase Agreement”), pursuant to which IPLO (the “Seller”) will sell to the Purchaser, and the Purchaser will purchase from the Seller, an aggregate of 3,915,000 newly issued shares of IPLO Common Stock (the “Shares”), which Shares represent 87% of the issued and outstanding shares of Common Stock. On July 1, 2016, we completed this transaction

 

On July 1, 2016, International Packaging and Logistics Group, Inc. (the “ Registrant ” or “ IPLO ”) executed a Share Exchange Agreement (“ Exchange Agreement ”) by and among Yibaoccyb Limited, a British Virgin Islands limited liability company (“ Yibaoccyb ”), and the stockholders of 51% of Yibaoccyb’s common stock (the “ Yibaoccyb Shareholders ”), on the one hand, and the Registrant, on the other hand. A copy of the Exchange Agreement is included as Exhibit 2.1 and filed with this current report on Form 8-K.

 

Yibaoccyb owns 100% of YibaoConfucian Co., Ltd. (“ YibaoHK ”), a Hong Kong company. YibaoHK owns or will own 100% of Shenzhen Confucian Biologics Co. Ltd. (“ Yibao WOFE ”), which is a wholly foreign-owned enterprise (“WFOE”) under the laws of the Peoples’ Republic of China (“ PRC ” or “ China ”). Yibao WOFE is expected to enter into a series of contractual arrangements with Shandong Confucian Biologics Co., Ltd. (“ Shandong Confucian Biologics ”) which is a limited liability company headquartered in, and organized under the laws of, the PRC. The contractual arrangements are discussed below in Item 2.01 under the section titled “Description of Business”. Throughout this Form 8-K, Yibaoccyb, Yibao WOFE and Shandong Confucian Biologics are sometimes collectively referred to as the “Yibao Group.”

 

At the closing of this transaction (the “ Closing ”), which is expected to occur upon the completion of the audit of Shandong Confucian Biologics (the “ Closing Date ”), the Registrant is expected to issue 2,040,000 shares of the Registrant’s common stock (the “ IPLO Shares ”) to the Yibaoccyb Shareholders in exchange for 51% of the common stock of Yibaoccyb (the “ Exchange Agreement ”).

 

On July 1, 2016, Standard Resources Ltd. (“Standard”) previously IPLO’s Majority Stockholder, and IPLO entered into a share purchase agreement (“H&H Vend Out”) whereby Standard will cancel 3,915,000 shares of IPLO common stock held by it in exchange for all of the outstanding shares of H&H Glass, Inc. (“H&H Glass”) The H&H Vend Out is expected to occur subsequent to the Closing Date. The description of other material terms and conditions of the Exchange Agreement and the Financing are set forth below under Item 2.01 and such description is incorporated herein by reference. A copy of the H&H Vend Out is included as Exhibit 10.2 and filed with this current report on Form 8-K.

 

Item 2.01 Acquisition or Disposition of Assets

 

On the Closing Date, we expect to consummate the Purchase Agreement, referenced in Item 1.01 of this Form 8-K. As a result, we will acquire 51% of the capital stock of Yibaoccyb and, consequently, control of the business and operations of the Yibao Group. Prior to the Share Exchange Transaction, through our subsidiary H&H Glass, we were a glass importer that supplies custom products such as perfume bottles and food condiment bottles, plus provides complementary services such as container design and mold making. H&H Glass imports glass containers from Asia and distributes to North America. H&H Glass acquires its products mainly from one supplier in China and Taiwan and sells its products through several distributors in the United States and Canada who service small to medium sized customers. H&H imports in excess of 1,000 shipping containers of glass a year. Depending on the size of the product, a container can contain anywhere from 3,000 to 300,000 pieces.

 

From and after the Closing Date of the Exchange Agreement, our primary operations will consist of the business and operations of the Yibao Group, which are conducted by Shandong Confucian Biologics in China. Therefore, we are disclosing information about the Yibao Group’s business, financial condition, and management in this Form 8-K.

 

  3  
 

 

The parties’ completion of the transactions contemplated under the Exchange Agreement is subject to the satisfaction of certain contingencies, including the Purchase Agreement and the H&H Vend Out. Most importantly the completion of the audit of Shandong Confucian Biologics.

 

Our board of directors (the “ Board ”) and IPLO’s Majority Stockholder, as well as the directors and the shareholders of Yibaoccyb, have each approved the Purchase Agreement, Exchange Agreement and H&H Vend Out, including the transactions contemplated thereunder. Following the Closing Date, Yibaoccyb is expected to become a 51% owned subsidiary.

 

DESCRIPTION OF BUSINESS

 

INTERNATIONAL PACKAGING AND LOGISTICS, INC. (“IPLO”)

 

IPLO was originally incorporated as Interactive Medical Technologies, Ltd., on June 2, 1986 in the state of Nevada. On April 17, 2008, IPL Group converted from a Nevada corporation to a Nevada Corporation.

 

Effective February 3, 1998, Interactive Medical Technologies, Ltd., changed its name to Kaire Holdings Incorporated, and effective May 28, 2008 its name changed from Kaire Holdings Incorporated to International Packaging and Logistics Group, Inc.

 

On July 2, 2007, IPLO through its wholly-owned subsidiary, YesRx.com (“YesRx”) acquired all the outstanding shares of H&H Glass. H&H Glass is a glass importer that supplies custom products such as perfume bottles and food condiment bottles, plus provides complementary services such as container design and mold making. H&H Glass imports glass containers from Asia and distributes to North America. H&H Glass acquires its products mainly from 3 to 5 suppliers in China and Taiwan and sells its products through several distributors in the United States and Canada who service small to medium sized customers. H&H imports in excess of 1,000 shipping containers of glass a year. Depending on the size of the product, a container can contain anywhere from 3,000 to 300,000 pieces. 

 

After evaluation of various alternatives by our Board and management, our Board approved and we entered into the Exchange Agreement with Yibaoccyb and the Yibaoccyb Shareholders on July 1, 2016. From and after the Closing Date, Yibaoccyb will become a 51% owned subsidiary.

 

YIBAOCCYB LIMITED (“Yibaoccyb”)

 

Yibaoccyb is a limited liability company incorporated under the laws of the British Virgin Islands on May 30, 2016, which was formed by the owners of the Shandong Confucian Biologics. At the Closing of the Share Exchange Transaction, Yibaoccyb will become a 51% owned subsidiary of IPLO. Yibaoccyb, in turn, is the sole owner of YibaoHK. YibaoHK, in turn, is the sole owner of Yibao WOFE, which is expected to enter into a series of contractual arrangements with the Shandong Confucian Biologics. Other than all of the issued and outstanding shares of YibaoHK, Yibaoccyb has no other assets or operations.

 

YIBAOCONFUCIAN CO. LTD. (“YibaoHK”)

 

YibaoHK is a limited liability company incorporated under the laws of the Hong Kong on June 15, 2016, which was formed by Yibaoccyb, a British Virgin Island. YibaoHK will own 100% of Shenzhen Confucian Biologics Co. Ltd.

 

SHENZHEN CONFUCIAN BIOLOGICS CO. LTD. (Yibao WOFE”)

 

Yibao WOFE, a wholly foreign owned enterprise under the laws of the PRC is in the process of being established.. All of the issued and outstanding shares of Yibao WOFE will be held by YibaoHK. The principal purpose of Yibao WOFE will be to manage, hold and own rights in the business of Shandong Confucian Biologics and other potential PRC businesses. Other than management contracts with the aforementioned companies and related activities, Yibao WOFE is expected to have no other separate operations of its own.

 

 

  4  
 

 

PRC law currently has limits on foreign ownership of certain companies. To comply with these foreign ownership restrictions, we operate our businesses in China through Shandong Confucian which is a limited liability company headquartered in China and organized under the laws of China. Shandong Confucian Biologics has the licenses and approvals necessary to operate our businesses in China. We have contractual arrangements with the Shandong Confucian Biologics and their respective shareholders pursuant to which we provide these companies with technology consulting and other general business operation services. Through these contractual arrangements, we also have the ability to substantially influence these companies’ daily operations and financial affairs, appoint their senior executives and approve all matters requiring shareholder approval. As a result of these contractual arrangements, which enable us to control Shandong Confucian Biologics, we are considered the primary beneficiary of the Shandong Confucian Biologics. Accordingly, we consolidate the results, assets and liabilities of the Shandong Confucian Biologics in our financial statements.

 

The following chart summarizes our expected organizational and ownership structure upon the Closing Date:

 

 

 

 

SHANDONG CONFUCIAN BIOLOGICS CO. LTD. (“Shandong Confucian Biologics”)

 

History

 

ShanDong Confucian Biologics Co. Ltd. (the “Confusion Biologics” or “Company”), was founded under the laws of the People's Republic of China on October 31, 2012. The Company is located in Food Industrial Park inside the economic development Zone of JinXiang County, Ji’ning City in the province of Shan Dong in China. The Company is a limited liability company.

 

 

  5  
 

 

Overview

Confusion Biologics is a manufacture and research based bio-science company. It has large capacity in manufacturing tablets, granule, oral liquid, powders, soft gels and capsules products. The Company distributes its products through its own network and white label products. It also has access to a member-based distribution system owned by its affiliated company.

 

The Company possesses manufacturing permits for food product, hygienic products, sanitary products, and health products. The Company's main business scope include technology study and transfer of Chondroitin and Garlic Oil; trading, cold storage, and pretreating of Garlic, fruit, and vegetables products; trading of Chemical products (excluding hazardous chemicals); Import and export of goods and technology (excluding those restricted by government); the manufacturing and sale of health products including powder, granules, tablets, hard capsule, soft capsule products.

 

Ownership

 

During the phase of incorporation, Qingbao Kong accounted for 51% of the initial equity, Xiuhua Song accounted for 49%.

 

In 2013 , Xiuhua Song transferred all of the 49% of equity to WenXiu Song.

 

In March 2016, Qingbao Kong transferred all of his 51% of equity to Hengchun Zhang.

 

As of today, the company’s equity is owned 51% by Hengchun Zhang, 49% by Wenxiu Song

 

Product Overview

The company’s main products can be divided into two groups, one is health food products and the other is hygienic products

 

Health Food Products

The health food product line includes the following products:

 

  • Phytocholesterol tabletting candy,

Phytosterol has strong anti-inflammatory effects to the human body, which can inhibit the absorption of cholesterol for human and  biochemical synthesis of cholesterol. Promote the degradation and metabolism of cholesterol. Phytosterol can be used for prevention & therapy of coronary atherosclerosis heart disease. In treating ulcers, skin squamous carcinoma and cervical cancer has obvious curative effect. Can promote wound healing, make muscle proliferation, enhance capillary circulation; also can be used as blocking agent of formation of gallstones.

 

  • Polydextrose tabletting candy,

Regulating blood lipid, reduce fat accumulation preventing the fat.

 

  • Dunaliella salina Haematococcus pluvialis tabletting candy,

Replenishing the body's astaxanthin, Natural carotene and variety of minerals, have a great effect of antioxidant activity, protect skin, protect vision and improve immunity.

 

  • Dunaliella salina Gum Base Candy,

Dunaliella salina is rich in antioxidant needed by the human body health, resistance to radiation and enhance human immunity of natural carotenoids and 70 kinds of minerals and trace elements.

 

  • Haematococcus pluvialis Gum Candy,

The main components of Haematococcus Pluvialis is astaxanthin. It has six anti-aging effect: can be Anti-aging and protect the skin; Protect the eye health; helps to support the cardiovascular system, maintain a healthy joints and connective tissue; increases strength and endurance.

 

 

  6  
 

 

  • Fish Oil Gum Candy,

Adjusting blood liquid, prevent blood clots, cerebral thrombosis, cerebral hemorrhage and stroke; prevent arthritis and alzheimer's disease,  improve the memory and vision, control presbyopia.

 

  • Earthworm Protein tabletting Candy,

Improve blood circulation, inhibiting platelet aggregation, reduce glucose concentrations, prevent blood clots, has the very good control efficiency for coronary heart disease, arteriosclerosis, and other  hematologic disorders.

 

  • Collagen Protein tabletting candy,

It is rich in glycine, proline hydroxyproline and other amino acid needed for human body. Have a good health care effect for skin, hair, bones and muscles.

 

  • Krill Oil Gum candy,

It is rich in EPA and DHA. Enhancing health effects, including cardiovascular, nerve, bones, joints, vision, skin care, etc.

 

  • Phosphatidylserine tabletting candy,

Improve the function of brain; help to repair the injure of brain; promote the recovery of brainfag; protect central nervous system. Used for auxiliary treatment dementia and agedness memory loss.

 

  • Milk Powder tabletting Candy.

Milk tablet is kind of leisure food. Supplement of the nutrition of human needed in pecific environment.

 

Hygienic Products

The hygienic product line include the following products:

  • Gel for women,

Anti-bacteria product. Auxiliary treatment bacterial, mould sex vaginitis.

 

  • Skin comfortable liquid

Anti-bacteria product. Used for sterilization, antibacterial of skin. Inhibit the bromhidrosis and relief beriberi itch

 

Shandong Confucian Biologics owns 100,000 stage purification workshops, advanced production lines and manufacturing equipment. The Company has a higher capacity for OEM processing of tablets, hard capsules, soft capsules, oral liquid, granules, and powders.

 

Plan

 

By following the company motto of "being passionate for health industry, bringing together the world's resources, focusing on consumer demand, creating a “win-win situation", the Company is eager to develop businesses in the international health and pharmaceutical market.

 

The company’s near term goal is to reach breakeven within a 6 month period time. In order to reach such goal, the Company is increasing its sales and production volume through arrangements and networking with its existing customers and its affiliated companies. Additionally, it plans to increase the size of its sales department to develop new customers.

 

The company’s ultimate goal is to make the business profitable and competitive in the international health and pharmaceutical market. To achieve such goal, the Company needs to cooperate with other businesses having capital, market, technology, or products, recruit sufficient workforce and various talents to serve the company, and actively develop new technology and new product through research and development,.

 

 

  7  
 

 

Market Overview

 

Domestic Markets

Through member based distribution network, the Company has access to the major markets in Jining City area and most other cities in the Shandong province.

 

International Market

The current market shows an interest in Chinese herb medicine. For instance, European and US companies in the food industry use advanced technology to extract Ginkgo biloba, then add it in gum, chocolate, and other health food. The Company focuses on product diversification and innovation, it plans to sell its produces in well-known retail stores in Europe and US, such as Walmart.

 

Market Opportunity

 

Consumers are increasingly concerned about their own health. The spending on health related products has increased year by year, and the demand for nutrition and health food is high. According to the international standard classification, medicine and health care is one of the world's fastest growing trade in five industries, the Sales of health food currently experiences rapid annual growth.

 

In China, the health products market is expanding along with the growth of economy, and acceleration of aged population. If people used to see health products as optional, now they become necessities of daily life. The 60 year and older group is over is expected to keep growing fast. The elderly group tends to draw attention to nutrition and health product, which will boost the development of the health market. In addition, young people are bringing to pay more attention to their heath, and health food and products are the new powerful impetus. Therefore, the company finds itself sitting in a market with huge demands.

 

Competition

 

At present, the Chinese health food manufacturers mainly concentrated in Shandong, Jiangsu, Zhejiang, Anhui, Ningxia and a few other regions. Although in recent years, the health and production conditions of the eastern coastal areas has been improved to some extent, overall, China’s nutrition and health food businesses are small scaled, using outdated technology, and lack brand recognition, especially some businesses from inland provinces.

 

Intellectual Property

Shandong Confucian Biologics is actively planning in research and development activities and its goal is to have its own patents for the products it owns.

 

Government Regulation

 

The great social demand of nutrition and health care products has led to the governmental policy support. In December 2011, the Nutrient agency released “125 Development Plan for Food Industry”, in which nutrition and health care products manufacturing was first listed as the most important development within the industry. In addition, “the opinions of State Council on Promoting Health Development of Service Industry” published in 2013, “Notice on Promoting Health and Pension Services” published in 2014, and “Chinese Food and Nutrition Development Program” published in 2014 all had positive effects on the development of health products industry.

 

Employees

 

Shandong Confucian Biologics currently has 38 full time employees, including 2 management employees, 7 office employees handling finance and administrative functions, 4 scientific researchers and technicians; and 25 production workers

 

Property

 

Shandong Confucian Biologics is located in Food Industrial Park inside the economic development Zone of JinXiang County, Ji’ning City in the province of Shan Dong in China. It has a land us right until 2065 which costs approximately $1,861,216. It has nearly 30,000 square meters standardized plant, excellent production environment, advanced technology resources. In addition, the Company has sufficient domestic first-class production equipment, including: high-speed grinder, vibration sieve, granulating equipment, drying equipment, three-dimensional movement mixer, automatic capsule filling machine, screw-type tableting machine, the existing soft capsules pellets machines, plastic packaging machines, bottling lines, and automatic aluminum foil sealing machine.

 

 

  8  
 

 

 

Litigation

 

There are potential known litigation.

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

Because we are subject to the requirements of the Securities Exchange Act, we file reports, proxy statements and other information with the SEC.  You may read and copy these reports, proxy statements and other information at the public reference room maintained by the SEC at its Public Reference Room, located at 100 F Street, N.E. Washington, D.C. 20549.  You may obtain information on the operation of the public reference room by calling the SEC at (800) SEC-0330.  In addition, we are required to file electronic versions of those materials with the SEC through the SEC’s EDGAR system. The SEC also maintains a web site at http://www.sec.gov, which contains reports, proxy statements and other information regarding registrants that file electronically with the SEC.

 

RISK FACTORS

 

You should carefully consider the risks described below together with all of the other information included in this report before making an investment decision with regard to our securities. The statements contained in or incorporated into this offering that are not historic facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in or implied by forward-looking statements. If any of the following risks actually occurs, our business, financial condition or results of operations could be harmed. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.

 

Risks Related to Our Industry

 

Our businesses are subject to fluctuations in operating results due to general economic conditions, specific economic conditions in the industries in which it operates and other external forces.

 

Our businesses and operations could be affected by the following, among other factors:

 

  changes in general economic conditions and specific conditions in industries in which our businesses operate that can result in the deferral or reduction of purchases by end-use customers;

 

  the effects of terrorist activity and international conflicts, which could lead to business interruptions;

 

  the size, timing and cancellation of significant orders, which can be non-recurring;

 

  market acceptance of new products and product enhancements;

 

  announcements, introductions and transitions of new products by us or our competitors;

 

  deferrals of customer orders in anticipation of new products or product enhancements introduced by us or our competitors;

 

  changes in pricing in response to competitive pricing actions;

 

  supply constraints;

 

 

  9  
 

 

  the level of expenditures on research and development and sales and marketing programs;

 

  our ability to achieve targeted cost reductions;

 

  rising interest rates; and

 

  excess facilities.

 

 

The loss of Shandong Confucian Biologics as our operating business would have a material adverse effect on our business and the price of our common stock.

 

We have no equity ownership interest in Shandong Confucian Biologics. Our ability to control Shandong Confucian Biologics and consolidate its financial results is through a series of contractual agreements between it and Yibao WOFE. Management of Shandong Confucian Biologics is affiliates of us and the stockholders of Shandong Confucian Biologics are also our stockholders. Thus the VIE Agreements were not entered into as a result of arms’ length negotiations because the parties to the agreement are under common control. Ms. Song, our CEO and Chairman has control over of the shares of Shandong Confucian Biologics and of our common stock.  The VIE Agreements may be terminated upon the termination of the business of Shandong Confucian Biologics. Any other termination would be a breach of the agreement. While the Company believes that the VIE Agreements are legal and enforceable under PRC law, these affiliates control the parties to the VIE Agreements and it could be possible for them to cause Shandong Confucian Biologics to breach the VIE Agreements and our unaffiliated investors would have little or no recourse because of the inherent difficulties in enforcing their rights since all our assets are located in the PRC. (See, PRC laws and regulations governing Shandong Confucian Biologics' current business are sometimes vague and uncertain.) In the event that management of Shandong Confucian Biologics decides to breach the VIE Agreements, the risk of loss of the affiliated shareholders of Shandong Confucian Biologics could be lower than unaffiliated investors and the interests of the management and shareholders of Shandong Confucian Biologics would be in conflict with the interest of our other stockholders.

 

Shandong Confucian Biologics’ failure to compete effectively may adversely affect our ability to generate revenue.

 

Shandong Confucian Biologics competes with other companies, many of whom are developing or can be expected to develop products similar to Shandong Confucian Biologics. Shandong Confucian Biologics’ market is a large market with many competitors. Many of its competitors are more established than Shandong Confucian Biologics is, and have significantly greater financial, technical, marketing and other resources than it presently possess. Some of Shandong Confucian Biologics’ competitors have greater name recognition and a larger customer base. These competitors may be able to respond more quickly to new or changing opportunities and customer requirements and may be able to undertake more extensive promotional activities, offer more attractive terms to customers, and adopt more aggressive pricing policies. We cannot assure you that Shandong Confucian Biologics will be able to compete effectively with current or future competitors or that the competitive pressures it faces will not harm it business.

 

We may not be able to effectively control and manage the growth of Shandong Confucian Biologics.

 

If Shandong Confucian Biologics’ business and markets grow and develop, it will be necessary for us to finance and manage expansion in an orderly fashion. An expansion would increase demands on its existing management, workforce and facilities. Failure to satisfy such increased demands could interrupt or adversely affect its operations and cause delay in production and delivery of its pharmaceutical prescription, over the counter and medical nutrient products as well as administrative inefficiencies.

 

 

  10  
 

 

We may require additional financing in the future and a failure to obtain such required financing will inhibit Shandong Confucian Biologics’ ability to grow.

 

The continued growth of Shandong Confucian Biologics’ business may require additional funding from time to time which we expect to raise in private placements of our equity or debt securities with accredited investors or by offering our securities for sale pursuant to an effective registration statement on a market where our common stock is traded. The proceeds of these funding will be forwarded to Shandong Confucian Biologics and accounted for as a loan to Shandong Confucian Biologics and eliminated during consolidation. The proceeds would be used for general corporate purposes of Shandong Confucian Biologics, which could include acquisitions, investments, repayment of debt and capital expenditures among other things. We may also use the proceeds to repurchase our capital stock or for our corporate overhead expenses. If we borrow funds we expect to be the primary obligor on any debt. Obtaining additional funding would be subject to a number of factors including market conditions, operating performance and investor sentiment, many of which are outside of our control. These factors could make the timing, amount, terms and conditions of additional funding unattractive or unavailable to us.

 

Our management believes that Shandong Confucian Biologics currently has sufficient funds from working capital to meet its current operating costs over the next 12 months.

 

The terms of any future financing may adversely affect your interest as stockholders.

 

If we require additional financing in the future, we may be required to incur indebtedness or issue equity securities, the terms of which may adversely affect your interests in us. For example, the issuance of additional indebtedness may be senior in right of payment to your shares upon our liquidation. In addition, indebtedness may be under terms that make the operation of Shandong Confucian Biologics' business more difficult because the lender's consent could be required before we take certain actions. Similarly the terms of any equity securities we issue may be senior in right of payment of dividends to your common stock and may contain superior rights and other rights as compared to your common stock. Further, any such issuance of equity securities may dilute your interest in us.

 

We may engage in future acquisitions that could dilute the ownership interests of our stockholders, cause us to incur debt and assume contingent liabilities.

 

We may review acquisition and strategic investment prospects that we believe would complement the current product offerings of Shandong Confucian Biologics, augment its market coverage or enhance its technical capabilities, or otherwise offer growth opportunities. From time to time we review investments in new businesses and expect to make investments in, and to acquire, businesses, products, or technologies in the future. We expect that when we raise funds from investors for any of these purposes we will be either the issuer or the primary obligor while the proceeds will be forwarded to Shandong Confucian Biologics and accounted for as a loan to Shandong Confucian Biologics and eliminated during consolidation. In the event of any future acquisitions, we could:

 

· issue equity securities which would dilute current stockholders’ percentage ownership;
· incur substantial debt;
· assume contingent liabilities; or
· expend significant cash.

 

These actions could have a material adverse effect on our operating results or the price of our common stock. Moreover, even if  we do obtain benefits in the form of increased sales and earnings, there may be a lag between the time when the expenses associated with an acquisition are incurred and the time when we recognize such benefits. Acquisitions and investment activities also entail numerous risks, including:

 

· difficulties in the assimilation of acquired operations, technologies and/or products;
· unanticipated costs associated with the acquisition or investment transaction;
· the diversion of management’s attention from other business concerns;
· adverse effects on existing business relationships with suppliers and customers;

 

  11  
 

 

 

· risks associated with entering markets in which Shandong Confucian Biologics has no or limited prior experience;
· the potential loss of key employees of acquired organizations; and
· substantial charges for the amortization of certain purchased intangible assets, deferred stock compensation or similar items.

 

We cannot ensure that we will be able to successfully integrate any businesses, products, technologies, or personnel that we might acquire in the future and our failure to do so could have a material adverse effect on our and/or Shandong Confucian Biologics' business, operating results and financial condition.

 

We are responsible for the indemnification of our officers and directors.

 

Our certificate of incorporation provides for the indemnification and/or exculpation of our directors, officers, employees, agents and other entities which deal with it to the maximum extent provided, and under the terms provided, by the laws and decisions of the courts of the state of Nevada. Since we do not hold any indemnification insurance, these indemnification provisions could result in substantial expenditures, which we may be unable to recoup, which could adversely affect our business and financial conditions. Xiuhua Song, our Chairman of Board, President, Chief Executive Officer, and Chief Financial Officer are key personnel with rights to indemnification under our certificate of incorporation.

 

We may not have adequate internal accounting controls. While we have certain internal procedures in our budgeting, forecasting and in the management and allocation of funds, our internal controls may not be adequate.

 

We are constantly striving to improve our internal accounting controls. We expect to continue to improve our internal accounting control for budgeting, forecasting, managing and allocating our funds and to better account for them as we grow. There is no guarantee that such improvements will be adequate or successful or that such improvements will be carried out on a timely basis. If we do not have adequate internal accounting controls, we may not be able to appropriately budget, forecast and manage our funds, we may also be unable to prepare accurate accounts on a timely basis to meet our continuing financial reporting obligations and we may not be able to satisfy our obligations under US securities laws.

 

Rules adopted by the SEC pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 require annual assessment of our internal control over financial reporting, and attestation of this assessment by our company's independent registered public accountants. The SEC extended the compliance dates for "non-accelerated filers," as defined by the SEC. Accordingly, we believe that the annual assessment of our internal controls requirement will first apply to our annual report for the 2007 fiscal year and the attestation requirement of management's assessment by our independent registered public accountants will first apply to our annual report for the 2009 fiscal year. The standards that must be met for management to assess the internal control over financial reporting as effective are new and complex, and require significant documentation, testing and possible remediation to meet the detailed standards. We have not yet evaluated our internal controls over financial reporting in order to allow management to report on, and our independent auditors to attest to, our internal controls over financial reporting, as will be required by Section 404 of the Sarbanes-Oxley Act of 2002 and the rules and regulations of the SEC. We have never performed the system and process evaluation and testing required in an effort to comply with the management assessment and auditor certification requirements of Section 404, which will initially apply to us as of December 31, 2007 and December 31, 2009 respectively. Our lack of familiarity with Section 404 may unduly divert management's time and resources in executing the business plan. If, in the future, management identifies one or more material weaknesses, or our external auditors are unable to attest that our management's report is fairly stated or to express an opinion on the effectiveness of our internal controls, this could result in a loss of investor confidence in our financial reports, have an adverse effect on our stock price and/or subject us to sanctions or investigation by regulatory authorities. So far, our external auditors have not reported to our board of directors any significant weakness on our internal control and provided recommendations accordingly.

 

 

  12  
 

 

Shandong Confucian Biologics is Dependent On Certain Key Personnel And Loss Of These Key Personnel Could Have A Material Adverse Effect On Our and Shandong Confucian Biologics' Business, Financial Condition And Results Of Operations.

 

Our success is, to a certain extent, attributable to the management, sales and marketing, and manufacturing expertise of key personnel at Shandong Confucian Biologics. Xiuhua Song, our President, Chief Executive Officer and Chairman of the Board, performs key functions in the operation of our and Shandong Confucian Biologics' business. There can be no assurance that Shandong Confucian Biologics will be able to retain these officers after the term of their employment contracts expire. The loss of these officers could have a material adverse effect upon our business, financial condition, and results of operations. Shandong Confucian Biologics must attract, recruit and retain a sizeable workforce of technically competent employees. We do not carry key man life insurance for any of our key personnel or personnel at Shandong Confucian Biologics nor do we foresee purchasing such insurance to protect against a loss of key personnel and the key personnel of Shandong Confucian Biologics.

 

We and Shandong Confucian Biologics are dependent upon the services of Mrs. Song, for the continued growth and operation of our company because of his experience in the industry and his personal and business contacts in China. Neither we nor Shandong Confucian Biologics have an employment agreement with Mrs. Song and do not anticipate entering into an employment agreement in the foreseeable future. Although we have no reason to believe that Mrs. Song will discontinue her services with us or Shandong Confucian Biologics, the interruption or loss of his services would adversely affect our ability to effectively run Shandong Confucian Biologics' business and pursue its business strategy as well as our results of operations.

 

Shandong Confucian Biologics may not be able to hire and retain qualified personnel to support its growth and if it is unable to retain or hire these personnel in the future, its ability to improve its products and implement its business objectives could be adversely affected.

 

Competition for senior management and senior personnel in the PRC is intense, the pool of qualified candidates in the PRC is very limited, and Shandong Confucian Biologics may not be able to retain the services of its senior executives or senior personnel, or attract and retain high-quality senior executives or senior personnel in the future. This failure could materially and adversely affect our future growth and financial condition. Shandong Confucian Biologics expects to hire additional sales and plant personnel throughout fiscal year 2016 in order to accommodate its growth.

 

If Shandong Confucian Biologics fails to increase its brand recognition, it may face difficulty in obtaining new customers and business partners.

 

We believe that establishing, maintaining and enhancing Shandong Confucian Biologics’ brand in a cost-effective manner is critical to achieving widespread acceptance of Shandong Confucian Biologics’ current and future products and services and is an important element in Shandong Confucian Biologics' effort to increase its customer base and obtain new business partners. We believe that the importance of brand recognition will increase as competition in Shandong Confucian Biologics’ market develops. Some of Shandong Confucian Biologics’ potential competitors already have well-established brands in the pharmaceutical promotion and distribution industry. Successful promotion of Shandong Confucian Biologics’ brand will depend largely on its ability to maintain a sizeable and active customer base, its marketing efforts and its ability to provide reliable and useful products and services at competitive prices. Brand promotion activities may not yield increased revenue, and even if they do, any increased revenue may not offset the expenses Shandong Confucian Biologics incurs in building its brand. If Shandong Confucian Biologics fails to successfully promote and maintain its brand, or if Shandong Confucian Biologics incurs substantial expenses in an unsuccessful attempt to promote and maintain its brand, it may fail to attract enough new customers or retain its existing customers to the extent necessary to realize a sufficient return on its brand-building efforts, in which case Shandong Confucian Biologics' business, operating results and financial condition, further ours would be materially adversely affected.

 

 

  13  
 

 

Shandong Confucian Biologics' operating results may fluctuate as a result of factors beyond its control.  

 

Shandong Confucian Biologics' operating results may fluctuate significantly in the future as a result of a variety of factors, many of which are beyond its control. These factors include:

 

· the costs of raw material and development;
· the relative speed and success with which Shandong Confucian Biologics can obtain and maintain customers, merchants and vendors for its products;
· capital expenditures for equipment;
· marketing and promotional activities and other costs;
· changes in Shandong Confucian Biologics’ pricing policies, suppliers and competitors;
· the ability of Shandong Confucian Biologics’ suppliers to provide products in a timely manner to its customers;
· changes in operating expenses;
· increased competition in Shandong Confucian Biologics’ markets; and
· other general economic and seasonal factors.

 

Shandong Confucian Biologics faces risks related to product liability claims.

 

Shandong Confucian Biologics does not maintain product liability insurance. It faces the risk of loss because adverse publicity associated with product liability lawsuits, whether or not such claims are valid. It may not be able to avoid such claims. Although product liability lawsuits in the PRC are rare, and Shandong Confucian Biologics has not to date experienced significant failure of its products, there is no guarantee that it will not face such liability in the future. This liability could be substantial and the occurrence of such loss or liability may have a material adverse effect on its business, financial condition and prospects.

 

Shandong Confucian Biologics faces marketing risks.

 

Newly developed dietary supplements and technologies may not be compatible with market needs. Because markets for drugs differentiate geographically inside China, Shandong Confucian Biologics must develop and manufacture its products to accurately target specific markets to ensure product sales. If Shandong Confucian Biologics fails to invest in extensive market research to understand the health needs of consumers in different geographic areas, it may face limited market acceptance of its products, which could have material adverse effect on its sales and earnings.

 

We face risks relating to difficulty in defending intellectual property rights from infringement.

 

Our success depends on protection of the current and future technologies and products of Shandong Confucian Biologics and its ability to defend its intellectual property rights. Shandong Confucian Biologics has filed for copyright protection for the various names and brands of its products sold in the PRC. However, it is possible for its competitors to develop similar competitive products even though it has taken steps to protect its intellectual property. If we fail to protect Shandong Confucian Biologics’ intellectual property adequately, competitors may manufacture and market products similar to Shandong Confucian Biologics.

 

Shandong Confucian Biologics also relies on trade secrets, non-patented proprietary expertise and continuing technological innovation that it shall seek to protect, in part, by entering into confidentiality agreements with licensees, suppliers, employees and consultants. These agreements may be breached and there may not be adequate remedies in the event of a breach. Disputes may arise concerning the ownership of intellectual property or the applicability of confidentiality agreements. Moreover, its trade secrets and proprietary technology may otherwise become known or be independently developed by its competitors. If patents are not issued with respect to products arising from research, Shandong Confucian Biologics may not be able to maintain the confidentiality of information relating to these products.

 

 

  14  
 

 

We face risks relating to third parties that may claim that Shandong Confucian Biologics infringes on their proprietary rights and may prevent Shandong Confucian Biologics from manufacturing and selling certain of its products.

 

There has been substantial litigation in the pharmaceutical industry with respect to the manufacturing, use and sale of new products. These lawsuits relate to the validity and infringement of patents or proprietary rights of third parties. We and/or Shandong Confucian Biologics may be required to commence or defend against charges relating to the infringement of patent or proprietary rights. Any such litigation could:

 

  - require Shandong Confucian Biologics or us to incur substantial expense, even if covered by insurance or are successful in the litigation;

 

  - require Shandong Confucian Biologics to divert significant time and effort of its technical and management personnel;

 

  - result in the loss of Shandong Confucian Biologics’ rights to develop or make certain products; and

 

  - require Shandong Confucian Biologics or us to pay substantial monetary damages or royalties in order to license proprietary rights from third parties.

 

Although patent and intellectual property disputes within our have often been settled through licensing or similar arrangements, costs associated with these arrangements may be substantial and could include the long-term payment of royalties. These arrangements may be investigated by regulatory agencies and, if improper, may be invalidated. Furthermore, the required licenses may not be made available to Shandong Confucian Biologics on acceptable terms. Accordingly, an adverse determination in a judicial or administrative proceeding or a failure to obtain necessary licenses could prevent Shandong Confucian Biologics from manufacturing and selling some of its products or increase its costs to market these products.

 

In addition, when seeking regulatory approval for some of its products, Shandong Confucian Biologics is required to certify to regulatory authorities, including the SFDA that such products do not infringe upon third party patent rights. Filing a certification against a patent gives the patent holder the right to bring a patent infringement lawsuit against Shandong Confucian Biologics. Any lawsuit would delay the receipt of regulatory approvals. A claim of infringement and the resulting delay could result in substantial expenses and even prevent Shandong Confucian Biologics from manufacturing and selling certain of its products.

 

Shandong Confucian Biologics’ launch of a product prior to a final court decision or the expiration of a patent held by a third party may result in substantial damages to Shandong Confucian Biologics or us. If Shandong Confucian Biologics is found to infringe a patent held by a third party and become subject to such damages, these damages could have a material adverse effect on the results of its operations and financial condition.

 

We face risks related to research and the ability to develop new products.

 

Our growth and survival depends on Shandong Confucian Biologics’ ability to consistently discover, develop and commercialize new products and find new and improve on existing technologies and platforms. As such, if Shandong Confucian Biologics fails to make sufficient investments in research, be attentive to consumer needs or does not focus on the most advanced technologies, its current and future products could be surpassed by more effective or advanced products of other companies.

 

Risk Related To Shandong Confucian Biologics’   Industry

 

Shandong Confucian Biologics’ certificates, permits, and licenses related to its operations are subject to governmental control and renewal and failure to obtain renewal will cause all or part of its operations to be terminated.

 

Shandong Confucian Biologics is subject to various PRC laws and regulations pertaining to our industry. Shandong Confucian Biologics has attained certificates, permits, and licenses required for the operation of a dietary supplement enterprise and the manufacturing of our products in the PRC.

 

 

  15  
 

 

Shandong Confucian Biologics intends to apply for renewal of these health food production permits prior to expiration. During the renewal process, Shandong Confucian Biologics will be re-evaluated by the appropriate governmental authorities and must comply with the then prevailing standards and regulations which may change from time to time. In the event that it is not able to renew the certificates, permits and licenses, all or part of its operations may be terminated. Furthermore, if escalating compliance costs associated with governmental standards and regulations restrict or prohibit any part of its operations, it may adversely affect its operation and our profitability.

 

According to Drug Administration Law of the PRC and its implemental rules, SFDA approvals may be suspended or revoked prior to the expiration date under circumstances that include:

 

  -   producing counterfeit medicine,
     
  -   producing inferior quality products
     
  -   failing to meet the drug GMP standards;
     
  -   purchasing medical ingredients used in the production of products sources that do not have t Pharmaceutical Manufacturing Permit or Pharmaceutical Trade Permit;
     
  -   fraudulent reporting of results or product samples in application process,
     
  -   failing to meet drug labeling and direction standards,
     
  -   bribing doctors or hospital personnel to entice them to use products,
     
  -   producing pharmaceuticals for use or resale by companies that are not approved by the SFDA, or
     
  -   the approved drug has a serious side effect.

 

If Shandong Confucian Biologics’ pharmaceutical products fail to receive regulatory approval or are severely limited in these products' scope of use, it may be unable to recoup considerable research and development expenditures.

 

Shandong Confucian Biologics’ research and development of pharmaceutical products is subject to the regulatory approval of the SFDA in China. The regulatory approval procedure for pharmaceuticals can be quite lengthy, costly, and uncertain. Depending upon the discretion of the SFDA, the approval process may be significantly delayed by additional clinical testing and require the expenditure of resources not currently available; in such an event, it may be necessary for Shandong Confucian Biologics to abandon its application. Even where approval of the product is granted, it may contain significant limitations in the form of narrow indications, warnings, precautions, or contra-indications with respect to conditions of use. If approval of Shandong Confucian Biologics’ product is denied, abandoned, or severely limited in terms of the scope of products use, it may result in the inability to recoup considerable research and development expenditures.

 

Price control regulations may decrease Shandong Confucian Biologics' profitability.

 

The laws of the PRC provide for the government to fix and adjust prices. The prices of certain medicines Shandong Confucian Biologics distributes, including those listed in the Chinese government's catalogue of medications that are reimbursable under China's social insurance program, or the Insurance Catalogue, are subject to control by the relevant state or provincial price administration authorities. The PRC establishes price levels for products based on market conditions, average industry cost, supply and demand and social responsibility. In practice, price control with respect to these medicines sets a ceiling on their retail price. The actual price of such medicines set by manufacturers, wholesalers and retailers cannot historically exceed the price ceiling imposed by applicable government price control regulations. Although, as a general matter, government price control regulations have resulted in drug prices tending to decline over time, there has been no predictable pattern for such decreases.

 

 

  16  
 

 

None of our products are subject to price controls. It is possible that products may be subject to price control, or that price controls may be increased in the future. To the extent that Shandong Confucian Biologics’ products are subject to price control, its revenue, gross profit, gross margin and net income will be affected since the revenue we derive from Shandong Confucian Biologics’ sales will be limited and it may face no limitation on its costs. Further, if price controls affect both Shandong Confucian Biologics’ revenue and costs, its ability to be profitable and the extent of our profitability will be effectively subject to determination by the applicable regulatory authorities in the PRC.

 

Adverse publicity associated with Shandong Confucian Biologics' products, ingredients or network marketing program, or those of similar companies, could harm its financial condition and operating results.

 

The results of Shandong Confucian Biologics’ operations may be significantly affected by the public's perception of Shandong Confucian Biologics’ product and similar companies. This perception is dependent upon opinions concerning:

 

· the safety and quality of its products and ingredients;
· the safety and quality of similar products and ingredients distributed by other companies; and
· its sales force.

 

Adverse publicity concerning any actual or purported failure of Shandong Confucian Biologics to comply with applicable laws and regulations regarding product claims and advertising, good manufacturing practices, or other aspects of Shandong Confucian Biologics’ business, whether or not resulting in enforcement actions or the imposition of penalties, could have an adverse effect on the goodwill of Shandong Confucian Biologics and could negatively affect its sales and ability generate revenue.

 

In addition, Shandong Confucian Biologics’ consumers' perception of the safety and quality of its products and ingredients as well as similar products and ingredients distributed by other companies can be significantly influenced by media attention, publicized scientific research or findings, widespread product liability claims and other publicity concerning Shandong Confucian Biologics’ products or ingredients or similar products and ingredients distributed by other companies. Adverse publicity, whether or not accurate or resulting from consumers' use or misuse of Shandong Confucian Biologics’ products, that associates consumption of its products or ingredients or any similar products or ingredients with illness or other adverse effects, questions the benefits of Shandong Confucian Biologics’ or similar products or claims that any such products are ineffective, inappropriately labeled or have inaccurate instructions as to their use, could negatively impact its reputation or the market demand for Shandong Confucian Biologics’ products.

 

If Shandong Confucian Biologics fails to develop new products with high profit margins, and its high profit margin products are substituted by competitor's products, our gross and net profit margins will be adversely affected.

 

There is no assurance that Shandong Confucian Biologics will be able to sustain its profit margins in the future. The supplement industry is very competitive, and there may be pressure to reduce sale prices of products without a corresponding decrease in the price of raw materials. In addition, the supplement industry in China is highly competitive and new products are constantly being introduced to the market. In order to increase the sales of Shandong Confucian Biologics’ products and expand its market, it may be forced to reduce prices in the future, leading to a decrease in gross profit margin. The research and development of new products and technologies is costly and time consuming, and there are no assurances that Shandong Confucian Biologics’ research and development of new products will either be successful or completed within the anticipate timeframe, if ever at all. There is no assurance that Shandong Confucian Biologics’ competitors' new products, technologies, and processes will not render its existing products obsolete or non-competitive. To the extent that Shandong Confucian Biologics fails to develop new products with high profit margins and its high profit margin products are substituted by competitors' products, our gross profit margins will be adversely affected.

 

 

  17  
 

 

Risks Related To Doing Business In The PRC

 

Changes in the policies of the PRC government could have a significant impact upon the business we may be able to conduct in the PRC and the profitability of such business .

 

Shandong Confucian Biologics’ business operations may be adversely affected by the current and future political environment in the PRC. The PRC has operated as a socialist state since the mid-1900s and is controlled by the Communist Party of China. The Chinese government exerts substantial influence and control over the manner in which we and it must conduct our business activities. The PRC has only permitted provincial and local economic autonomy and private economic activities since 1988. The government of the PRC has exercised and continues to exercise substantial control over virtually every sector of the Chinese economy, particularly the pharmaceutical industry, through regulation and state ownership. Our ability to operate in China may be adversely affected by changes in Chinese laws and regulations, including those relating to taxation, import and export tariffs, raw materials, environmental regulations, land use rights, property and other matters. Under current leadership, the government of the PRC has been pursuing economic reform policies that encourage private economic activity and greater economic decentralization. There is no assurance, however, that the government of the PRC will continue to pursue these policies, or that it will not significantly alter these policies from time to time without notice.

 

The PRC's economy is in a transition from a planned economy to a market oriented economy subject to five-year and annual plans adopted by the government that set national economic development goals. Policies of the PRC government can have significant effects on the economic conditions of the PRC. The PRC government has confirmed that economic development will follow the model of a market economy. Under this direction, we believe that the PRC will continue to strengthen its economic and trading relationships with foreign countries and business development in the PRC will follow market forces. While we believe that this trend will continue, there can be no assurance that this will be the case.

 

A change in policies by the PRC government could adversely affect our interests by, among other factors: changes in laws, regulations or the interpretation thereof, confiscatory taxation, restrictions on currency conversion, imports or sources of supplies, or the expropriation or nationalization of private enterprises. Although the PRC government has been pursuing economic reform policies for more than two decades, there is no assurance that the government will continue to pursue such policies or that such policies may not be significantly altered, especially in the event of a change in leadership, social or political disruption, or other circumstances affecting the PRC's political, economic and social life.

 

The PRC laws and regulations governing Shandong Confucian Biologics’ current business operations are sometimes vague and uncertain. Any changes in such PRC laws and regulations may harm its business.

 

The PRC laws and regulations governing Shandong Confucian Biologics’ current business operations are sometimes vague and uncertain. The PRC’s legal system is a civil law system based on written statutes, in which system decided legal cases have little value as precedents unlike the common law system prevalent in the United States. There are substantial uncertainties regarding the interpretation and application of PRC laws and regulations, including but not limited to the laws and regulations governing its business, or the enforcement and performance of its arrangements with customers in the event of the imposition of statutory liens, death, bankruptcy and criminal proceedings. The Chinese government has been developing a comprehensive system of commercial laws, and considerable progress has been made in introducing laws and regulations dealing with economic matters such as foreign investment, corporate organization and governance, commerce, taxation and trade. However, because these laws and regulations are relatively new, and because of the limited volume of published cases and judicial interpretation and their lack of force as precedents, interpretation and enforcement of these laws and regulations involve significant uncertainties. New laws and regulations that affect existing and proposed future businesses may also be applied retroactively. We are considered a foreign persons or foreign funded enterprises under PRC laws, and as a result, we are required to comply with PRC laws and regulations. We cannot predict what effect the interpretation of existing or new PRC laws or regulations may have on its businesses. If the relevant authorities find that we are in violation of PRC laws or regulations, they would have broad discretion in dealing with such a violation, including, without limitation:

 

 

  18  
 

 

  - levying fines;

 

  - revoking Shandong Confucian Biologics’ business and other licenses;

 

  - requiring that we restructure its ownership or operations; and

 

  - requiring that we discontinue any portion or all of our business.

 

A slowdown, inflation or other adverse developments in the PRC economy may harm Shandong Confucian Biologics’ customers and the demand for Shandong Confucian Biologics’ services and products.

 

All of Shandong Confucian Biologics’ operations are conducted in the PRC and all of its revenues are generated from sales in the PRC. Although the PRC economy has grown significantly in recent years, we cannot assure you that this growth will continue. A slowdown in overall economic growth, an economic downturn, a recession or other adverse economic developments in the PRC could significantly reduce the demand for its products and harm Shandong Confucian Biologics’ business.

 

While the PRC economy has experienced rapid growth, such growth has been uneven among various sectors of the economy and in different geographical areas of the country. Rapid economic growth could lead to growth in the money supply and rising inflation. If prices for Shandong Confucian Biologics’ products rise at a rate that is insufficient to compensate for the rise in the costs of supplies, it may harm its profitability. In order to control inflation in the past, the PRC government has imposed controls on bank credit, limits on loans for fixed assets and restrictions on state bank lending. Such an austere policy can lead to a slowing of economic growth. In October 2004, the People's Bank of China, the PRC's central bank, raised interest rates for the first time in nearly a decade and indicated in a statement that the measure was prompted by inflationary concerns in the Chinese economy. Repeated rises in interest rates by the central bank would likely slow economic activity in China which could, in turn, materially increase its costs and also reduce demand for its products.

 

Governmental control of currency conversion may affect the value of your investment.

 

The PRC government imposes controls on the convertibility of Renminbi into foreign currencies and, in certain cases, the remittance of currency out of the PRC. We receive substantially all of our revenues in Renminbi, which is currently not a freely convertible currency. Shortages in the availability of foreign currency may restrict our ability to remit sufficient foreign currency to pay dividends, or otherwise satisfy foreign currency dominated obligations. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and expenditures from the transaction, can be made in foreign currencies without prior approval from the PRC State Administration of Foreign Exchange by complying with certain procedural requirements. However, approval from appropriate governmental authorities is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of bank loans denominated in foreign currencies.

 

The PRC government may also in the future restrict access to foreign currencies for current account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currency to satisfy our currency demands, we may not be able to pay certain of our expenses as they come due.

 

The fluctuation of the Renminbi may harm your investment.

 

The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in the PRC's political and economic conditions.  As we rely entirely on revenues earned in the PRC, any significant revaluation of the Renminbi may materially and adversely affect our cash flows, revenues and financial condition. For example, to the extent that we need to convert U.S. dollars we receive from an offering of our securities into Renminbi for Shandong Confucian Biologics’ operations, appreciation of the Renminbi against the U.S. dollar would diminish the value of the proceeds of the offering and this could harm Shandong Confucian Biologics’ business, financial condition and results of operations because it would reduce the proceeds available to us for capital investment in proportion to the appreciation of the Renminbi. In addition, the depreciation of significant RMB denominated assets could result in a charge to our income statement and a reduction in the dollar value of these assets.

 

 

  19  
 

 

On July 21, 2005, the PRC government changed its decade-old policy of pegging the value of the Renminbi to the U.S. dollar. Under the new policy, the Renminbi is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. While the international reaction to the Renminbi revaluation has generally been positive, there remains significant international pressure on the PRC government to adopt an even more flexible currency policy, which could result in a further and more significant appreciation of the Renminbi against the U.S. dollar.

 

PRC state administration of foreign exchange ("SAFE") regulations regarding offshore financing activities by PRC residents which may increase the administrative burden we face. The failure by our shareholders who are PRC residents to make any required applications and filings pursuant to such regulations may prevent us from being able to distribute profits and could expose us and our PRC resident shareholders to liability under PRC law.

 

SAFE, issued a public notice ("SAFE #75") effective from November 1, 2005, which requires registration with SAFE by the PRC resident shareholders of any foreign holding company of a PRC entity. Without registration, the PRC entity cannot remit any of its profits out of the PRC as dividends or otherwise.

 

In October 2005, SAFE issued a public notice, the Notice on Relevant Issues in the Foreign Exchange Control over Financing and Return Investment Through Special Purpose Companies by Residents Inside China, or the SAFE notice, which requires PRC residents, including both legal persons and natural persons, to register with the competent local SAFE branch before establishing or controlling any company outside of China, referred to as an "offshore special purpose company," for the purpose of overseas equity financing involving onshore assets or equity interests held by them. In addition, any PRC resident that is the shareholder of an offshore special purpose company is required to amend its SAFE registration with the local SAFE branch with respect to that offshore special purpose company in connection with any increase or decrease of capital, transfer of shares, merger, division, equity investment or creation of any security interest over any assets located in China. Moreover, if the offshore special purpose company was established and owned the onshore assets or equity interests before the implementation date of the SAFE notice, a retroactive SAFE registration is required to have been completed before March 31, 2006. If any PRC shareholder of any offshore special purpose company fails to make the required SAFE registration and amendment, the PRC subsidiaries of that offshore special purpose company may be prohibited from distributing their profits and the proceeds from any reduction in capital, share transfer or liquidation to the offshore special purpose company. Moreover, failure to comply with the SAFE registration and amendment requirements described above could result in liability under PRC laws for evasion of applicable foreign exchange restrictions.

 

It is unclear whether our other PRC resident shareholders must make disclosure to SAFE. We believe that only PRC resident shareholders who receive ownership of the foreign holding company in exchange for ownership in the PRC operating company are subject to SAFE #75, there can be no assurance that SAFE will not require our other PRC resident shareholders to register and make the applicable disclosure. In addition, SAFE #75 requires that any monies remitted to PRC residents outside of the PRC be returned within 180 days; however, there is no indication of what the penalty will be for failure to comply or if shareholder non-compliance will be considered to be a violation of SAFE #75 by us or otherwise affect us.

 

In the event that the proper procedures are not followed under SAFE #75, we could lose the ability to remit monies outside of the PRC and would therefore be unable to pay dividends or make other distributions. Our PRC resident shareholders could be subject to fines, other sanctions and even criminal liabilities under the PRC Foreign Exchange Administrative Regulations promulgated January 29, 1996, as amended.

 

 

  20  
 

 

The PRC's legal and judicial system may not adequately protect our business and operations and the rights of foreign investors.

 

The PRC legal and judicial system may negatively impact foreign investors. In 1982, the National People's Congress amended the Constitution of China to authorize foreign investment and guarantee the "lawful rights and interests" of foreign investors in the PRC. However, the PRC's system of laws is not yet comprehensive. The legal and judicial systems in the PRC are still rudimentary, and enforcement of existing laws is inconsistent. Many judges in the PRC lack the depth of legal training and experience that would be expected of a judge in a more developed country. Because the PRC judiciary is relatively inexperienced in enforcing the laws that do exist, anticipation of judicial decision-making is more uncertain than would be expected in a more developed country. It may be impossible to obtain swift and equitable enforcement of laws that do exist, or to obtain enforcement of the judgment of one court by a court of another jurisdiction. The PRC's legal system is based on the civil law regime, that is, it is based on written statutes; a decision by one judge does not set a legal precedent that is required to be followed by judges in other cases. In addition, the interpretation of Chinese laws may be varied to reflect domestic political changes.

 

The promulgation of new laws, changes to existing laws and the pre-emption of local regulations by national laws may adversely affect foreign investors. However, the trend of legislation over the last 20 years has significantly enhanced the protection of foreign investment and allowed for more control by foreign parties of their investments in Chinese enterprises. There can be no assurance that a change in leadership, social or political disruption, or unforeseen circumstances affecting the PRC's political, economic or social life, will not affect the PRC government's ability to continue to support and pursue these reforms. Such a shift could have a material adverse effect on Shandong Confucian Biologics’ business and prospects.

 

The practical effect of the PRC legal system on Shandong Confucian Biologics’ business operations in the PRC can be viewed from two separate but intertwined considerations. First, as a matter of substantive law, the Foreign Invested Enterprise laws provide significant protection from government interference. In addition, these laws guarantee the full enjoyment of the benefits of corporate Articles and contracts to Foreign Invested Enterprise participants. These laws, however, do impose standards concerning corporate formation and governance, which are qualitatively different from the general corporation laws of the United States. Similarly, the PRC accounting laws mandate accounting practices, which are not consistent with U.S. generally accepted accounting principles. PRC's accounting laws require that an annual "statutory audit" be performed in accordance with PRC accounting standards and that the books of account of Foreign Invested Enterprises are maintained in accordance with Chinese accounting laws. Article 14 of the People's Republic of China Wholly Foreign-Owned Enterprise Law requires a wholly foreign-owned enterprise to submit certain periodic fiscal reports and statements to designated financial and tax authorities, at the risk of business license revocation. While the enforcement of substantive rights may appear less clear than United States procedures, the Foreign Invested Enterprises and Wholly Foreign-Owned Enterprises are Chinese registered companies, which enjoy the same status as other Chinese registered companies in business-to-business dispute resolution. Any award rendered by an arbitration tribunal is enforceable in accordance with the United Nations Convention on the Recognition and Enforcement of Foreign Arbitral Awards (1958). Therefore, as a practical matter, although no assurances can be given, the Chinese legal infrastructure, while different in operation from its United States counterpart, should not present any significant impediment to the operation of Foreign Invested Enterprises

 

Any Recurrence Of Severe Acute Respiratory Syndrome, Or SARS, Or Another widespread public health problem, could harm Shandong Confucian Biologics’ Operations.

 

A renewed outbreak of SARS or another widespread public health problem (such as bird flu) in the PRC, where all of our revenues are derived, could significantly harm Shandong Confucian Biologics’ operations. Shandong Confucian Biologics’ operations may be impacted by a number of health-related factors, including quarantines or closures of some of its offices that would adversely disrupt its operations. Any of the foregoing events or other unforeseen consequences of public health problems could significantly harm its operations.

 

Because Our Principal Assets Are Located Outside Of The United States And Most Of Our Directors And All Of Our Officers Reside Outside Of The United States, It May Be Difficult For You To Enforce Your Rights Based On U.S. Federal Securities Laws Against Us And Our Officers Or To Enforce U.S. Court Judgment Against Us Or Them In The PRC.

 

Most of our directors and all of our officers reside outside of the United States. In addition, Shandong Confucian Biologics’ operating company is located in the PRC and substantially all of its assets are located outside of the United States. It may therefore be difficult for investors in the United States to enforce their legal rights based on the civil liability provisions of the U.S. Federal securities laws against us in the courts of either the U.S. or the PRC and, even if civil judgments are obtained in U.S. courts, to enforce such judgments in PRC courts. Further, it is unclear if extradition treaties now in effect between the United States and the PRC would permit effective enforcement against us or our officers and directors of criminal penalties, under the U.S. Federal securities laws or otherwise.

 

 

  21  
 

 

The relative lack of public company experience of our management team may put us at a competitive disadvantage.

 

Our management team lacks public company experience, which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley Act of 2002. The individuals who now constitute our senior management have never had responsibility for managing a publicly traded company. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Our senior management may not be able to implement programs and policies in an effective and timely manner that adequately responds to such increased legal, regulatory compliance and reporting requirements. Our failure to comply with all applicable requirements could lead to the imposition of fines and penalties and distract our management from attending to the growth of our business.

 

RISKS RELATED TO OUR COMMON STOCK.

 

Our Officers And Directors Control Us Through Their Positions And Stock Ownership And Their Interests May Differ From Other Stockholders.

 

As of the Closing Date, there will be 8,504,214 shares of our common stock issued and outstanding. Our officers and directors beneficially own approximately 92% of our common stock. As a result, he is able to influence the outcome of stockholder votes on various matters, including the election of directors and extraordinary corporate transactions including business combinations. Yet Mrs. Song's interests may differ from those of other stockholders. Furthermore, ownership of 92% of our common stock by our officers and directors reduces the public float and liquidity, and may affect the market price.

 

We Are Not Likely To Pay Cash Dividends In The Foreseeable Future.

 

We intend to retain any future earnings for use in the operation and expansion of Shandong Confucian Biologics' business. We do not expect to pay any cash dividends in the foreseeable future but will review this policy as circumstances dictate. Should we decide in the future to do so, as a holding company, our ability to pay dividends and meet other obligations depends upon the receipt of dividends or other payments from our operating subsidiaries. In addition, our operating subsidiaries, from time to time, may be subject to restrictions on their ability to make distributions to us, including restrictions on the conversion of local currency into U.S. dollars or other hard currency and other regulatory restrictions.

 

Our common stock is illiquid and subject to price volatility unrelated to Shandong Confucian Biologics’ operations.

 

If a market for our common stock does develop, its market price could fluctuate substantially due to a variety of factors, including market perception of our ability to achieve Shandong Confucian Biologics’ planned growth, quarterly operating results of other companies in the same industry, trading volume in our common stock, changes in general conditions in the economy and the financial markets or other developments affecting Shandong Confucian Biologics or its competitors. In addition, the stock market itself is subject to extreme price and volume fluctuations. This volatility has had a significant effect on the market price of securities issued by many companies for reasons unrelated to their operating performance and could have the same effect on our common stock.

 

 

  22  
 

 

Investors May Have Difficulty Liquidating Their Investment Because Our Common Stock Is Subject To The "Penny Stock" Rules, Which Require Delivery Of A Schedule Explaining The Penny Stock Market And The Associated Risks Before Any Sale.

 

Our common stock may be subject to regulations prescribed by the SEC relating to "penny stocks." The SEC has adopted regulations that generally define a penny stock to be any equity security that has a market price (as defined in such regulations) of less than $5 per share, subject to certain exceptions. These regulations impose additional sales practice requirements on broker-dealers who sell penny stocks to persons other than established customers and accredited investors (generally institutions with assets in excess of $5,000,000 and individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 (individually) or $300,000 (jointly with their spouse). For transactions covered by these rules, the broker-dealer must make a special suitability determination for the purchase of these securities and have received the purchaser's prior written consent to the transaction. Additionally, for any transaction, other than exempt transactions, involving a penny stock, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the SEC relating to the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market-maker, the broker-dealer must disclose this fact and the broker-dealer's presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

Legal remedies, which may be available to the investor, are as follows:

 

-  If penny stocks are sold in violation of the investor's rights listed above, or other federal or state securities laws, the investor may be able to cancel his purchase and get his money back.

 

-  If the stocks are sold in a fraudulent manner, the investor may be able to sue the persons and firms that caused the fraud for damages.

 

-  If the investor has signed an arbitration agreement, however, s/he may have to pursue a claim through arbitration.

 

If the person purchasing the securities is someone other than an accredited investor or an established customer of the broker-dealer, the broker-dealer must also approve the potential customer's account by obtaining information concerning the customer's financial situation, investment experience and investment objectives. The broker-dealer must also make a determination whether the transaction is suitable for the customer and whether the customer has sufficient knowledge and experience in financial matters to be reasonably expected to be capable of evaluating the risk of transactions in such securities. Accordingly, the SEC's rules may limit the number of potential purchasers of the shares of our common stock and stockholders may have difficulty selling their securities. 

 

A large number of shares will be eligible for future sale and may depress our stock price.

 

We may be required, under terms of future financing arrangements, to offer a large number of common shares to the public, or to register for sale by future private investors a large number of shares sold in private sales to them.

 

Sales of substantial amounts of common stock, or a perception that such sales could occur, and the existence of options or warrants to purchase shares of common stock at prices that may be below the then-current market price of our common stock, could adversely affect the market price of our common stock and could impair our ability to raise capital through the sale of our equity securities, either of which would decrease the value of any earlier investment in our common stock.

 

We are authorized to issue "blank check" preferred stock, which, if issued without stockholders approval, may adversely affect the rights of holders of our common stock.

 

We are authorized to issue 50,000,000 shares of preferred stock, of which 974,730 have been issued as Series A Preferred Stock. The Series A Preferred shares are convertible into common shares on a 1:1 ratio at a fixed rate of $3 per share.  Preferred shares have no voting rights, have no redemption rights and earn no dividends. Holders of Series A Convertible Preferred Stock are not permitted to convert their stock into common shares until the Company’s market capital reaches $15,000,000. Upon dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of the then outstanding shares of Series A Convertible Preferred Stock shall be entitled to receive out of the assets of the Company the sum of $0.0001 per share (the “Liquidation Rate”) before any payment or distribution shall be made on any other class of capital stock of the Company ranking junior to the Series A Convertible Preferred Stock. This could dilute your ownership.

 

 

  23  
 

 

The Board of Directors is authorized under our Articles of Amendment to provide for the issuance of additional shares of preferred stock by resolution, and to fix the designation, powers, preferences and rights of the shares of each such series and the qualifications, limitations or restrictions thereof without any further vote or action by the stockholders. Any shares of preferred stock so issued are likely to have priority over the common stock with respect to dividend or liquidation rights. In the event of issuance, the preferred stock could be utilized, under certain circumstances, as a method of discouraging, delaying or preventing a change in control, which could have the effect of discouraging bids for our company and thereby prevent stockholders from receiving the maximum value for their shares. We have no present intention to issue any shares of its preferred stock in order to discourage or delay a change of control. However, there can be no assurance that preferred stock will not be issued at some time in the future. 

 

 

DESCRIPTION OF PROPERTY

 

Shandong Confucian Biologics is located in Food Industrial Park inside the economic development Zone of JinXiang County, Ji’ning City in the province of Shan Dong in China. It has a land us right until 2065 which costs approximately $1,861,216. It has nearly 30,000 square meters standardized plant.

 

SECURITY OWNERSHIP PRIOR TO CHANGE OF CONTROL

 

The following table sets forth certain information concerning the number of our common shares owned beneficially as of July 1, 2016 by: (i) each person (including any group) known to us to own more than five percent (5%) of any class of our voting securities, (ii) each of our directors and named executive officers, and (iii) officers and directors as a group. Unless otherwise indicated, our shareholders listed possess sole voting and investment power with respect to the common shares shown.

 

 

       
    Shares beneficially
owned (1)
Number of shares
    Percentage
of class
(2)
 
             
Standard Resources Ltd. (3) 
8/F Hing Wong Court 
21-23 Tai Wong Street East 
Wanchi, Hong Kong
    3,915,000       86.9%  
                 
Allen Lin     3,915,000       86.9%  
                 
Owen Naccarato     226,875       5.0%  
                 
William Gresher     -       -  
                 
Officers and Directors as a group     4,141,875       91.9%  

 

(1) Beneficial Ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities. Shares of common stock subject to options or warrants currently exercisable or convertible, or exercisable or convertible within 60 days of December 31, 2015 are deemed outstanding for computing the percentage of the person holding such option or warrant but are not deemed outstanding for computing the percentage of any other person. Except as pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect to all shares of common stock beneficially owned.

 

(2) Percentage based on 4,504,214 shares of common stock outstanding as of June 20, 2016.

 

(3) Standard Resources LTD is a related company to Allen Lin, the founder and CEO of H&H Glass.

 

 

  24  
 

 

SECURITY OWNERSHIP IMMEDIATELY AFTER CHANGE OF CONTROL

 

The following table sets forth certain information regarding IPLO’s common stock beneficially owned after the Closing, for (i) each stockholder known to be the beneficial owner of 5% or more of IPLO’s outstanding common stock, (ii) each current and incoming executive officers and directors, and (iii) all current and incoming executive officers and directors as a group.

 

     

 

Name and Address

Amount and Nature of

Beneficial Ownership

 

Percentage of Class

Xiuhua Song (1)

 

3,915,000 86.9%
Owen Naccarato 226,875 5.0%
     

All Directors and Officers as a Group

(1 individual)

3,915,000 86.9%

 

 

(1) At the Closing, Mrs. Song will become the sole director, President, Chief Financial Officer and Secretary of the Company.

 

MANAGEMENT

 

Appointment of New Officers and Directors

 

William Gresher resigned from the board of directors and Xiuhua Song was appointed to the board of directors on July 1, 2016. In connection with the Purchase Agreement and upon the effectiveness of the H&H Vend Out, Owen Naccarato and Allen Lin will tender their resignations from Company’s Board of Directors. Our Board appointed Xiuhua Song as the successor director (the “ Successor Director ”). Furthermore, concurrent with the Closing of the Purchase Agreement, Mr. Naccarato will resign from his positions as IPLO’s President, Vice President, Chief Financial Officer, Treasurer and Secretary. We will appoint Xiuhua as IPLO’s President, Vice President, Chief Financial Officer, Treasurer and Secretary (“Successor Officers”). Descriptions of the Successor Director and the Successor Officers can be found below in the section titled “New Management.”

 

New Management

 

The following table sets forth the names and ages of the Successor Director and Successor Officers, who assumed their positions on the Closing Date of the Purchase Agreement and upon the effectiveness of the H&H Vend Out:

 

         
Name   Age   Position
Xiuhua Song   45   President, Chief Financial Officer, Secretary and Director

 

Based on information provided by the Purchaser, the following biographical information on the directors and officers of the Company after the Change of Control is presented below:

 

Mrs. Song has been the Managing Director of Shandong Yibao Biologics Co., Ltd. from May 2011 to present. Additionally, Mrs. Song has served as President of YBCC, Inc. from November 2012 to present. Mrs. Song received an Associate Degree in Economics and Management from HuBei University of Economics. Additionally, Mrs. Song completed the CEO training program at TsingHua University and received her Executive MBA from Peking University. Mrs. Song is an active member of the American Nutrition and Health Association. Mrs. Song plans to dedicate a minimum of 40 hours per week to the Company.

 

 

  25  
 

 

Involvement in Certain Legal Proceedings

 

To the best of IPLO’s knowledge, none of the Successor Officers and Successor Director have been convicted in a criminal proceeding, excluding traffic violations or similar misdemeanors, nor have they been a party to any judicial or administrative proceeding during the past five years, except for matters that were dismissed without sanction or settlement, that resulted in a judgment, decree or final order enjoining the person from future violations of, or prohibiting activities subject to, federal or state securities laws, or a finding of any violation of federal or state securities laws.

 

Code of Ethics

 

On September 7, 2004, the Board of Directors of the Company adopted the Code of Ethics for Chief Executive Officer and the Principal Financial Officer, which was included as exhibit 14.1 with the December 31, 2004 Form 10KSB.

 

Section 16(a) Beneficial Ownership Compliance

 

Section 16(a) of the Securities Exchange Act of 1934 , as amended, requires our executive officers and directors, and persons who beneficially own more than 10% of a registered class of our equity securities to file with the Securities and Exchange Commission initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common shares and other equity securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and greater than 10% shareholders are required by the Securities and Exchange Commission regulations to furnish us with copies of all Section 16(a) reports they file. Based on our review of the copies of such forms received by us, and to the best of our knowledge, other than reported in our annual report on Form 10-K filed on April 19, 2016, all executive officers, directors and greater than 10% shareholders filed the required reports in a timely manner except for Messrs. Naccarato, Gresher and Lin and Standard Resources Ltd.

 

Board of Directors, Board Meetings and Committees

 

Our Board will comprise of one (1) member, Xiuhua Song is a management member of the Shandong Confucian Biologics. All members of the Board serve in this capacity until their terms expire or until their successors are duly elected and qualified.

 

Mrs. Song has been appointed as the Chairman of the Board of Directors. In this capacity she is responsible for meeting with our Chief Financial Officer to review our financial and operating results, agendas and minutes of board and committee meetings, and presiding at the meetings of the committees of the Board.

 

Our Board held no formal meetings during the most recently completed fiscal year. All proceedings of the Board were conducted by resolutions, consented to in writing by all the directors and filed with the minutes of the proceedings of the directors. Such resolutions consented to in writing by the directors entitled to vote on that resolution at a meeting of the directors are, according to the corporate laws of the State of Nevada and our By-laws, as valid and effective as if they had been passed at a meeting of the directors duly called and held.

 

Board Committees; Director Independence

 

As of this date our Board has not appointed a nominating committee, audit committee or compensation committee, or committees performing similar functions nor do we have a written nominating, compensation or audit committee charter. Our Board does not believe that it is necessary to have such committees because it believes the functions of such committees can be adequately performed by our Board. Further, we are not a "listed company" under SEC rules and thus we are not required to have a compensation committee or a nominating committee. We are not currently required to have such committees. Accordingly, we do not have an “audit committee financial expert” as such term is defined in the rules promulgated under the Securities Act of 1933 and the Securities and Exchange Act of 1934. The functions ordinarily handled by these committees are currently handled by our entire Board. Our Board intends, however, to review our governance structure and institute board committees as necessary and advisable in the future, to facilitate the management of our business.

 

 

  26  
 

 

We do not believe that our incoming director is considered “independent” under Rule 4200(a)(15) of the National Association of Securities Dealers listing standards. We are not currently subject to any law, rule or regulation, however, requiring that all or any portion of our Board include "independent" directors.

 

We do not have any defined policy or procedure requirements for shareholders to submit recommendations or nominations for directors. Our Board believes that, given the early stages of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. We do not currently have any specific or minimum criteria for the election of nominees to our Board and we do not have any specific process or procedure for evaluating such nominees. Our Board assesses all candidates, whether submitted by management or shareholders, and makes recommendations for election or appointment.

 

A shareholder who wishes to communicate with our Board may do so by directing a written request addressed to our Chief Executive Officer at the address appearing on the face page of this Current Report. IPLO does not have a policy regarding the attendance of board members at the annual meeting of shareholders.

 

Compensation Committee Interlocks and Insider Participation

 

No interlocking relationship exists between our Board and the board of directors or compensation committee of any other company, nor has any interlocking relationship existed in the past.

 

EXECUTIVE COMPENSATION

 

The following summary compensation table indicates the cash and non-cash compensation earned during the fiscal year ended December 31, 2015.

 

 

SUMMARY COMPENSATION TABLE
Name and principal position     Year       Salary
($)
      Bonus
($)
      Stock
Awards ($)
      Option
Awards ($)
      Non-Equity
Incentive
Plan
Compensation
($)
      Nonqualified
Deferred
Compensation
Earnings
($)
      All Other
Compensation
($)
      Total
($)
 
Owen Naccarato, CEO and CFO     2015       0       0       0       0       0       0       42,000       42,000  
      2014       0       0       0       0       0       0       42,000       42,000  
Allen Lin, President H&H Glass     2015       276,000       0       0       0       0       0       50,000       326,000  
      2014       268,000       0       0       0       0       0       37,000       305,000  

 

During 2015 and 2014, Mr. Naccarato received $6,000 in annual director’s fees, included above.

 

Outstanding Equity Awards at Fiscal Year-end

 

The following table sets forth certain summary information regarding outstanding equity awards as of December 31, 2015 to the Company's Chief Executive Officer and Chief Financial Officer and most highly paid executive officers during such period.

 

 

  27  
 

 

OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
OPTION AWARDS       STOCK AWARDS  
Name     Number of
Securities
Underlying
Unexercised
Options

(#)
Exercisable
      Number of
Securities
Underlying
Unexercised
Options

(#)
Unexercisable
      Equity
Incentive
Plan
Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options (#)

      Option
Exercise
Price

($)
      Option
Expiration
Date
      Number
of
Shares
or Units
of Stock
That
Have
Not
Vested

(#)
      Market
Value of
Shares
or Units
of Stock
That
Have
Not
Vested

($)
      Equity
Incentive
Plan
Awards:
Number
of
Unearned
Shares,
Units or
Other
Rights
That
Have Not
Vested

(#)
      Equity
Incentive
Plan
Awards:
Market
or Payout
Value of
Unearned
Shares,
Units or
Other
Rights
That
Have Not
Vested

(#)
 
Owen Naccarato     0       0       0       0       0       0       0       0       0  
Allen Lin     0       0       0       0       0       0       0       0       0  

 

 

Compensation of Directors

 

DIRECTOR COMPENSATION  
Name     Fees
Earned
or Paid
in
Cash

($)
      Stock
Awards
($)
      Option
Awards
($)
      Non-Equity
Incentive

Plan
Compensation

($)
      Non-
Qualified Deferred
Compensation
Earnings

($)
      All
Other
Compensation
($)
      Total
($)
 
Owen Naccarato   $ 6,000       0       0       0       0       0     $ 6,000  
William Gresher   $ 6,000       0       0       0       0       0     $ 6,000  
Allen Lin   $ 0       0       0       0       0       0     $ 0  

 

Grants of Plan-Based Awards

 

We did not make any grants of plan-based awards during the fiscal year-ended December 31, 2015.

 

Outstanding Equity Awards

 

There are no unexercised options, stock that has not vested, or equity incentive plan awards outstanding as of December 31, 2015.

 

Option Exercises and Stock Vested

 

There were no exercises of stock options, SARs or similar instruments, and no vesting of stock, including restricted stock, restricted stock units and similar instruments, during the last completed fiscal year.

 

Pension Benefits

 

We currently have no plans that provide for payments or other benefits.

 

 

  28  
 

 

Nonqualified defined contribution and other nonqualified deferred compensation plans.

 

We currently have no defined contribution or other plans that provide for the deferral of compensation on a basis that is not tax-qualified.

 

Potential Payments upon Termination or Change-In-Control

 

SEC regulations state that we must disclose information regarding agreements, plans or arrangements that provide for payments or benefits to our executive officers in connection with any termination of employment or change in control of the company. We currently have no employment agreements with any of our executive officers providing for payments or benefits in connection with a termination of employment or change in control of the company, nor any compensatory plans or arrangements resulting from the resignation, retirement or any other termination of any of our executive officers, from a change-in-control, or from a change in any executive officer's responsibilities following a change-in-control. As a result, we have omitted this table. 

 

Employment Agreements

 

None

 

Director Compensation

 

Directors received remuneration totaling in aggregate of $12,000 during the years ended December 31, 2015 and 2014. Directors receive $500 a month in directors’ fees with the exception of Mr. Lin who received no compensation for director’s services for the years ended December 31, 2015 and 2014.

 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

Other than the foregoing and the below, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, has any material interest, direct or indirect, in any transaction that has occurred during the past fiscal year, or in any proposed transaction, which has materially affected or will affect the Company.

 

Related Party Transactions Prior to Change in Control

 

Allen Lin

 

The Company paid Mr. Allen Lin, President of H&H Glass and a member of the board of directors of the Company, compensation of $326,000 and $305,000 for the years ended December 31, 2015 and 2014, respectively.

 

Josephine Lin

 

Josephine Lin, Mr. Lin’s wife, is employed by the Company and was paid a salary of $60,000 and $58,000 for the years ended December 31, 2015 and 2014, respectively.

 

Owen Naccarato

 

During 2015 and 2014, Mr. Naccarato, the Company’s Chief Executive Office and acting Chief Financial Officer, was paid director fees of $6,000 and $36,000 for legal fees performed.

 

William Gresher

 

During 2015 and 2014, Mr. Gresher, a member of the Board of Directors, was paid $6,000 per year director fees.

 

 

  29  
 

 

Purchase Agreement

 

On May 15, 2016, IPLO and Xiuhua Song entered into a Purchase Agreement to sell to the Purchaser, and the Purchaser will purchase from the IPLO, an aggregate of 3,915,000 newly issued shares of IPLO Common Stock. This transaction was consummated on July 1, 2016.

 

Agreement and Plan of Share Exchange

 

On July 1, 2016, IPLO executed the Exchange Agreement by and among Yibaoccyb and the Yibaoccyb Shareholders, on the one hand, and IPLO, on the other hand. Yibaoccyb owns 100% of YibaoHK. Yibao will own 100% of Yibao WOFE, which is a WFOE under the laws of the PRC. Yibao WOFE has entered into a series of contractual arrangements with the Shandong Confucian Biologics, comprising of Shandong Confucian Biologics, which is a limited liability company headquartered in, and organized under the laws of, the PRC. Yibaoccyb, Yibao WOFE and the Shandong Confucian Biologics are sometimes referred to together as the Yibao Group. On the Closing Date of the Exchange Agreement, the Registrant will issue 2,040,000 shares of IPLO common stock to the Yibaoccyb Shareholders in exchange for 51% of the common stock of Yibaoccyb.

 

As a result of the Share Exchange Transaction and the Purchase Agreement and upon the Closing Date, the Xiuhua and Yibaoccyb Shareholders became our controlling shareholders and Yibaoccyb became our 51% owned subsidiary. We expect to acquire the business and operations of the Yibao Group, and our principal business activities will be conducted through the Yibao Group’s operating companies in China, namely Shandong Confucian Biologics. All of these parties are related parties of Xiuhua Song, our sole director and officer.

 

Our Contractual Arrangements with the Shandong Confucian Biologics and Their Respective Shareholders

 

PRC law currently limits foreign equity ownership of Chinese companies. To comply with these foreign ownership restrictions, we expect to operate our business in China through a series of contractual arrangements with the Shandong Confucian Biologics and their respective shareholders that were executed on Closing Date.

 

Related Party Transactions of the Shandong Confucian Biologics

 

Set forth below are the related party transactions since December 31, 2015, among the Shandong Confucian Biologics’ shareholders, officers and/or directors, and the Shandong Confucian Biologics. As a result of the share exchange transaction, we have contractual arrangements with the Shandong Confucian Biologics which give us the ability to substantially influence the Shandong Confucian Biologics’ daily operations and financial affairs, appoint its senior executives and approve all matters requiring shareholder approval.

 

H&H Vend Out

 

Upon the Closing Date, subsequent to the completion of the Purchase Agreement and Exchange Agreement, IPLO is expected to vend out H&H Glass, Inc. back to Standard Resources Ltd., (holder of the shares of H&H Glass) in exchange for the return of 3,915,000 common shares of IPLO held and owned by Standard Resources, Inc. Standard Resources, Inc. is controlled by Allen Lin who is a director of IPLO and therefore makes this a related party transaction.

 

  30  
 

 

DESCRIPTION OF SECURITIES

 

Common Stock

 

Our Company’s Certificate of Incorporation, as amended, provide for authority to issue 900,000,000 shares of common stock with par value of $0.001 per share.

 

After the Closing Date of the Purchase Agreement and Exchange Agreement, we shall have approximately 8,504,214 shares of our common stock issued and outstanding held by approximately 828 stockholders of record.

 

Preferred Stock

 

We currently have 974,730 shares of preferred stock Series A issued and outstanding. A total of 50,000,000 preferred shares with par value of $0.0001 per share are authorized.

 

Series A Preferred Shares

 

The Series A Preferred shares are convertible into common shares on a 1:1 ratio at a fixed rate of $3 per share.  Preferred shares have no voting rights, have no redemption rights and earn no dividends. Holders of Series A Convertible Preferred Stock are not permitted to convert their stock into common shares until the Company’s market capital reaches $15,000,000. Upon dissolution, liquidation or winding up of the Company, whether voluntary or involuntary, the holders of the then outstanding shares of Series A Convertible Preferred Stock shall be entitled to receive out of the assets of the Company the sum of $0.0001 per share (the “Liquidation Rate”) before any payment or distribution shall be made on any other class of capital stock of the Company ranking junior to the Series A Convertible Preferred Stock.

 

ASC Topic 480, “Distinguishing Liabilities from Equity,” establishes standards for how an issuer classifies and measures certain financial instruments with characteristics of both liabilities and equity.

 

A mandatorily redeemable financial instrument shall be classified as a liability unless the redemption is required to occur only upon the liquidation or termination of the reporting entity. A financial instrument issued in the form of shares is mandatorily redeemable if it embodies an unconditional obligation requiring the issuer to redeem the instrument by transferring its assets at a specified or determinable date (or dates) or upon an event certain to occur. A financial instrument that embodies a conditional obligation to redeem the instrument by transferring assets upon an event not certain to occur becomes mandatorily redeemable—and, therefore becomes a liability—if that event occurs, the condition is resolved, or the event becomes certain to occur.

 

The Company determined that the preferred shares are not mandatorily or conditionally redeemable and are properly classified as permanent equity in the accompanying unaudited condensed consolidated financial statements.

 

Series B Preferred Shares

 

As of January 1, 2010 pursuant to the purchase agreement for 51% ownership in EZ Link Holdings Ltd., approximately 47% of the purchase price amount $400,000 was paid in Series B convertible preferred shares of IPL Group, Inc. at a per share value of $1.00, or 400,000 shares. As a result of the divesture of EZ Link, the Company received from EZ Link shareholders the 400,000 shares of Series B preferred stock. As of December 31, 2015, there are no shares of Series B preferred stock issued and outstanding.

 

  31  
 

 

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

 

Our common stock is quoted on the Over-the Counter Bulletin Board, (“the OTCBB”), under the trading symbol “IPLO”. The following table set forth the quarterly high and low bid prices per share for our common stock. The bid prices reflect inter-dealer prices, without retail markup, markdown, or commission and may not represent actual transactions. The low prices are often arbitrary prices put in the system by market makers.

 

      High       Low  
Year ended December 31, 2015                
First quarter   $ 0.59     $ 0.15  
Second quarter   $ 0.22     $ 0.02  
Third quarter   $ 0.04     $ 0.02  
Fourth quarter   $ 0.12     $ 0.04  
Year ended December 31, 2014                
First quarter   $ 0.85     $ 0.12  
Second quarter   $ 0.75     $ 0.12  
Third quarter   $ 0.75     $ 0.12  
Fourth quarter   $ 0.75     $ 0.01  

 

As of December 31, 2015, there were approximately 828 registered shareholders of the Company’s Common Stock with 4,504,214 shares issues and outstanding.

 

Dividends

 

To date, the Company has not declared or paid dividends on its Preferred or Common Stock.

 

Transfer Agent and Registrar

 

The Company’s transfer agent is Jersey Transfer and Trust Company located at 1250 Sussex Turnpike, #606; Mount Freedom, NJ 07970-0606.

 

Securities authorized for issuance under equity compensation plans.

 

N/A

 

Recent Sales of Unregistered Securities

 

N/A

 

Dividend Policy

 

We do not currently intend to pay any cash dividends in the foreseeable future on our common stock and, instead, intend to retain earnings, if any, for future operation and expansion. Any decision to declare and pay dividends in the future will be made at the discretion of our Board and will depend on, among other things, our results of operations, cash requirements, financial condition, contractual restrictions and other factors that our Board may deem relevant.

 

EQUITY COMPENSATION PLAN INFORMATION

 

We currently do not have any equity compensation plans.  

 

 

  32  
 

 

LEGAL PROCEEDINGS

 

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

 

RECENT SALES OF UNREGISTERED SECURITIES

 

Reference is made to Item 3.02 of this Current Report on Form 8-K for a description of recent sales of unregistered securities, which is hereby incorporated herein by reference.

 

INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

Chapter 78 of the Nevada Revised Statutes ("NRS") provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with such action, suit or proceeding if he is not liable pursuant to NRS Section 78.138 or acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. NRS Chapter 78 further provides that a corporation similarly may indemnify any such person serving in any such capacity who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred in connection with the defense or settlement of such action or suit if he is not liable pursuant to NRS Section 78.138 or acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation and except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the court or other court of competent jurisdiction in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court or other court of competent jurisdiction shall deem proper.

 

Our bylaws provide that it may indemnify its officers, directors, agents and any other persons to the fullest extent permitted by the NRS.

 

We have been advised that, in the opinion of the SEC, indemnification for liabilities arising under federal securities laws is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable. In the event that a claim for indemnification for liabilities arising under federal securities laws, other than the payment by us of expenses incurred or paid by a director, officer or controlling person in the successful defense of any action, suit or proceeding, is asserted by a director, officer or controlling person in connection with our activities, we will (unless in the opinion of our counsel, the matter has been settled by controlling precedent) submit to a court of appropriate jurisdiction, the question whether indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. The legal process relating to this matter if it were to occur is likely to be very costly and may result in us receiving negative publicity, either of which factors is likely to materially reduce the market and price for our shares, if such a market ever develops.

 

 

  33  
 

 

Item 3.02 Unregistered Sales of Equity Securities

 

On July 1, 2016, and as described under Item 2.01 above, pursuant to the Purchase Agreement, IPLO issued 3,915,000 shares of its common stock to Xiuhua Song for a purchase price of $225,000. The issuance of these shares was exempt from registration pursuant to Section 4(2) and/or Regulation S thereof. We made this determination based on the representations of Xiuhua Song which included, in pertinent part, that such shareholders were either (a) "accredited investors" within the meaning of Rule 501 of Regulation D promulgated under the Securities Act, or (b) not a "U.S. person" as that term is defined in Rule 902(k) of Regulation S under the Act, and that such shareholders were acquiring our common stock, for investment purposes for their own respective accounts and not as nominees or agents, and not with a view to the resale or distribution thereof, and that each member understood that the shares of our common stock may not be sold or otherwise disposed of without registration under the Securities Act or an applicable exemption therefrom.  

 

Upon the Closing Date as described under Item 2.01 above, pursuant to the Exchange Agreement, IPLO will issue 2,040,000 shares of its common stock to the Yibaoccyb Shareholders in exchange for 51% of the outstanding shares of Yibaoccyb. The issuance of these shares was exempt from registration pursuant to Section 4(2) and/or Regulation S thereof. We made this determination based on the representations of the Shareholders which included, in pertinent part, that such shareholders were either (a) "accredited investors" within the meaning of Rule 501 of Regulation D promulgated under the Securities Act, or (b) not a "U.S. person" as that term is defined in Rule 902(k) of Regulation S under the Act, and that such shareholders were acquiring our common stock, for investment purposes for their own respective accounts and not as nominees or agents, and not with a view to the resale or distribution thereof, and that each member understood that the shares of our common stock may not be sold or otherwise disposed of without registration under the Securities Act or an applicable exemption therefrom.  

 

Item 5.01 Changes in Control of Registrant.

 

As more fully described in Items 1.01 and 2.01 above, on July 1, 2016, IPLO Closed the Purchase Agreement and the Exchange Agreement. Reference is made to the disclosures set forth under Items 1.01 and 2.01 of this Current Report on Form 8-K, which disclosures are incorporated herein by reference.

 

Under the Purchase Agreement, we issued 3,915,000 shares of our common stock to Xiuhua Song for a purchase price of $225,000. Under the Exchange Agreement, on the Closing Date, we expect to issue 2,040,000 shares of our common stock, to the Yibaoccyb Shareholders in exchange for 51% of the capital stock of Yibaoccyb. Each share of our outstanding common stock entitles the holders of common stock to one vote. Thus, Xiuhua Song and the Yibaoccyb Shareholders hold the majority number of voting shares of our company on a fully diluted basis. The closing of the transactions under the Purchase Agreement and Exchange Agreement, which resulted in the change in control of the Registrant, occurred on July 1, 2016. A copy of the Purchase Agreement is included as Exhibit 10.1 to this Current Report on Form 8-K. A copy of the Exchange Agreement is included as Exhibit 2.1 to this Current Report on Form 8-K.

 

In connection with this change in control, and as explained more fully in Item 2.01 above under the section titled “Management” and in Item 5.02 below, effective on Closing date, Owen Naccarato will resign as IPLO’s President, Vice President, Chief Financial Officer, Treasurer and Secretary. Concurrently, Xiuhua Song will be appointed as IPLO’s President, Vice President, Chief Financial Officer, Treasurer and Secretary. Messrs. Naccarato and Lin will resign from the Company’s Board of directors and leaving Xiuhua as sole director.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(b)   Resignation of Officers and Directors

 

In connection with this change in control, and as explained more fully in Item 2.01 above under the section titled “Management” and in Item 5.02 below, effective on July 1, 2016, Mr. Gresher resigned from the board of directors. Upon the Closing Date, Owen Naccarato will resign as IPLO’s President, Vice President, Chief Financial Officer, Treasurer and Secretary. Messrs. Naccarato and Lin will resign from the Company’s Board of directors and leaving Xiuhua as sole director.

 

 

  34  
 

 

(c)   Appointment of Officers

 

In connection with the Purchase Agreement, effective upon the Closing Date, the following persons were appointed as our officers:

 

         
Name   Age   Position
Xiuhua Song   45   President, Chief Financial Officer, Secretary and Director

 

None of our officers currently has an employment agreement with IPLO. Related party transactions involving are described in Item 2.01 above. 

 

Descriptions of our officers can be found in Item 2.01 above, in the section titled “New Management.”  

 

(d)   Appointment of Directors

 

In connection with the Purchase Agreement, effective July 1, 2016, the following persons were appointed as a director:

 

         
Name   Age   Position
Xiuhua Song   45   Director

 

 

Item 9.01   Financial Statement and Exhibits

 

As more fully described in Item 2.01 above, on July 1, 2016, we executed the Exchange Agreement by and among Yibaoccyb and the Yibaoccyb Shareholders on the one hand, and the Registrant on the other hand. The Closing of this Exchange Transaction is expected to occur on the Closing Date. Yibaoccyb has established and owns 100% of the equity in YibaoHK and YibaoHK will own 100% of the equity in Yibao WOFE, a WFOE in the PRC. Yibao WOFE will enter into a series of contractual arrangements with Shandong Confucian Biologics which is a PRC limited liability company. Throughout this Current Report, Yibaoccyb, Yibao WOFE, and Shandong Confucian Biologics are sometimes collectively referred to as the “Yibao Group.” As a result of our acquisition of the Yibao Group, our principal business activities after the Exchange Transaction shall continue to be conducted through the Yibao Group’s operating company in China, Shandong Confucian Biologics.

 

(a)  Financial statements of businesses acquired .

 

The audited statements of Shandong Confucian Biologics as of December 31, 2015 and 2014 will be filed shortly after the audit of Shandong Confucian Biologics is completed.

 

 

(d) Exhibits

 

Exhibit Number   Description
2.1   Share Exchange Agreement among IPLO, Yibaoccyb and Xiuhua Song dated July 1, 2016
10.1   Stock Purchase Agreement between IPLO and Xiuhua Song dated May 15, 2016
10.2   Stock Purchase Agreement among IPLO, Standard Resources Ltd., and H&H Glass Inc. dated July 1, 2016.  

 

 

  35  
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 7, 2016 International Packaging and Logistics Group, Inc.
   
   
By:   /s/ Owen Naccarato
  Owen Naccarato
  Chief Executive Officer

 

 

 

  36  

EXHIBIT 2.1

SHARE EXCHANGE AGREEMENT

 

This Share Exchange Agreement (the “ Agreement ”), dated as of July 1, 2016, is by and among International Packaging and Logistics Group Inc., a corporation organized under the laws of Nevada with principle executive offices located at 7700 Irvine Center Dr., Suite 870, Irvine, California 92618 (“ IPL ” or the “ Buyer ”), Yibaoccyb, Ltd., company organized under the laws of the British Virgin Islands, with principle offices located at Xinglong Industry Park,Yanzhou City, , Jining, Shandong, China (“ Yibao BVI ” or the “ Company ”), and the persons and/or entities listed on Exhibit A hereto who are the holders in the aggregate of all of the issued and outstanding capital shares of the Company (referred to collectively as the “ Seller ”) (Buyer, Company, and Seller may be referred to collectively as the “ Parties ”).

 

RECITALS

 

A. The capital stock of the Company consists of 50,000 authorized shares of Common Stock, US$ 1 par value (the “ Company Shares ”), of which 50,000 shares are currently issued and outstanding and held by Seller (“ Shares ”).

 

B. Upon the terms and conditions set forth below, Seller desires to assign fifty-one percent (51%) of the Company Shares, or 25,500 Company Shares in the aggregate, to Buyer, such that, following such transaction, the Company will be a majority owned subsidiary of Buyer.

 

C. The parties agree that 51% ownership of the issued and outstanding shares of the Company has a present estimated market value of the Company (the “ Purchase Price ”).

 

D. The parties intend that this transaction qualify as a tax-free stock for stock Reorganization within the meaning of section 368(a)(1)(B) of the Internal Revenue Code of 1986, as amended.

 

NOW, THEREFORE, in consideration of the mutual covenants, agreements, representations and warranties contained in this Agreement, the Parties hereto agree as follows:

 

ARTICLE 1

 

SALE AND PURCHASE OF THE SHARES

 

1.1 Sale of Shares. Subject to the terms and conditions herein set forth, and on the basis of the representations, warranties and agreements herein contained, Seller shall sell and transfer to Buyer 25,500 Company Shares of the Company’s common stock that constitute 51% of the issued and outstanding shares of capital stock of the Company.

 

1.2 Consideration.    Buyer shall issue Seller the following as consideration (the “ Consideration Shares ”);

 

(a) Purchase Price amount shall be paid in 2,040,000 common shares of IPL (the “ Common Shares ”).  Such shares shall bear the appropriate restrictions.

 

ARTICLE 2

 

Article 2 Intentionally Left Blank

 
 

ARTICLE 3

 

DUE DILIGENCE

 

3.1. This Agreement is conditional upon completion of the following diligence by the Buyer, and the Company agrees to cooperate therewith.  The due diligence requirements will be usual and customary for transactions of this type including a review of, but not limited to, the following:

 

- Access to management and all key facilities
- Review historical and projected financials and internal control procedures

- Review of product portfolio, product roadmap, technology and infrastructure
- Review of contracts, IP rights, etc.

- Reference checks of customer, partner and management
- Accounting and legal review

 

  1  
 

 

ARTICLE 4

 

REPRESENTATIONS AND WARRANTIES

 

4.1 Representations and Warranties of Seller and the Company.   Except as disclosed in Exhibit 4 referring specifically to the representations and warranties in this Agreement that identifies by section number the section and subsection to which such disclosure relates and is delivered by the Seller and the Company to the Buyer prior to the execution of this Agreement (the “ Disclosure Schedules ”), the Seller and the Company represent and warrant to the Buyer, as of the date hereof and as of the Closing, as follows:

 

4.1.1 Organization, Standing, Power . Company is a corporation duly organized, validly existing, and in good standing under the laws of the British Virgin Islands.  It has all requisite corporate power, franchises, licenses, permits, and authority to own its properties and assets and to carry on its business as it has been and is being conducted.  Company is duly qualified and in good standing to do business in each jurisdiction in which a failure to so qualify would have a Material Adverse Effect (as defined below) on Company.  For purposes of this Agreement, the term “ Material Adverse Effect ” means any change or effect that, individually or when taken together with all other such changes or effects which have occurred prior to the date of determination of the occurrence of the Material Adverse Effect, is or is reasonably likely to be materially adverse to the business, assets (including intangible assets), financial condition, or results of operations of the entity.

  

4.1.2 Authority .  The Company and Seller have all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby.  The execution and delivery by the Company and Seller of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the parts of the Company and Seller, including the approval of the Board of Directors of each Party.  This Agreement has been duly executed and delivered by the Company and Seller to the Buyer and constitutes a valid and binding obligation of the Seller and the Company enforceable in accordance with its terms, except that such enforceability may be subject to: (a) bankruptcy, insolvency, reorganization, or other similar laws relating to enforcement of creditors’ rights generally; and (b) general equitable principles.  Subject to the satisfaction of the conditions set forth in Article 5 below, the execution and delivery of this Agreement do not, and the consummation of the transactions contemplated hereby will not, conflict with or result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, or acceleration of any obligation, or to loss of a material benefit under, or the creation of a lien, pledge, security interest, charge, or other encumbrance on any assets of the Company (any such conflict, violation, default, right, loss, or creation being referred to herein as a “ Violation ”) pursuant to: (i) any provision of the organization documents of the Company and Seller; or  (ii) any loan or credit agreement, note, bond, mortgage, indenture, contract, lease, or other agreement, or instrument, permit, concession, franchise, license, judgment, order, decree, statute, law, ordinance, rule, or regulation applicable to each of the Company’s and Seller’s respective properties or assets, other than in the case of  any such Violation which individually or in the aggregate would not have a Material Adverse Effect on the Company.

 

4.1.3 Capitalization of the Company .

 

(a) The Company .  The capital stock of the Company consists of 50,000 authorized shares of Common Stock, US$ 1 par value of which 50,000 shares are currently validly issued and outstanding and held by Seller free of all liens and encumbrances.  For purposes of this subparagraph, the representations and warranties of each individual Seller are limited to representations and warranties made about the Company and about himself, individually, but not about the other Seller, except that to the best knowledge of each individual Seller, none of the representations and warranties made by the other individual Seller is untrue.

 

(b) No Rights to Acquire Shares. Except as set forth on the Disclosure Schedules, there are no options, warrants, rights, calls, commitments, plans, contracts, or other agreements of any character granted or issued by any of the Company and Seller which provide for the purchase, issuance, or transfer of any additional shares of the capital stock of the Company nor are there any outstanding securities granted or issued by any of the Company and Seller that are convertible into any shares of the equity securities of the Company, and none is authorized. None of the Company and Seller have outstanding any bonds, debentures, notes, or other indebtedness the holders of which have the right to vote (or convertible or exercisable into securities having the right to vote) with holders of the Company s capital stock on any matter.

  

(c) No Voting Agreements. Except as set forth on the Disclosure Schedules, none of the Company and Seller are a party or subject to any agreement or understanding, and, to the best of the Company and Seller' knowledge, there is no agreement or understanding between any persons and/or entities, which affects or relates to the voting or giving of written consents with respect to any security or by a shareholder or director of any of the Company.

 

  2  
 

 

(d) No Registration Rights. Except as set forth on the Disclosure Schedules the Company has not granted or agreed to grant any registration rights, including piggyback rights, to any person or entity.

 

4.1.4 Subsidiaries.   “ Subsidiary ” or “ Subsidiaries ” means all corporations, trusts, partnerships, associations, joint ventures, or other Persons, as defined below, of which the Company or any Subsidiary of the Company owns not less than twenty percent (20%) of the voting securities or other equity or of which the Company or any Subsidiary of the Company possesses, directly or indirectly, the power to direct or cause the direction of the management and policies, whether through ownership of voting shares, management contracts, or otherwise. “ Person ” means any individual, corporation, trust, association, partnership, proprietorship, joint venture, or other entity.  Prior to the Closing of this Agreement, there are no Subsidiaries of the Company other than as disclosed herein or disclosed on the Disclosure Schedules.

 

4.1.5 No Defaults.   None of the Company and Seller has received notice that they would be, with the passage of time, in default or violation of any term, condition, or provision of: (i) their Articles of Incorporation or Bylaws; (ii) any judgment, decree, or order applicable to any of the Company and Seller; or (iii) any loan or credit agreement, note, bond, mortgage, indenture, contract, agreement, lease, license, or other instrument to which any of the Company and Seller is now a party or by which they or any of their properties or assets may be bound, except for defaults and violations which, individually or in the aggregate, would not have a Material Adverse Effect on any of the Company and Seller.

 

4.1.6 Governmental Consents .  Any consents, approvals, orders, or authorizations of or registrations, qualifications, designations, declarations, or filings with or exemptions by (collectively “ Consents ”), any court, administrative agency, or commission, or other federal, state, or local governmental authority or instrumentality, whether domestic or foreign (each a “ Governmental Entity ”), which may be required by or with respect to any of the Company and Seller in connection with the execution and delivery of this Agreement or the consummation by the Company and Seller of the transactions contemplated hereby, except for such Consents which if not obtained or made would not have a Material Adverse Effect on any of the Company and Seller for the transactions contemplated by this Agreement, are the responsibility of the Seller and the Company. Each of the Company and Seller hereby represents and warrants that such Consents have been obtained by them.

  

4.1.7 Financial Statements .  The Company and Seller will furnish Buyer upon completion with a true and complete copy of its audited financial statements for the periods ending December 31, 2015 and 2014, (the “ Financial Statements ”), which comply as to form in all material respects with all applicable accounting requirements with respect thereto and have been prepared internally and fairly present the financial positions of the Company as at the dates thereof and the results of its operations and cash flows for the periods then ended (subject, in the case of unaudited statements, to normal, recurring audit adjustments not material in scope or amount). There has been no change in the Company's accounting policies or the methods of making accounting estimates or changes in estimates that are material to the Financial Statements, except as described in the notes thereto.

 

4.1.8 Absence of Undisclosed Liabilities .  None of the Company and Seller have any liabilities or obligations (whether absolute, accrued, or contingent) except: (i) Liabilities that are accrued or reserved against in their respective Balance Sheets; or (ii) additional Liabilities reserved against since December 31, 2015 that (x) have arisen in the ordinary course of business; (y) are accrued or reserved against on their books and records; and (z) amount in the aggregate to less than US$250,000.

 

4.1.9 Absence of Changes.   Since December 31, 2015 the Company has conducted its businesses in the ordinary course and there has not been: (i) any Material Adverse Effect on the business, financial condition, liabilities, or assets of the Company or any development or combination of developments of which management of the Company and Seller has knowledge which is reasonably likely to result in such an effect; (ii) any damage, destruction, or loss, whether or not covered by insurance, having a Material Adverse Effect on the Company; (iii) any declaration, setting aside or payment of any dividend or other distribution (whether in cash, stock, or property) with respect to the capital stock of the Company; (iv) any increase or change in the compensation or benefits payable or to become payable by the Company to any of their employees, except in the ordinary course of business consistent with past practice; (v) any sale, lease, assignment, disposition, or abandonment of a material amount of property of the Company, except in the ordinary course of business; (vi) any increase or modification in any bonus, pension, insurance, or other employee benefit plan, payment, or arrangement made to, for, or with any of their employees; (vii) the granting of stock options, restricted stock awards, stock bonuses, stock appreciation rights, and similar equity based awards; (viii) any resignation or termination of employment of any office of the Company; and the Company, to the best of their knowledge, do not know of the impending resignation or termination of employment of any such office; (ix) any merger or consolidation with another entity, or acquisition of assets from another entity except in the ordinary course of business; (x) any loan or advance by the Company to any person or entity, or guaranty by the Company of any loan or advance; (xi) any amendment or termination of any contract, agreement, or license to which any of the Company is a party, except in the ordinary course of business; (xii) any mortgage, pledge, or other encumbrance of any asset of any of the Company; (xiii) any waiver or release of any right or claim of the Company, except in the ordinary course of business; (xiv) any write off as uncollectible any note or account receivable or portion thereof; or (xv) any agreement by any of the Company to do any of the things described in this Section 4.9.

  

 

  3  
 

 

4.1.10 Compliance with Other Instruments .  The Company is not in violation or default of any provision of its articles of incorporation or bylaws, or of any instrument, judgment, order, writ, decree, or contract to which it is a party or by which it is bound, or, to the best of their knowledge, of any provision of any federal or state statute, rule, or regulation which may be applicable to them. The execution, delivery, and performance of this Agreement and the consummation of the transactions contemplated hereby will not result in any such violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either a default under any such provision, instrument, judgment, order, writ, decree, or contract, or an event that results in the creation of any lien, charge, or encumbrance upon any assets of the Company or the suspension, revocation, impairment, forfeiture, or non-renewal of any material permit, license, authorization, or approval applicable to the Company, its businesses, or operations, or any of its assets or properties.

 

4.1.11 Disputes and Litigation.   Except as disclosed in the Disclosure Schedules, there is no suit, claim, action, litigation, or proceeding pending or, to the knowledge of the Company and Seller, threatened against or affecting the Company, respectively, or any of their properties, assets, or business or to which the Company is a party, in any court or before any arbitrator of any kind or before or by any Governmental Entity, which would, if adversely determined, individually or in the aggregate, have a Material Adverse Effect on the Company and Seller, nor is there any judgment, decree, injunction, rule, or order of any Governmental Entity or arbitrator outstanding against the Company, respectively, and having, or which, insofar as reasonably can be foreseen, in the future could have, any such effect.  To the knowledge of the Company and Seller, there is no investigation pending or threatened against any of the respective Company and Seller before any foreign, federal, state, municipal, or other governmental department, commission, board, bureau, agency, instrumentality, or other Governmental Entity.

 

4.1.12  Compliance with Laws.   Except as set forth in the Disclosure Schedules, none of the Company and Seller' businesses is being conducted in violation of, or in a manner which could cause liability under any applicable law, rule, or regulation, judgment, decree, or order of any Governmental Entity, except for any violations or practices, which, individually or in the aggregate, have not had and will not have a Material Adverse Effect on the Company and Seller.  The Company and Seller each have all franchises, permits, licenses, and any similar authority necessary for the conduct of their business as now being conducted by them, the lack of which could materially and adversely affect the business, properties, prospects, or financial condition of the Company and Seller and believes they can obtain, without undue burden or expense, any similar authority for the conduct of their business as it is planned to be conducted.  None of the Company and Seller is in default in any material respect under any of such franchises, permits, licenses, or other similar authority.  A true and complete list of all such franchises, permits, and licenses held by the Company and Seller is set forth in the Disclosure Schedules.

  

4.1.13 Minute Books .  The minute books of the Company provided to Buyer contain a complete summary of all meetings of directors and shareholders since the time of incorporation and reflect all transactions referred to in such minutes accurately in all material respects.

 

4.1.14 Disclosure .  No representation or warranty made by the Company in this Agreement, nor any document, written information, statement, financial statement, certificate, or exhibit prepared and furnished or to be prepared and furnished by the Company and Seller or their representatives pursuant hereto or in connection with the transactions contemplated hereby, when taken together, contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements or facts contained herein or therein not misleading in light of the circumstances under which they were furnished.

 

4.1.15 Reliance .  The foregoing representations and warranties are made by each of the Seller and the Company with the knowledge and expectation that the Buyer is placing reliance thereon.

 

4.1.16 Status of Seller.

 

(a) The Seller has access to the complete SEC filings of the Buyer filed on or before March 31, 2016, and has carefully read such filings in their entirety, and understands the contents thereof.  Each Seller has relied only on the information contained therein, information otherwise provided by the Company in response to the request of each Seller or each Seller's financial advisor or representative, or information from books and records made available to each Seller by the Buyer.

 

(b) Each Seller confirms that, in making the decision to purchase the Consideration Shares, each Seller has relied solely upon independent investigations made by each Seller and/or each Seller's financial advisors or representatives, including each Seller's own professional tax, accounting, financial, legal and other advisors, and that each Seller and such financial representatives and advisors have been given the opportunity to ask questions of, and receive answers from, the Company concerning the terms and conditions of the Offering and to obtain any additional information, to the extent such persons possess such information or can acquire it without unreasonable effort or expense. Each Seller is an " accredited investor " as that term is defined in Section 501(a) of Regulation D under the 1933 Act.

 

  4  
 

 

(c) Each Seller understands that the certificate representing the Consideration Shares will bear a restrictive legend regarding the restricted transferability thereof and, therefore, the Consideration Shares are and will be " restricted securities ," as that term is defined in the 1933 Act.  The Seller is not acquiring the Consideration Shares with any view towards the resale or distribution thereof.

 

(d) Except as allowed by applicable securities laws, rules and regulations, the Consideration Shares are being purchased solely for the Seller's own account and not for the account of any other person or entity, and not for distribution, assignment or resale to others and no other person or entity has a direct or indirect beneficial interest in such Consideration Shares.

 

(e) Each Seller agrees that the Seller will neither directly nor indirectly seek to assign, transfer or sell the Consideration Shares in any way inconsistent with the legend that will be placed on the certificate evidencing the Consideration Shares.

 

4.2 Representations and Warranties of Buyer.   Except as disclosed in Schedule 4.2 referring specifically to the representations and warranties in this Agreement that identifies by section number the section and subsection to which such disclosure relates and is delivered by the Buyer to the Seller and the Company prior to the execution of this Agreement (the “ Disclosure Schedules ”), the Seller and the Company represent and warrant to the Buyer, as of the date hereof and as of the Closing, as follows:

 

4.2.1 Organization, Standing, Power . Buyer is a corporation duly organized, validly existing, and in good standing under the laws of the state of Nevada.  It has all requisite corporate power, franchises, licenses, permits, and authority to own its properties and assets and to carry on its business as it has been and is being conducted.  Buyer is duly qualified and in good standing to do business in each jurisdiction in which a failure to so qualify would have a Material Adverse Effect on Buyer.

 

4.2.2 Authority . The Buyer has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby.  The execution and delivery by the Buyer of this Agreement and the consummation of the transactions contemplated hereby have been duly authorized by all necessary action on the parts of the Buyer, including the approval of the Board of Directors of each Party. This Agreement has been duly executed and delivered by the Buyer to the Company and Seller and constitutes a valid and binding obligation of the Buyer enforceable in accordance with its terms, except that such enforceability may be subject to: (a) bankruptcy, insolvency, reorganization, or other similar laws relating to enforcement of creditors’ rights generally; and (b) general equitable principles.  Subject to the satisfaction of the conditions set forth in Article 5 below, the execution and delivery of this Agreement do not, and the consummation of the transactions contemplated hereby will not, conflict with or result in any violation of, or default (with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation, or acceleration of any obligation, or to loss of a material benefit under, or the creation of a lien, pledge, security interest, charge, or other encumbrance on any assets of the Buyer (any such conflict, violation, default, right, loss, or creation being referred to herein as a “ Violation ”) pursuant to: (i) any provision of the organization documents of the Buyer; or (ii) any loan or credit agreement, note, bond, mortgage, indenture, contract, lease, or other agreement, or instrument, permit, concession, franchise, license, judgment, order, decree, statute, law, ordinance, rule, or regulation applicable to Buyer’s respective properties or assets, other than in the case of any such Violation which individually or in the aggregate would not have a Material Adverse Effect on the Buyer.

 

4.2.3 Capitalization of the Buyer .

 

(a) The Buyer .  The capital stock of the Buyer consists of 900,000,000 authorized shares of Common Stock, US$0.001 par value (the “ Buyer Shares ”), of which 4,504,214 are currently validly issued and outstanding or committed to be issued. In addition the Buyer has 50,000,000 authorized share of convertible Preferred Shares of which 974,730 shares are validly issued and outstanding.

 

(b) No Rights to Acquire Shares. Except as set forth on the Disclosure Schedules and in filings with the Securities and Exchange Commission, there are no options, warrants, rights, calls, commitments, plans, contracts, or other agreements of any character granted or issued by Buyer which provide for the purchase, issuance, or transfer of any additional shares of the capital stock of the Buyer nor are there any outstanding securities granted or issued by Buyer that are convertible into any shares of the equity securities of the Buyer, and none is authorized. The Buyer has no outstanding bonds, debentures, notes, or other indebtedness the holders of which have the right to vote (or convertible or exercisable into securities having the right to vote) with holders of the Buyer s capital stock on any matter.

 

4.2.4 SEC Filings. As of the date of this Agreement, the Buyer has made all filings required by law to be made with the Securities and Exchange Commission. None of such filings contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading.

 

 

  5  
 

 

4.2.5 Change of Control. The execution and closing of this Agreement shall not cause a default under or trigger the application of any “ change of control ” provision in any contract to which the Buyer is a party which would result in the issuance of additional shares or the right to acquire shares of the Buyer to any other party.

 

4.2.6 Dilution. Except as set forth in filings made with the Securities and Exchange Commission, the Buyer is not a party to any contract, agreement, arrangement, or understanding that requires, or that with the passage of time or the happening of events, might require the Buyer to issue equity securities or rights to acquire equity securities of the Buyer.

 

4.2.7 Governmental Consents . All consents, approvals, orders, or authorizations of or registrations, qualifications, designations, declarations, or filings with or exemptions by (collectively “ Consents ”), any third party, including any court, administrative agency, or commission, or other federal, state, or local governmental authority or instrumentality, whether domestic or foreign (each a “ Governmental Entity ”), which may be required by or with respect to Buyer in connection with the execution and delivery of this Agreement or the consummation by the Buyer of the transactions contemplated hereby, except for such Consents which if not obtained or made would not have a Material Adverse Effect on the Buyer for the transactions contemplated by this Agreement, are the responsibility of the Buyer. The Buyer hereby represents and warrants that such Consents have been obtained.

 

 

ARTICLE 5

 

CONDITIONS PRECEDENT

 

5.1 Conditions to Each Party’s Obligations .  The respective obligations of each Party hereunder shall be subject to the satisfaction prior to or at the Closing of the following conditions:

 

(a) No Restraints .  No statute, rule, regulation, order, decree, or injunction shall have been enacted, entered, promulgated, or enforced by any court or Governmental Entity of competent jurisdiction that enjoins or prohibits the consummation of this Agreement and shall be in effect.

 

(b) Legal Action .  There shall not be pending or threatened in writing any action, proceeding, or other application before any court or Governmental Entity challenging or seeking to restrain or prohibit the consummation of the transactions contemplated by this Agreement, or seeking to obtain any material damages.

 

5.2 Conditions to Seller’s Obligations .  The obligations of Seller shall be subject to the satisfaction prior to or at the Closing of the following conditions unless waived by Seller.

 

(a) Representations and Warranties of Buyer .  The representations and warranties of Buyer set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing as though made on and as of the Closing, except: (i) as otherwise contemplated by this Agreement; or (ii) in respects that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.  Buyer shall have received certificates signed on behalf of Buyer by the Chief Executive Officer or President of each Seller and the Company to such effect on the Closing.

 

(b) Consents of Other Third Parties .  Buyer shall have received and delivered to Company and Seller all requisite consents and approvals of all lenders, lessors, and other third parties whose consent or approval is required in order for Buyer to consummate the transactions contemplated by this Agreement, or in order to permit the continuation after the Closing of the business activities of the Buyer in the manner such business is presently carried on by it.  The Company and the Seller shall have received copies of any necessary written consent(s) to this Agreement and the transactions contemplated herein.

  

(c) Performance of Obligations of Buyer .  Buyer shall have performed all agreements and covenants required to be performed by it under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.

 

(d) Material Adverse Change .  Since the date hereof and through Closing, there shall not have occurred any change, occurrence, or circumstance in Buyer having or reasonably likely to have, individually or in the aggregate, in the reasonable judgment of the Company and the Seller, a Material Adverse Effect on the Parties or on the transactions contemplated by this Agreement.

 

 

  6  
 

 

5.3 Conditions to Buyer’s Obligations .  The obligations of Buyer shall be subject to the satisfaction prior to or at the Closing of the following conditions unless waived by Buyer:

 

(a) Representations and Warranties of Seller and the Company .  The representations and warranties of Seller and the Company set forth in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing as though made on and as of the Closing, except: (i) as otherwise contemplated by this Agreement; or (ii) in respects that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.  Buyer shall have received certificates signed on behalf of Seller and the Company by the Chief Executive Officer or President of each Seller and the Company to such effect on the Closing.

 

(b) Performance of Obligations of Seller and the Company .  Seller and the Company shall have performed all agreements and covenants required to be performed by them under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement.  Buyer shall have received certificates signed on behalf of Seller and the Company by the Chief Executive Officer or President of each Seller and the Company to such effect on the Closing.

 

(c) Governmental Approvals .  All Consents of Governmental Entities legally required by Seller and the Company for the transactions contemplated by this Agreement shall have been filed, occurred, or been obtained, other than such Consents, the failure of which to obtain would not have a Material Adverse Effect on the consummation of the transactions contemplated by this Agreement.

 

(d) Consents of Other Third Parties .  Seller and the Company shall have received and delivered to Buyer all requisite consents and approvals of all lenders, lessors, and other third parties whose consent or approval is required in order for Seller and the Company to consummate the transactions contemplated by this Agreement, or in order to permit the continuation after the Closing of the business activities of the Company in the manner such business is presently carried on by it.  Buyer shall have received copies of any necessary written consent(s) to this Agreement and the transactions contemplated herein.

  

(e) Material Adverse Change .  Since the date hereof and through Closing, there shall not have occurred any change, occurrence, or circumstance in Seller or the Company having or reasonably likely to have, individually or in the aggregate, in the reasonable judgment of Buyer, a Material Adverse Effect on the Parties or on the transactions contemplated by this Agreement.

 

(f) Due Diligence Investigation . The Buyer shall have completed its due diligence investigation and analysis of information and evaluation of the Company to its satisfaction in its sole judgment.

 

ARTICLE 6

 

CLOSING AND DELIVERY OF DOCUMENTS

 

6.1 Time and Place .  The closing of the transactions contemplated by this Agreement shall occur upon the issuance of audited financial statements of Shandong Confucian Biologics Co. Ltd by a PCAOB auditor and take place at the offices of Naccarato & Associates, located in Irvine, California, or at such other time and place as the Parties mutually agreed upon in writing (which time and place are hereinafter referred to as the “ Closing ”).

 

6.2 Deliveries by Seller . At Closing, Seller shall make the following deliveries to Buyer:

 

(a) A stock certificate(s) representing the newly Company Shares;

 

(b) A certificate executed by Seller certifying that: (i) all Seller’s representations and warranties under this Agreement are true as of the Closing, as though each of those representations and warranties had been made on that date; and (ii) Seller has performed all agreements and covenants required to be performed by it under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement; and

 

 

  7  
 

 

(c) Certified resolutions of the Board of Directors of Seller, if Seller is an entity, in form satisfactory to counsel for Buyer, authorizing the execution and performance of this Agreement.

 

6.3 Deliveries by the Company .  At Closing, the Company shall make the following deliveries to Buyer:

 

(a) A stock certificate(s) representing the Company Shares that Buyer is acquiring as set forth in Section 1.1 above;

 

(b) A certificate executed by the Company certifying that: (i) all of the Company's representations and warranties under this Agreement are true as of the Closing, as though each of those representations and warranties had been made on that date; and (ii) the Company has performed all agreements and covenants required to be performed by it under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement; and

 

(c) Certified resolutions of the Board of Directors of the Company, in form satisfactory to counsel for Buyer, authorizing the execution and performance of this Agreement; and

 

6.4 Deliveries by Buyer . At Closing, Buyer shall make the following deliveries to Seller:

 

(a) A certificate executed by Buyer certifying that: (i) Buyer’s representations and warranties under this Agreement are true as of the Closing, as though each of those representations and warranties had been made on that date; and (ii) Buyer has performed all agreements and covenants required to be performed by it under this Agreement prior to the Closing, except for breaches that do not have a Material Adverse Effect on the Parties or on the benefits of the transactions provided for in this Agreement;

 

(b) Certified resolutions of the Board of Directors of Buyer in form satisfactory to counsel for Seller, authorizing the execution and performance of this Agreement.

 

(c) Stock Certificates for the Consideration Shares duly issued by the Buyer in the names and for the number of Consideration Shares set forth in Schedule 6.4(c).

 

ARTICLE 7

 

INDEMNIFICATION

 

7.1 Seller and the Company’s Indemnity Obligations .

 

(a) Upon receipt of notice thereof, Seller and the Company shall, jointly and severally, indemnify, defend, and hold harmless Buyer from any and all claims, demands, liabilities, damages, deficiencies, losses, obligations, costs and expenses, including attorney fees and any costs of investigation that Buyer shall incur or suffer, that arise, result from or relate to: (i) any breach of, or failure by Seller or the Company to perform, any of their representations, warranties, covenants, or agreements in this Agreement or in any schedule, certificate, exhibit, or other instrument furnished or to be furnished by Seller and/or the Company under this Agreement; and (ii) the employment of any of the Company’s employees which is in violation of any law, regulation, or ordinance of any Governmental Entity either under the conduct of its business.

 

(b) If additional liabilities or claims become known and claims are made upon the Company for occurrences prior to June 30, 2016, Buyer shall have the right to offset the liabilities and claims against the Consideration Shares as well as pursue all other remedies.

 

(c) Buyer shall notify promptly Seller and the Company of the existence of any claim, demand, or other matter to which Seller and the Company’s indemnification obligations would apply, and shall give them a reasonable opportunity to defend the same at their own expense and with counsel of their own selection, provided that Seller shall at all times also have the right to fully participate in the defense. If Seller and the Company, within a reasonable time after this notice, fails to defend, Buyer shall have the right, but not the obligation, to undertake the defense of, and, with the written consent of Seller and the Company, to compromise or settle the claim or other matter on behalf, for the account, and at the risk, of Seller and the Company.

 

 

  8  
 

 

7.2 Buyer’s Indemnity Obligations .

 

(a) Upon receipt of notice thereof, Buyer shall indemnify, defend, and hold harmless Seller and/or the Company from any and all claims, demands, liabilities, damages, deficiencies, losses, obligations, costs, and expenses, including attorney fees and any costs of investigation that Seller and/or the Company shall incur or suffer, that arise, result from or relate to any breach of, or failure by Buyer to perform any of its representations, warranties, covenants, or agreements in this Agreement or in any schedule, certificate, exhibit, or other instrument furnished or to be furnished by Buyer under this Agreement.

 

(b) Upon receipt of notice thereof, Buyer shall indemnify, defend, and hold harmless Seller and/or the Company from any and all claims, demands, liabilities, damages, deficiencies, losses, obligations, costs, and expenses, including attorney fees and any costs of investigation that Seller shall incur or suffer, that arise, result from or relate to the conduct of the Buyer subsequent to the Closing.

 

(c) Seller shall notify promptly Buyer of the existence of any claim, demand or other matter to which Buyer’s indemnification obligations would apply, and shall give it a reasonable opportunity to defend the same at its own expense and with counsel of its own selection, provided that Seller shall at all times also have the right to fully participate in the defense. If Buyer, within a reasonable time after this notice, fails to defend, Seller shall have the right, but not the obligation, to undertake the defense of, and, with the written consent of Buyer, to compromise or settle the claim or other matter on behalf, for the account, and at the risk, of Buyer.

 

 

ARTICLE 8

 

COVENANTS OF THE PARTIES

 

8.1 Covenants. The Parties agree as follows with respect to the period between the execution of this Agreement and the Closing.

 

(a) General . Each of the Parties will reasonable best efforts to take all action and to do all things necessary, proper, or advisable in order to consummate and make effective the transactions contemplated by this Agreement (including satisfaction, but not waiver, of the closing conditions set forth herein).

 

(b) Notices and Consents . The Seller and Company shall give any notices to third parties and obtain any third party consents that the Buyer reasonably may request in connection with this Agreement, including giving any notices to, make any filings with, obtaining any authorizations, consents, and approvals of governments and governmental agencies in connection with this Agreement.

 

(c) Operation of Business . The Seller shall not cause or permit the Company to engage in any practice, take any action, or enter into any transaction outside the ordinary course of business.

 

(d) Full Access . Each of the Seller and the Company shall permit representatives of the Buyer to have full access at all reasonable times, and in a manner so as not to interfere with the normal business operations of the Company, to all premises, properties, personnel, books, records (including tax records), contracts, and documents of or pertaining to the Company. The Buyer shall treat and hold as such any confidential information it receives from the Company in the course of the reviews contemplated by this Agreement, and shall not use any of the confidential information except in connection with this Agreement, and, if this Agreement is terminated for any reason whatsoever, shall return to the Company all tangible embodiments (and all copies) of the confidential information which are in its possession.

 

(e) Notice of Developments .

 

(i) Any of the Seller and the Company shall notify the Buyer immediately of any development causing a breach of any of the representations and warranties in this Agreement.

 

(ii) Seller and the Company shall give prompt written notice to the Buyer of any material adverse development causing a breach of any of its representations and warranties in this Agreement. No disclosure by the Company pursuant to this subsection (e)(ii), however, shall be deemed to amend or supplement the Disclosure Schedule or to prevent or cure any misrepresentation or breach of warranty.

 

 

  9  
 

 

(f) Exclusivity . The Seller nor the Company shall solicit, initiate, or encourage the submission of any proposal or offer from any other person relating to the acquisition of all or substantially all of the capital stock or assets of any of the Company (including any acquisition structured as a merger, consolidation, or share exchange); provided, however, that the Seller and their directors and officers will remain free to participate in any discussions or negotiations regarding, furnish any information with respect to, assist or participate in, or facilitate in any other manner any effort or attempt by any Person to do or seek any of the foregoing to the extent their fiduciary duties may require

 

8.2 Post-Closing Covenants . The Parties agree as follows with respect to the period following the Closing.

 

(a) General . In case at any time after the Closing any further action is necessary or desirable to carry out the purposes of this Agreement, each of the Parties will take such further action (including the execution and delivery of such further instruments and documents) as any other Party may request, all at the sole cost and expense of the requesting Party (unless the requesting Party is entitled to indemnification therefor as set forth below).

 

(b) Litigation Support . If and for so long as any Party actively is contesting or defending against any action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand in connection with (i) any transaction contemplated under this Agreement or (ii) any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing Date involving the Company, each of the Seller and the Company shall cooperate with Buyer and its counsel in the defense or contest, make available their personnel, and provide such testimony and access to their books and records as shall be necessary in connection with the defense or contest, all at the sole cost and expense of the contesting or defending Party (unless the contesting or defending Party is entitled to indemnification therefor under this Agreement).

 

 

ARTICLE 9

 

DEFAULT, WAIVER AND AMENDMENT

 

9.1 Default.   Upon a breach or default under this Agreement by any of the Parties (following the cure period provided herein), the non-defaulting party shall have all rights and remedies given hereunder or now or hereafter existing at law or in equity or by statute or otherwise.  Notwithstanding the foregoing, in the event of a breach or default by any Party hereto in the observance or in the timely performance of any of its obligations hereunder which is not waived by the non-defaulting Party, such defaulting Party shall have the right to cure such default within 15 days after receipt of notice in writing of such breach or default.

 

9.2 Waiver and Amendment.   Any term, provision, covenant, representation, warranty, or condition of this Agreement may be waived, but only by a written instrument signed by the party entitled to the benefits thereof.  The failure or delay of any party at any time or times to require performance of any provision hereof or to exercise its rights with respect to any provision hereof shall in no manner operate as a waiver of or affect such party's right at a later time to enforce the same.  No waiver by any party of any condition, or of the breach of any term, provision, covenant, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or breach or waiver of any other condition or of the breach of any other term, provision, covenant, representation, or warranty.  No modification or amendment of this Agreement shall be valid and binding unless it be in writing and signed by all Parties hereto.

 

 

ARTICLE 10

 

MISCELLANEOUS

 

10.1 Expenses.   Whether or not the transactions contemplated hereby are consummated, each of the Parties hereto shall bear all taxes of any nature (including, without limitation, income, franchise, transfer, and sales taxes) and all fees and expenses relating to or arising from its compliance with the various provisions of this Agreement and such party's covenants to be performed hereunder, and except as otherwise specifically provided for herein, each of the Parties hereto agrees to pay all of its own expenses (including, without limitation, attorneys and accountants' fees, and printing expenses) incurred in connection with this Agreement, the transactions contemplated hereby, the negotiations leading to the same and the preparations made for carrying the same into effect, and all such taxes, fees, and expenses of the Parties hereto shall be paid prior to Closing.

 

 

  10  
 

 

10.2 Notices.   Any notice, request, instruction, or other document required by the terms of this Agreement, or deemed by any of the Parties hereto to be desirable, to be given to any other party hereto shall be in writing and shall be given by facsimile, personal delivery, overnight delivery, or mailed by registered or certified mail, postage prepaid, with return receipt requested, to the following addresses:

 

The persons and addresses set forth above may be changed from time to time by a notice sent as aforesaid.  If notice is given by facsimile, personal delivery, or overnight delivery in accordance with the provisions of this Section, said notice shall be conclusively deemed given at the time of such delivery.  If notice is given by mail in accordance with the provisions of this Section, such notice shall be conclusively deemed given seven days after deposit thereof in the United States mail.

 

10.3 Entire Agreement .  This Agreement, together with the Schedule and Exhibits hereto, sets forth the entire agreement and understanding of the Parties hereto with respect to the transactions contemplated hereby, and supersedes all prior agreements, arrangements and understandings related to the subject matter hereof.  No understanding, promise, inducement, statement of intention, representation, warranty, covenant, or condition, written or oral, express or implied, whether by statute or otherwise, has been made by any party hereto which is not embodied in this Agreement, or in the schedules or exhibits hereto or the written statements, certificates, or other documents delivered pursuant hereto or in connection with the transactions contemplated hereby, and no party hereto shall be bound by or liable for any alleged understanding, promise, inducement, statement, representation, warranty, covenant, or condition not so set forth.

 

10.4 Survival of Representations .  All statements of fact (including financial statements) contained in the Schedules, the exhibits, the certificates, or any other instrument delivered by or on behalf of the Parties hereto, or in connection with the transactions contemplated hereby, shall be deemed representations and warranties by the respective party hereunder.  All representations, warranties, agreements, and covenants hereunder shall survive the Closing and remain effective regardless of any investigation or audit at any time made by or on behalf of the Parties or of any information a party may have in respect hereto.  Consummation of the transactions contemplated hereby shall not be deemed or construed to be a waiver of any right or remedy possessed by any party hereto, notwithstanding that such party knew or should have known at the time of closing that such right or remedy existed.

 

10.5 Incorporated by Reference .  The schedules, exhibits, and all documents (including, without limitation, all financial statements) delivered as part hereof or incident hereto are incorporated as a part of this Agreement by reference.

 

10.6 Remedies Cumulative .  No remedy herein conferred upon the Parties is intended to be exclusive of any other remedy and each and every such remedy shall be cumulative and shall be in addition to every other remedy given hereunder or now or hereafter existing at law or in equity or by statute or otherwise.

 

10.7 Execution of Additional Documents .  Each Party hereto shall make, execute, acknowledge, and deliver such other instruments and documents, and take all such other actions as may be reasonably required in order to effectuate the purposes of this Agreement and to consummate the transactions contemplated hereby.

 

10.8 Finders' and Related Fees .  Each of the Parties hereto is responsible for, and shall indemnify the other against, any claim by any third party to a fee, commission, bonus, or other remuneration arising by reason of any services alleged to have been rendered to or at the instance of said party to this Agreement with respect to this Agreement or to any of the transactions contemplated hereby.

 

10.9 Governing Law .  This Agreement has been negotiated and executed in the State of Nevada and shall be construed and enforced in accordance with the laws of such state.

 

10.10 Forum .  Each of the Parties hereto agrees that any action or suit which may be brought by any party hereto against any other party hereto in connection with this Agreement or the transactions contemplated hereby may be brought only in a federal or state court in Orange County California or Los Angeles, California.

 

10.11 Professional Fees .  In the event any Party hereto shall commence legal proceedings against the other to enforce the terms hereof, or to declare rights hereunder, as the result of a breach of any covenant or condition of this Agreement, the prevailing party in any such proceeding shall be entitled to recover from the losing party its costs of suit, including reasonable attorneys' fees, accountants’ fees, and experts’ fees.

  

10.12 Binding Effect and Assignment .  This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective heirs, executors, administrators, legal representatives, and assigns.

 

10.13 Counterparts; Facsimile Signatures .   This Agreement may be executed simultaneously in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  The Parties agree that facsimile signatures of this Agreement shall be deemed a valid and binding execution of this Agreement.

 

10.14 Representation . All Parties to this Agreement have been given the opportunity to consult with counsel of their choice regarding their rights under this Agreement.

 

  11  
 

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement, as of the date first written hereinabove.

 

 

INTERNATIONAL PACKAGING AND LOGISTICS GROUP INC.

 

 

 

/s/ Owen Naccarato

By: Owen Naccarato

Its:  Chief Executive Officer

 

 

YIBAOCCYB, LTD.

 

/s/ Xiuhua Song

By:  Xiuhua Song

Its:  Managing Director

 

 

THE SELLER:

 

/s/ Xiuhua Song

Xiuhua Song

 

 

 

 

 

 

  12  

EXHIBIT 10.1

 

STOCK PURCHASE AGREEMENT

 

 

BETWEEN

 

 

XIUHUA SONGSHANDONG

 

TBD CHINA COMPANY.

 

And

 

INTERNATIONAL PACKAGING AND LOGISTICS GROUP, INC.

 

STANDARD RESOURCES LTD.

 

 

 

 

 

 

 

 

 

  1  
 

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT , dated as of May 15, 2016, by and between Xiuhua Song (the “Buyer”), and TBD China Company ( Shangdong Kangfusen Biotech Co. Ltd., a China Company or Shandong Yibao Biologics Co. LTD) and International Packaging and Logistics Group, Inc. (the “Seller”)(the “Company”) and Standard Resources Ltd.. As used herein, the term “Parties” shall be used to refer to the Buyer and the Seller, jointly.

 

WHEREAS:

 

A. The Buyer seeks to acquire Three Million Nine Hundred and Fifteen Thousand (3,915,000) shares of the Common Stock (par value $0.001) (the “Subject Shares”) of International Packaging and Logistics Group, Inc., a Nevada corporation (the “Company”).

 

B. The Seller is willing to sell newly issued shares with all rights, title, and interest to the Subject Shares to the Buyer.

 

C. The Seller warrants and represents that he is sophisticated and experienced in financial and investment matters and holds and will hold, at the Closing, all right, title, and interest in and to the Subject Shares so as to convey full and unencumbered title to the Buyer pursuant to this Agreement.

 

D. The Buyer warrants and represents that he is sophisticated and experienced in financial and investment matters.

 

E. The Company has approved the private sale and transfer of the Subject Shares from the Seller to the Buyer in accordance with this Agreement.

 

F. At the time of the acquisition of the Shares, Buyer shall cause a TBD China Company (Shangdong Kangfusen Biotech Co. Ltd., a China Company or Shandong Yibao Biologics Co. LTD, a China Company) to become owned or controlled by the Company or its subsidiary (“China Acquisition”).

 

G. Subsequent to the acquisition of the Shares by Buyer of the shares and the China Acquisition, IPLO is to vend out H&H Glass back to Standard Resources, (holder of the shares of H&H Glass) in exchange for the return of 3,915,000 common shares of IPLO held and owned by Standard Resources. Such shares shall thereafter be cancelled and returned to the authorized but unissued status under a return to treasury agreement (“H&H Vend Out”).

 

NOW, THEREFORE, in consideration of the premises and the mutual promises herein made, and in consideration of the representations, warranties, and covenants herein contained, the parties agree as follows:

 

ARTICLE I
DEFINITIONS

 

SECTION 1.1. Definitions. The following terms shall have the following meanings for the purposes of this Agreement.

 

  2  
 

 

“Adverse Consequences” means all actions, suits, proceedings, hearings, investigations, charges, complaints, claims, demands, injunctions, judgments, orders, decrees, rulings, damages, dues, penalties, fines, costs, amounts paid in settlement, Liabilities, obligations, Taxes, Liens, losses, expenses, and fees, including court costs and attorneys’ fees and expenses where the aggregate sum of said amount is greater than Two Hundred Fifty Dollars ($250.00).

 

“Affiliate” means, with respect to any specified Person, a Person that directly or indirectly, through one or more intermediaries, controls or is controlled by, or is under common control with, the Person specified.

 

“Affiliated Group” means any affiliated group within the meaning of Code §1504(a) or any similar group defined under a similar provision of state, local or foreign law.

 

“Agreement” means this Stock Purchase Agreement, including all exhibits and schedules hereto, as it may be amended from time to time.

 

“Amendment” has the meaning set forth in Section 6.6 below.

 

“Authority” means any governmental regulatory or administrative body, governmental agency, governmental subdivision or authority, any court or judicial authority, any public, private or industry governmental regulatory authority, whether foreign, national, federal, state or local or otherwise, or any Person lawfully empowered by any of the foregoing to enforce or seek compliance with any regulation.

 

“Backlog” means orders for which there is a specific delivery date for a specified product at a specified price.

 

“Business” means with respect to the Company, the business and assets of the Company as currently conducted as of the date of this Agreement.

 

“Buyer” has the meaning set forth in the preface above.

 

“Buyer’s Representatives” has the meaning set forth in Section 5.4 below.

 

“Buyer Indemnified Parties” has the meaning set forth in Section 8.2 below.

 

“Closing” has the meaning set forth in Section 2.5 below.

 

“Closing Date” has the meaning set forth in Section 2.5 below.

 

“Code” means the Internal Revenue Code of 1986, as amended.

 

“Confidential Information” means any information concerning the Business and affairs of the Company that is not already generally available to the public.

 

“Contract“ means any contract, lease, commitment, understanding, sales order, purchase order, agreement, indenture, mortgage, note, bond, right, warrant, instrument, plan, permit or license, whether written or oral, which is intended or purports to be binding and enforceable.

 

“Directors” shall mean all of the members of the Board of Directors of the Company.

 

“Employee” means each employee and leased employee regardless of whether the term is initially capitalized.

 

  3  
 

 

“Employee Benefit Plan” means any (a) nonqualified deferred compensation or retirement plan or arrangement, (b) qualified defined contribution retirement plan or arrangement which is an Employee Pension Benefit Plan, (c) qualified defined benefit retirement plan or arrangement which is an Employee Pension Benefit Plan (including any Multiemployer Plan), or (d) Employee Welfare Benefit Plan or material fringe benefit or other retirement, bonus, or incentive plan or program.

 

“Employee Pension Benefit Plan” has the meaning set forth in ERISA §3(2).

 

“Employee Welfare Benefit Plan” has the meaning set forth in ERISA §3(1).

 

“Environmental Laws” mean all federal, state, provincial, local and foreign statutes, regulations, ordinances and other provisions having the force or effect of law, all judicial and administrative orders and determinations, all contractual obligations and all common law concerning public health and safety, worker health and safety, and pollution or protection of the environment including, without limitation, all those relating to the presence, use, production, generation, handling, transportation, treatment, storage, disposal, distribution, labeling, testing, processing, discharge, release, threatened release, control, or cleanup of any Hazardous Substances, materials or wastes, chemical substances or mixtures, pesticides, pollutants, contaminants, toxic chemicals, petroleum products or byproducts, asbestos, polychlorinated biphenyls, noise or radiation, each as amended and as now or hereafter in effect, including (but not limited to) the Comprehensive Environmental Response, Compensation and Liability Act of 1980, the Superfund Amendments and Reauthorization Act of 1986, as amended, the Resource Conservation and Recovery Act of 1976, as amended, the Toxic Substances Control Act of 1976, as amended, the Federal Water Pollution Control Act Amendments of 1972, the Clean Water Act of 1977, as amended, and any other similar federal, state, or local statutes.

 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.

 

“Escrow Agent” means the Law Office of Eric Stoppenhagen.

 

“ERISA Affiliate” means, with respect to the Company, any other Person that, together with the Company, would be treated as a single employer under Section 414 of the Code.

 

“Escrow Agreement” shall mean the Escrow Agreement entered into by and among the Buyer, the Seller and the Escrow Agent with respect to the Escrowed Funds, in the form attached hereto as Exhibit A with only such changes as shall be in form and substance satisfactory to the parties, acting reasonably.

 

“Escrowed Funds” has the meaning set forth in Section 2.3 below.

 

“Financial Statements” means the following:

 

(a) the audited financial statements of the Company for the fiscal year ended December 31, 2015, consisting of the balance sheet at such dates and the related statements of earnings and cash flows for the corresponding periods then ended; and

 

(b) the interim unaudited (reviewed) financial statements of Company for the three (3) month period ended March 31, 2016.

 

“GAAP” means United States generally accepted accounting principles as in effect from time to time as consistently applied by the Company.

 

“Hazardous Substance” means any material or substance which (i) constitutes a hazardous substance, toxic substance or pollutant (as such terms are defined by or pursuant to any Environmental Laws) or (ii) is regulated or controlled as a hazardous substance, toxic substance, pollutant or other regulated or controlled material, substance or matter pursuant to any Environmental Laws.

 

  4  
 

 

“Indemnified Party” has the meaning set forth in Section 8.4 below.

 

“Indemnifying Party” has the meaning set forth in Section 8.4 below.

 

“Intellectual Property” means (a) all inventions (whether patentable or unpatentable and whether or not reduced to practice), all improvements thereto, and all patents, patent applications, and patent disclosures, together with all reissuances, continuations, continuations-in-part, revisions, extensions, and reexaminations thereof, (b) all trademarks, service marks, trade dress, logos, trade names, and corporate names, together with all translations, adaptations, derivations, and combinations thereof and including all goodwill associated therewith, and all applications, registrations, and renewals in connection therewith, (c) all copyrightable works, all copyrights, and all applications, registrations, and renewals in connection therewith, (d) all mask works and all applications, registrations, and renewals in connection therewith, (e) all trade secrets and confidential business information (including ideas, research and development, know-how, formulas, compositions, manufacturing and production processes and techniques, technical data, designs, drawings, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), (f) all computer software (including data and related documentation), (g) all other proprietary rights, and (h) all copies and tangible embodiments thereof (in whatever form or medium).

 

“Knowledge” means what is known or should have been known after reasonable investigation.

 

“Latest Balance Sheet” means the unaudited balance sheet of the Company dated as of March 31, 2016 as filed with the Securities and Exchange Commission.

 

“Law” means any law, statute, regulation, ordinance, rule, order, decree, judgment, consent decree, settlement agreement or governmental requirement enacted, promulgated, entered into, agreed or imposed by any Authority.

 

“Leased Property” has the meaning set forth in Section 3.14(b) below.

 

“Leases” has the meaning set forth in Section 3.14(b) below.

 

“Liability” means any liability (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due), including any liability for Taxes.

 

“Lien” means any mortgage, lien (except for any lien for Taxes not yet due and payable), charge, restriction, pledge, security interest, option, lease or sublease, claim, right of any third party, easement, encroachment or encumbrance.

 

“Limit Amount” shall mean $225,000.

 

“Material Adverse Effect” shall mean any circumstances, developments or matters whose effect on the Company, its prospects, either alone or in the aggregate, is or would reasonably expected to be materially adverse including, but not limited to, the assertion of any claims relating to or arising out of any undisclosed liability.

 

“Multiemployer Plan” has the meaning set forth in ERISA §3(37).

 

“Name Change” has the meaning set forth in Section 6.6 below.

 

“Ordinary Course of Business” means the ordinary course of business consistent with past custom and practice (including with respect to quantity and frequency).

 

  5  
 

 

“Owned Property” has the meaning set forth in Section 3.14(a) below.

 

“PBGC” means the Pension Benefit Guaranty Corporation.

 

“Permits” has the meaning set forth in Section 3.28 below.

 

“Person” means an individual, a partnership, a corporation, an association, a joint stock company, a trust, a joint venture, an unincorporated organization, or a governmental entity (or any department, agency, or political subdivision thereof).

 

“Purchase Price” means Two Hundred and Twenty-Five Thousand Dollars ($225,000).

 

“Schedules” means the disclosure schedules accompanying this Agreement.

 

“Securities Act” means the Securities Act of 1933, as amended.

 

“Securities Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

“Seller” has the meaning set forth in the preface above.

 

“Share Issuance Documents” means (a) a letter of instruction from the Seller to the Transfer Agent instructing the Transfer Agent to issue the Subject Shares to the Buyer, and (b) a stock power duly endorsed by the Seller to sell, transfer, convey and assign the Subject Shares to the Buyer (which shall include a guarantee of the Seller’s signature by an Eligible Guarantor, as provided on the stock power), both of which documents are in form and substance satisfactory to the Buyer and the Transfer Agent.

 

“Shares” means shares of the Company’s Common Stock (par value $0.001).

 

“Subject Shares” means the 3,915,000 newly issued shares of common stock, par value $0.001 per share, of the Company.

 

“Subsidiary” means any corporation, partnership or limited liability company with respect to which a specified Person (or a Subsidiary thereof) owns, directly or indirectly, a majority of the common stock or other equity securities or has the power to vote or direct the voting of sufficient securities to elect a majority of the directors or other managing body.

  

“Tax” means any federal, state, local, or foreign income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes under Code §59A), customs duties, capital stock, franchise, profits, withholding, social security (or similar), unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.

 

“Tax Return” means any return, declaration, report, claim for refund, or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

 

“Transfer Agent” means Jersey Transfer and Trust Company, the Company’s transfer agent for the Shares.

 

“Third Party Claim” has the meaning set forth in Section 8.4 below.

 

  6  
 

 

“Threshold Amount” has the meaning set forth in Section 8.2(a) below.

 

“Transaction” means the acquisition by the Buyer of all of the Subject Shares of the Company from the Seller, which is the subject of this Agreement.

 

“Ancillary Transaction Documents” Documents related to China Acquisition and H&H Vend Out.

 

ARTICLE II
PURCHASE AND SALE OF THE SUBJECT SHARES

 

 

SECTION 2.1. Basic Transaction. On and subject to the terms and conditions of this Agreement, the Buyer agrees to purchase from the Seller, and the Seller agrees to sell, or cause to be sold, to the Buyer, all of the Subject Shares for the Purchase Price specified herein.

 

SECTION 2.2. Payment of Purchase Price; Deposit of Share Issuance Documents. The Buyer shall deposit with the Escrow Agent (pursuant to the terms of the Escrow Agreement) the sum of $125,000 (“Escrowed Funds”). The Escrowed Funds and the previously paid $100,000 deposit (“Deposit”) shall constitute payment for the Purchase Price for the purchase of the Subject Shares and the Seller shall deposit with the Escrow Agent the Share Issuance Documents and all other Ancillary Transaction Documents.

 

SECTION 2.3. At the time of the acquisition of the Shares, Buyer shall cause a TBD China Company to become owned or controlled by the Company or its subsidiary (“China Acquisition”).

 

Subsequent to the acquisition of the Shares by Buyer of the shares and China Acquisition, IPLO is to vend out H&H Glass back to Standard Resources, (holder of the shares of H&H Glass) in exchange for the return of 3,915,000 common shares of IPLO held and owned by Standard Resources. Such shares shall thereafter be cancelled and returned to the authorized but unissued status under a return to treasury agreement (“H&H Vend Out”).

 

SECTION 2.4. The Closing. The closing of this Transaction (the “Closing”) shall take place at 7700 Irvine Center Drive, Suite 870, Irvine, California, commencing at 10:00 a.m. PST time on the earlier of (i) July 01, 2016 or (ii) five (5) business days following the satisfaction or waiver of all conditions to the obligations of the parties to consummate this Transaction (other than conditions with respect to actions the respective parties will take at the Closing itself) or such other date as the parties may mutually determine, but in any event no later than July 01, 2016 unless mutually agreed to extend (the date of the Closing, the “Closing Date”). It is the intent of the parties that the Buyer shall assume control of the Company immediately at the Closing. The Closing will include the China Acquisition and H&H Vend Out as set forth in Ancillary Documents.

 

SECTION 2.5. Closing Deliveries by the Seller. To effect the transfer of the Subject Shares and the delivery of the Purchase Price, the Seller shall deliver the following at the Closing:

 

(a) a total of 3,915,000 shares in certificate form, all of which are and shall be, at Closing, free and clear of any and all Liens, which shall be effected by delivery to Buyer or, at the direction of Buyer, to the Transfer Agent, the Share Issuance Documents;

 

  7  
 

 

(b) all consents, approvals, releases and waivers from governmental Authorities and other third parties required or necessary to consummate this Transaction satisfactory in form and substance to the Buyer and its counsel;

 

(c) an executed copy of the Escrow Agreement as duly executed by the Seller and the Escrow Agent;

 

(d) manually executed Action of the Board of Directors of the Company electing the Buyer’s nominee(s) as the Director (s) of Company’s Board of Directors and as the President, Chief Financial Officer and Secretary of the Company and accepting the resignation of all current Directors of the Company’s Board of Directors; and all current officers of the Company; The resignation of all current directors will take place concurrent with the H&H Vend Out.

 

(e) a certificate of the Company’s President, Chief Financial Officer and Secretary, Owen Naccarato, certifying that the statements made in this Agreement are accurate and complete and that this Agreement has been duly approved by the Company’s Board of Directors, both as reasonably determined by the Buyer;

 

(f) manually-executed resignation of the Company’s current officers and directors to be effective as of the H&H Vend Out;

 

(g) all documents, instruments, codes and utilities to allow the Buyer and the Buyer’s nominee to upload filings for the Company with Edgar and FINRA;

 

(h) a copy of all of the Company’s federal tax returns, as filed with the U.S. Internal Revenue Service, respectively, for the tax year ended December 31, 2015;

 

(i) a copy of all available Board and Shareholder minutes and actions from inception of the Company to the present that the Company’s officers have in their position;

 

(j) all other documents required to be delivered to the Buyer pursuant to Section 3.7 or Article VI hereof not specifically mentioned above in this Section 2.5; and

 

(k) Buyer will assume responsibility for all filings under the Securities and Exchange Act to the extent applicable.

 

(l) QuickBooks data file.

 

All instruments and documents executed and delivered to the Buyer pursuant hereto shall be in form and substance and shall be executed in a manner satisfactory to the Buyer and its counsel.

 

SECTION 2.6. Closing Deliveries by the Buyer. To effect the transfer referred to in Section 2.1 hereof and the delivery of the Purchase Price, the Buyer shall deliver the following to the Escrow Agent at the Closing:

 

(a) a wire transfer delivered to and payable to the Escrow Agent in an amount equal to the Escrowed Funds;

 

(b) a duly executed copy of the Escrow Agreement as executed by the Buyer; and

 

(c) all other documents required to be delivered to the Seller pursuant to Article VII hereof not specifically mentioned above in this Section 2.6,

 

All instruments and documents executed and delivered to the Seller pursuant hereto shall be in form and substance, and shall be executed in a manner, satisfactory to the Seller and his counsel.

 

  8  
 

 

ARTICLE III
REPRESENTATIONS OF THE SELLER

 

The Seller hereby represents and warrants to the Buyer that the statements contained in this Article III are correct and complete as of the date of this Agreement, and except as amended pursuant to Section 5.8, will be correct and complete as of the Closing Date (as though made then and as though the Closing Date were substituted for the date of this Agreement throughout this Article III), except as set forth in the Schedules hereto. Nothing in the Schedules shall be deemed adequate to disclose an exception to a representation or warranty made herein, however, unless the Schedule identifies the exception with reasonable particularity. Without limiting the generality of the foregoing, the mere listing (or inclusion of a copy) of a document or other item shall not be deemed adequate to disclose an exception to a representation or warranty made herein (unless the representation or warranty has to do with the existence of the document or other item itself). An item disclosed in any Schedule shall be deemed disclosed for purposes of all Schedules.

 

SECTION 3.1. Authorization of Transaction. The Seller has full power and authority to execute and deliver this Agreement and to perform his obligations hereunder. This Agreement constitutes the valid and legally binding obligation of the Seller, enforceable in accordance with its terms and conditions. The Seller need not give any notice to, make any filing with, or obtain any authorization, consent, or approval of any government or governmental agency in order to consummate this Transaction.

 

SECTION 3.2. Brokers’ Fees. Neither the Seller nor the Company has any Liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to this Transaction for which the Buyer or the Company could become liable or obligated.

 

SECTION 3.3. The Subject Shares. The Seller is authorized to issue all of the Subject Shares, free and clear of any restrictions on transfer (other than any restrictions under the Securities Act and state securities Laws), Taxes, Liens, options, warrants, purchase rights, Contracts, commitments, equities, claims, and demands. The Seller is not a party to any option, warrant, purchase right, or other Contract or commitment that could require the Seller to not sell, transfer, or otherwise dispose of any of the Subject Shares (other than this Agreement). The Seller is not a party to any voting trust, proxy, or other agreement or understanding. The transfer of the Subject Shares to the Buyer in accordance with this Agreement do not require any registration, filing or other notification under any Federal or State securities Laws.

 

SECTION 3.4. Organization, Qualification, and Corporate Power.

 

(a) The Company is a corporation duly organized, validly existing, and in good standing under the Laws of the State of Nevada. The Company is duly authorized to conduct business and is in good standing under the Laws of each jurisdiction except where the failure to be so qualified would not have a Material Adverse Effect on the Company. The Company has full corporate power and authority and all licenses, Permits, and authorizations necessary to carry on the Business in which it is engaged and to own and use the properties owned and used by it. The copies of the Certificate of Incorporation and Bylaws of the Company (as amended to date) which have been delivered to the Buyer are correct and complete. The minute books (containing the records of meetings of the stockholders, the board of directors, and any committees of the board of directors), the stock certificate books, and the stock record books of the Company are correct and complete. The Company is not in default under or in violation of any provision of its Certificate of Incorporation or Bylaws.

 

  9  
 

 

SECTION 3.5. Capitalization.

 

(a) The entire authorized capital stock of the Company consists of 900,000,000 Shares, of which 4,504,214 shares are issued and outstanding, 50,000,000 shares of blank check preferred stock, $0.0001 par value, of which 974,730 shares of Series A are issued and outstanding, and no shares are held in treasury. All of the issued and outstanding Shares of the Company have been duly authorized, are validly issued, fully paid, and non-assessable, and 3,915,000 Subject Shares are available for issuance by the Seller. There are no outstanding or authorized options, warrants, purchase rights, subscription rights, conversion rights, exchange rights, or other Contracts or commitments that could require the Company to issue, sell, or otherwise cause to become outstanding any of the Shares of the Company. There are no outstanding or authorized stock appreciation, phantom stock, profit participation, or similar rights with respect to the Shares of the Company. There are no voting trusts, proxies, or other agreements or understandings with respect to the voting of the Shares of the Company.

 

(b) The assignments, endorsements, stock powers and other instruments of transfer delivered by the Seller to the Buyer at the Closing will be sufficient to transfer the Seller’s entire interest, legal and beneficial, in the Subject Shares and, after such transfer, the Buyer shall own all of the Subject Shares. The Seller has full power and authority (including full corporate power and authority) to convey good and marketable title to all of the Subject Shares, and upon transfer to the Buyer of the certificates representing such Subject Shares, the Buyer will receive good and marketable title to the Subject Shares, free and clear of all Liens.

 

SECTION 3.6. Noncontravention. Neither the execution and the delivery of this Agreement, nor the consummation of this Transaction will (i) violate any constitution, Law, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government, governmental agency, or court to which the Seller or the Company is subject or any provision of the Articles of Incorporation or Bylaws of the Company, or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under any Contract, lease, license, instrument, or other arrangement to which either the Seller or the Company is a party or by which either is bound or to which any of their respective assets are subject (or result in the imposition of any Lien upon any of or their assets). The Company does not need to give any notice to, make any filing with, or obtain any authorization, consent, or approval of any government or governmental agency in order for the parties to consummate this Transaction (does not take into account any desired Company related corporate actions with FINRA as relates to this Transaction).

 

SECTION 3.7. Settlement of All Liabilities. At the Closing, the Seller agrees that the Company shall deliver to Buyer executed agreements, as reasonably acceptable to the Buyer, showing the release and settlement of all debts, obligations, commitments, and liabilities, whether accrued or contingent, whether oral or written, of the Company if any.

 

SECTION 3.8. Subsidiaries. Accept as listed in Schedule 3.8, the Company does not have any direct or indirect Subsidiaries, either wholly or partially owned and the Company does not have any direct or indirect economic, voting or management interest in any Person or own any securities issued by any Person.

 

  10  
 

 

SECTION 3.9. Financial Statements. The Financial Statements of the Company are set forth in the Company’s filings on www.sec.gov. The Financial Statements have been and will be prepared in accordance with GAAP and present fairly the financial position, assets and Liabilities of the Company as of the dates thereof and the revenues, expenses, results of operations of the Company for the periods covered thereby. The Financial Statements were prepared from the books and records of the Company and do not reflect any transactions which are not bona fide transactions.

 

SECTION 3.10 Events Subsequent to Latest Balance Sheet. Since the date of the Latest Balance Sheet, there has not been any change in the Business, financial condition, operations, results of operations, or future prospects of the Company or in any item set forth on any of the Schedules attached hereto, which would have a Material Adverse Effect on the Company. Without limiting the generality of the foregoing, since the date of the Latest Balance Sheet:

 

(a) the Company has not sold, leased, transferred, or assigned any of its assets, tangible or intangible, except that it will use its cash on hand to settle a portion of its Liabilities, as contemplated in Section 3.11;

 

(b) the Company has not entered into any Contract, lease, or license (or series of related Contracts, leases, and licenses) involving more than Two Hundred Dollars ($200.00) either individually or in the aggregate or outside the Ordinary Course of Business to which the Company is or will be bound on or after the Closing;

 

(c) no party (including the Company) has accelerated, terminated, modified, or canceled any agreement, Contract, lease or license (or series of related Contracts, leases and licenses) to which the Company is a party or by which it is or will be bound on or after the Closing;

 

(d) the Company has not imposed and is not aware of any Lien upon any of its assets, tangible or intangible to which the Company is or will be bound on or after the Closing;

 

(e) the Company has not made any capital investment in, any loan to, or any acquisition of the securities or assets of, any other Person (or series of related capital investments, loans, and acquisitions) to which the Company is or will be bound on or after the Closing;

 

(f) the Company has not issued any note, bond, or other debt security or created, incurred, assumed, or guaranteed any indebtedness for borrowed money or capitalized lease obligation involving more than One Hundred Dollars ($100.00) either individually or in the aggregate to which the Company is or will be bound on or after the Closing;

 

(g) [Intentionally Omitted];

 

(h) the Company has not delayed or postponed the payment of accounts payable and other Liabilities outside the Ordinary Course of Business to which the Company is or will be bound on or after the Closing;

 

(i) the Company has not cancelled, compromised, waived, or released any right or claim (or series of related rights and claims) either involving more than One Hundred Dollars ($100.00) either individually or in the aggregate or outside the Ordinary Course of Business to which the Company is or will be bound on or after the Closing;

 

(j) the Company has not granted any license or sublicense of any rights under or with respect to any Intellectual Property to which the Company is or will be bound on or after the Closing;

 

  11  
 

 

(k) there has been no change made or authorized in the Certificate of Incorporation or Bylaws of the Company, except the Name Change, and there are no commitments or arrangements which would reasonably cause or result in such change;

 

(l) the Company has not issued, sold, or otherwise disposed any of its capital stock, or granted any options, warrants, or other rights to purchase or obtain (including upon conversion, exchange, or exercise) any of its capital stock to which the Company is or will be bound on or after the Closing;

 

(m) the Company has not declared, set aside, or paid any dividend or made any distribution with respect to its capital stock (whether in cash or in kind) or redeemed, purchased, or otherwise acquired any capital stock;

 

(n) the Company does not have any outstanding any loan from, or entered into any other transaction with, any of its Directors, officers, employees or Affiliates;

 

(o) the Company is not a party to any employment Contract or collective bargaining agreement, written or oral, or modified the terms of any existing such Contract or agreement;

 

(p) at Closing, the Company will not have any obligation to any Person for any employment compensation, consulting fees, or any taxes arising out of or related thereto;

 

(q) the Company has no outstanding bonus, profit sharing, incentive, severance, or other plan, Contract, or commitment for the benefit of any of its Directors, officers, and employees (or taken any such action with respect to any other Employee Benefit Plan); and

 

(r) there has not been any other occurrence, event, incident, action, failure to act, or transaction outside the Ordinary Course of Business of the Company.

 

SECTION 3.11. Undisclosed Liabilities; Contracts.

 

(a) Except as set forth on Schedule 3.11 , the Company has no Liability (and to the Knowledge of the Seller and the Directors and officers of the Company, there is no basis for any present or future action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand against it giving rise to any Liability), except for Liabilities set forth on the face of the Latest Balance Sheet (rather than in any notes thereto). None of the Liabilities set forth on the face of the Latest Balance Sheet results from, arises out of, relates to, is in the nature of, or was caused by any breach of Contract, breach of warranty, tort, infringement, or violation of Law or arose out of any charge, complaint, actions, suit, claim, proceeding or demand. Without limiting the generality of the foregoing, Seller acknowledges that the Company has no Liabilities owing or potentially owing to Seller. At Closing, the Seller will pay the “Settled Amount” with respect to the liabilities set forth on Schedule 3.11 in full satisfaction of such liabilities. After such payments, the Company will have no Liabilities.

 

(b) Schedule 3.18 sets forth all Contracts to which the Company is a party or with respect to which the Company has or could have any Liability.

 

SECTION 3.12. Legal Compliance. The Company has complied with all applicable Laws (including rules, regulations, codes, plans, injunctions, judgments, orders, decrees, rulings, and charges there under) of federal, state, local, and foreign governments (and all agencies thereof), and, to the Knowledge of the Seller and the Directors and officers the Company, no action, suit, proceeding, hearing, investigation, charge, complaint, claim, demand, or notice has been filed or commenced against the Company or any of them alleging any failure so to comply.

 

  12  
 

 

SECTION 3.13. Tax Matters.

 

(a) The Company has filed all Tax Returns that it has been required to file for all periods through and including the Closing Date. All such Tax Returns were correct and complete in all respects. All Taxes owed by the Company (whether or not shown on any Tax Return) have been timely paid. The Company has not requested or been granted any extension of time within which to file any Tax Return.

 

(b) The Company has maintained adequate provision for all unpaid Liabilities for Taxes, whether or not disputed, that have accrued with respect to or are applicable to the period ended on and including the Closing Date or to any years and periods prior thereto and for which the Company may be directly or contingently liable in its own right or as a transferee of the assets of, or successor to, any Person. The Company has not incurred any Tax Liabilities other than in the Ordinary Course of Business for any taxable year for which the applicable statute of limitations has not expired. No claim has ever been made by an Authority in a jurisdiction where the Company does not pay Taxes or file Tax Returns and is or may be subject to taxation by that jurisdiction. There are no Liens on any of the assets of any of the Company that arose in connection with any failure (or alleged failure) to pay any Tax.

 

(c) Since inception, none of the Tax Returns of the Company have ever been audited or investigated by any taxing Authority, and no facts exist which would constitute grounds for the assessment of any additional Taxes by any taxing Authority with respect to the taxable years covered in such Tax Returns. No issues have been raised in any examination by any taxing Authority with respect to the businesses and operations of the Company which, by application of similar principals, reasonably could be expected to result in a proposed adjustment to the Liability for Taxes for any other period not so examined. Neither the Seller nor the Directors or officers (or employees responsible for Tax matters) of the Company have received, or expect to receive, from any taxing Authority any written notice of a proposed adjustment, deficiency, underpayment of Taxes or any other such notice which has not been satisfied by payment or been withdrawn, and no claims have been asserted relating to such Taxes against the Company.

 

(d) Schedule 3.13 lists all federal, state, local, and foreign income Tax Returns filed with respect to the Company for the prior four taxable periods for which the applicable statue of limitations has not expired, none of those Tax Returns have been audited, and none of those Tax Returns that currently are the subject of audit. The State of Nevada has no state taxes, so the Company has not been required to file any Tax Returns with the State of Nevada. The Seller has delivered to the Buyer the prior four years of correct and complete copies of all federal, state, local and foreign income Tax Returns, examination reports, and statements of deficiencies assessed against or agreed to by the Company for taxable periods for which the applicable statute of limitations has not expired. The Company has not waived any statute of limitations in respect of Taxes or agreed to any extension of time with respect to a Tax assessment or deficiency.

 

(e) The Company has withheld and paid all Taxes required to have been withheld and paid including, without limitation, sales and use taxes, and all Taxes in connection with amounts paid or owing to any employee, independent contractor, creditor, stockholder, or other third party.

 

(f) The Company has not filed a consent to the application of Section 341(f) of the Code.

 

  13  
 

 

(g) The Company will not be required, as a result of (i) a change in accounting method for a Tax period beginning on or before the Closing Date, to include any adjustment under Section 481(c) of the Code (or any corresponding provision of state, local or foreign Tax Law) in taxable income for any Tax period beginning on or after the Closing Date, or (ii) any “closing agreement,” as described in Section 7121 of the Code (or any corresponding provision of state, local or foreign Tax Law), to include any item of income in, or exclude any item of deduction from, any Tax period beginning on or after the Closing Date.

 

(h) The Company has disclosed on its income Tax Returns all positions taken therein that could give rise to an accuracy-related penalty under Section 6662 of the Code (or any corresponding provision of Tax law).

 

(i) The Company has not made any payments, is not obligated to make any payments and is not a party to any agreement that under any certain circumstances could obligate it to make any “excess parachute payment” as defined in Section 280G of the Code or any payments that will not be deductible under Section 162(m) of the Code.

 

(j) The Company is not a party to any Tax allocation or sharing agreement. The Company is not subject to any joint venture, partnership or other arrangement or Contract which is treated as a partnership for federal income Tax purposes.

 

(k) None of the assets of the Company constitutes tax-exempt bond financed property or tax-exempt use property within the meaning of Section 168 of the Code, and none of the assets reflected on the Financial Statements is subject to a lease, safe harbor lease or other arrangement as a result of which the Company holding legal title to the asset is not treated as the owner for federal income Tax purposes.

 

(l) The basis of all depreciable or amortizable assets, and the methods used in determining allowable depreciation or amortization (including cost recovery) deductions of the Company, are correct and in compliance with the Code and the regulations thereunder in all material respects.

 

(m) The Seller is not a “foreign person” as defined in Section 1445(f)(3) of the Code.

 

(n) The Company has not: (A) been a member of an Affiliated Group filing a consolidated federal income Tax Return or (B) any Liability for the Taxes of any Person (other than itself) under Treas. Reg. §1.1502-6 (or any similar provision of state, local, or foreign Law), as a transferee or successor, by Contract, or otherwise.

 

(o) The Company is not a party to or otherwise subject to any arrangement having the effect of or giving rise to the recognition of a deduction or loss in a taxable period ending on or before the Closing Date and a corresponding recognition of taxable income or gain in a taxable period ending after the Closing Date, or any other arrangement that would have the effect of or give rise to the recognition of taxable income or gain in a taxable period ending after the Closing Date without the receipt of or entitlement to a corresponding amount of cash.

 

SECTION 3.14. Real Property.

 

(a) The Company does not own or hold any interest in any real property. In addition, the Company does not own or hold any leases, subleases, licenses, concessions, or other Contracts, written or oral, granting to any party or parties the right of use or occupancy of any portion of the parcel of Owned Property. The Company does not hold any real property leased or subleased to it (the “Leased Property”).

 

  14  
 

 

SECTION 3.15. Intellectual Property.

 

(a) The Company does not own or hold any interest in any Intellectual Property.

 

(b) To the Knowledge of the Seller, there are no outstanding or threatened claims asserting that the Company has interfered with, infringed upon, misappropriated, or otherwise come into conflict with, any Intellectual Property rights of third parties.

 

SECTION 3.16. Tangible Assets. The Company does not own any machinery, equipment, and other tangible assets necessary for the conduct of its Businesses as presently conducted.

 

SECTION 3.17. Inventory. The Company has no Inventory.

 

SECTION 3.18. Contracts. At Closing the Company is not and shall not be liable under any contracts to any third party, except as set forth on Schedule 3.18.

 

SECTION 3.19. Notes and Accounts Receivable. There are no notes or accounts receivable of the Company.

 

SECTION 3.20. Powers of Attorney. There are no outstanding powers of attorney executed on behalf of the Company.

 

S ECTION 3.21. Insurance. The Company has not maintained any insurance at any time. The Seller is not aware of any claims against the Company that are not covered by insurance.

 

SECTION 3.22. Litigation. The Company is not a party to any Litigation and is not (a) subject to any outstanding injunction, judgment, order, decree, ruling, or charge or (b) a party or, to the Knowledge of the Seller, threatened to be made a party to any action, suit, proceeding, baring, or investigation of, in, or before any court or quasi-judicial or administrative agency of any federal, state, local, or foreign jurisdiction or before any arbitrator. There are no known actions, suits, proceedings, hearings, and investigations which would reasonably be expected to result in any adverse change in the business, financial condition, operations, results of operations, or future prospects of the Company. The Seller has no reason to believe that any such action, suit, proceeding, hearing, or investigation may be brought or threatened against the Company. Neither the Seller nor the Company has any Liability with respect to any claims or threatened claims by third parties relating to any sale or proposed sale of the Subject Shares or any other securities of the Company. Neither the Seller nor the Company is a party to any litigation relating to such claims and, to the Knowledge of the Seller, no such litigation is threatened.

 

SECTION 3.23. Product Warranty. The Company has not manufactured, sold, or delivered any product or service to any Person.

 

SECTION 3.24. Product Liability. The Company does not have Liability (whether known or unknown, whether asserted or unasserted, whether absolute or contingent, whether accrued or unaccrued, whether liquidated or unliquidated, and whether due or to become due) arising out of any injury to individuals or property.

 

SECTION 3.25. Directors, Officers and Employees. The Company has no employees. The Company has no Liability to any current or former officer, director, employee, consultant, contractor, and other Person, other than the Liabilities set forth on Schedule 3.11, both of which will be settled in full at Closing for the “Settled Amounts” set forth on Schedule. 3.11.

 

  15  
 

 

SECTION 3.26. Employee Benefits.

 

(a) General. The Company (x) is not and has never been a plan sponsor of, (y) does not and never has been, required to maintain, contribute to or participate in, and (z) has no Liability or contingent Liability with respect to:

 

(i) any Employee Welfare Benefit Plan or Employee Pension Benefit Plan;

 

(ii) any retirement or deferred compensation plan, incentive compensation plan, stock plan, unemployment compensation plan, vacation pay, severance pay, bonus or benefit arrangement, insurance or hospitalization program or any other fringe benefit arrangements for any current or former employee, director, consultant or agent, whether pursuant to Contract, arrangement, custom or informal understanding, which does not constitute an Employee Welfare Benefit Plan or Employee Pension Benefit Plan; or

 

(iii) any employment agreement.

 

(b) Compliance with Employee Benefit Laws; Liabilities. The Company has no Liability under any Employee Benefit Plans and the Company has no Liability or contingent Liability for providing, under any Employee Benefit Plan or otherwise, any post-retirement medical or life insurance benefits. The Company does not contribute to, has not contributed to, does not participate in, and has not participated in, and has no Liability or contingent Liability with respect to any Multiemployer Plan.

 

SECTION 3.27. Environmental Matters. The Company and its Affiliates has complied and is in compliance with all Environmental Laws and no action, suit, proceeding, hearing, investigation, charge, complaint, claim, demand or notice has been filed or, to the Knowledge of the Seller or the Company, commenced against any of them alleging any such failure to comply.

 

SECTION 3.28. Improper and Other Payments.

 

(a) None of the Company or any Affiliate or any Person acting on behalf of either of them, has made, paid or received any bribes, kickbacks or other similar payments to or from any Person, whether lawful or unlawful;

 

(b) No contributions have been made, directly or indirectly, to a domestic or foreign political party or candidate.

 

(c) No improper foreign payment (as defined in the Foreign Corrupt Practices Act) has been made; and

 

(d) The internal accounting controls of the Company are adequate to detect any of the foregoing.

 

SECTION 3.29. Investments/Loans; Affiliates; Bank Accounts.

 

(a) On the Closing Date the Company shall have no equity interests in, or loans or other advances to or from any third party.

 

  16  
 

 

(b) The only bank, brokerage or similar account maintained by the Company is. This account will be closed concurrent with closing.

 

SECTION 3.30. Taxes. On the Closing Date the Company shall have no Liability for any Taxes with respect to any periods ending on or before the Closing Date.

 

SECTION 3.31. Pension. On the Closing Date, the Company shall have made all contributions required under the terms of all Employee Benefit Pension Plans and shall have made all contributions which have accrued on its books as of the Closing Date .

 

SECTION 3.32. Debt. On the Closing Date, the Company will not have any Liabilities unless the Buyer’s written consent thereto has been delivered by the Buyer to the Seller before the Closing Date.

 

SECTION 3.33. SEC Reporting; Issuance of Securities. The Company is subject to the reporting requirements of the Securities Exchange Act pursuant to Section 15(d) of the Securities Exchange Act. The Company does not have a class of securities registered under Section 12(b) or 12(g) of the Securities Exchange Act. All of the filings required to be made by the Company with the Securities and Exchange Commission, including without limitation under the Securities Act or the Securities Exchange Act, until the Closing Date have been made when required to be made and each such filing did not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements contained herein or therein, in light of the circumstances in which they are made, not misleading. All securities that have been issued by the Company were issued in compliance with all applicable Federal, State or foreign securities laws.

 

SECTION 3.34. Accuracy of Statements. Neither this Agreement nor any Schedule, exhibit, statement, list, document, certificate or other information furnished or to be furnished by or on behalf of the Seller to the Buyer or any of the Buyer’s Representatives or any Affiliate of the Buyer in connection with this Agreement or this Transaction contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary to make the statements contained herein or therein, in light of the circumstances in which they are made, not misleading.

 

ARTICLE IV
REPRESENTATIONS AND WARRANTIES OF THE BUYER

 

The Buyer represents and warrants to the Seller that the statements contained in this Article IV are correct and complete as of the date of this Agreement and will be correct and complete as of the Closing Date (as though made then and as though the Closing Date were substituted for the date of this Agreement throughout this Article IV).

 

SECTION 4.1. [Intentionally Omitted] .

 

SECTION 4.2. Authorization of Transaction. The Buyer has full power and authority to execute and deliver this Agreement and to perform his obligations hereunder. This Agreement constitutes the valid and legally binding obligation of the Buyer, enforceable in accordance with its terms and conditions. The Buyer need not give any notice to, make any filing with, or obtain any authorization, consent, or approval of any government or governmental agency in order to consummate this Transaction.

 

SECTION 4.3. Noncontravention. Neither the execution and the delivery of this Agreement, nor the consummation of this Transaction, will (i) violate any constitution, Law, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government, governmental agency, or court to which the Buyer is subject or (ii) conflict with, result in a breach of, constitute a default under, result in the acceleration of, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice or consent under any agreement, Contract, lease, license, instrument, or other arrangement to which the Buyer is a party or by which it is bound or to which any of his assets is subject.

 

  17  
 

 

SECTION 4.4. Brokers’ Fees. The Buyer has no Liability or obligation to pay any fees or commissions to any broker, finder, or agent with respect to this Transaction for which the Seller could become liable or obligated.

 

SECTION 4.5. Accuracy of Statements. Neither this Agreement nor any Schedule, exhibit, statement, list, document, certificate or other information furnished or to be furnished by or on behalf of the Buyer to the Seller or any representative or Affiliate of the Seller in connection with this Agreement or this Transaction contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary to make the statements contained herein or therein, in light of the circumstances in which they are made, not misleading.

 

ARTICLE V
COVENANTS

 

SECTION 5.1. General. Each of the parties will use his or its best efforts to take all action and to do all things necessary in order to consummate and make effective this Transaction (including satisfaction, but not waiver, of the closing conditions set forth in Articles VI and VII below).

 

SECTION 5.2. Notices and Consents. The Seller will cause the Company to give any notices to third parties, and will cause the Company to obtain any third party consents, that the Buyer may reasonably request.

 

SECTION 5.3. Operation of Business. From the date of this Agreement until the Closing Date, the Seller shall cause the Company to be operated in the Ordinary Course of Business and to use commercially reasonable efforts to preserve intact the present business organization and personnel of the Company, preserve the business relationships of the Company with other Persons material to the operation of the Company, and not permit any action or omission which would cause any of the representations or warranties of the Company contained herein to become inaccurate or any of the covenants of the Company to be breached. Without limiting the generality of the foregoing, prior to the Closing and without the prior written consent of the Buyer, the Seller shall cause the Company to:

 

(a) not incur any obligation or enter into any Contract outside the Ordinary Course of Business or which (i) requires a payment by any party in excess of, or a series of payments which in the aggregate exceed, $10,000.00 and (ii) has a term of, or requires the performance of any obligations by the Company over a period in excess of one week;

 

(b) not take any action, or enter into or authorize any Contract or transaction involving more than $10,000.00) in the aggregate, other than this Transaction;

 

(c) not sell, transfer, convey, assign or otherwise dispose of any of its assets or properties;

 

(d) not waive, release or cancel any claims against third parties or debts owing to it, or any other rights;

 

(e) not make any changes in its accounting systems, policies, principles or practices;

 

  18  
 

 

(f) not enter into, authorize, or permit any transaction with the Seller or any Affiliate thereof, or enter into any Contract relating to compensation or benefits with any Person, or, modify any compensation amounts or levels of any officer or employee;

 

(g) except as required for this Transaction, not change or amend its Certificate of Incorporation or Bylaws;

 

(h) not authorize for issuance, issue, sell, deliver or agree or commit to issue, sell or deliver (whether through the issuance or granting of options, warrants, convertible or exchangeable securities, commitments, subscriptions, rights to purchase or otherwise) any shares of capital stock or any other securities of the Company, or amend any of the terms of any such capital stock or other securities, except as required for this Transaction;

 

(i) not split, combine, or reclassify any shares of its capital stock, declare, set aside or pay any dividend or other distribution in property other than cash in respect of its capital stock, or redeem or otherwise acquire any capital stock or other securities of the Company;

 

(j) not make any borrowings, incur any debt, or assume, guarantee, endorse or otherwise become liable (whether directly, contingently or otherwise) for the obligations of any other Person, or make any payment or repayment in respect of any indebtedness, except to the extent provided on Schedule 3.11;

 

(k) not make any loans, advances or capital contributions to, or investments in, any other Person or the operating assets of any Person;

 

(l) not enter into, adopt, amend or terminate any bonus, profit sharing, compensation, termination, stock option, stock appreciation right, restricted stock, performance unit, pension, retirement, deferred compensation, employment, severance or other employee benefit agreements, trusts, plans, funds or other arrangements for the benefit or welfare of any Director, manager, officer or employee, or increase in any manner the compensation or fringe benefits of any Director, manager, officer or employee or pay any benefit not required by any existing plan and arrangement or enter into any Contract, agreement, commitment or arrangement to do any of the foregoing;

 

(m) not acquire, lease, encumber or otherwise impose a Lien on any assets, whether tangible or intangible;

 

(n) not authorize or make any capital expenditures;

 

(o) not make any Tax election or settle or compromise any federal, state, local or foreign income Tax Liability, or waive or extend the statute of limitations in respect of any such Taxes;

 

(p) not pay any amount, perform any obligation or agree to pay any amount or perform any obligation, in settlement or compromise of any suits or claims of Liability against the Company or any of its Directors, managers, officers, employees or agents, except to the extent provided on Schedule 3.11;

 

(q) not terminate, modify, amend or otherwise alter or change any of the terms or provisions of any agreement, or pay any amount not required by Law or by any Contract;

 

(r) other than overnight deposits or money market instruments and investments existing on the date hereof, not make any investments with cash or the proceeds of existing investments;

 

  19  
 

 

(s) not declare set aside or pay any dividend or make any distribution with respect to the Shares; and

 

(t) not grant, award or pay any bonuses to any employees, independent contractors or other representatives.

 

SECTION 5.4. Full Access. The Seller will permit and cause the Company to permit, representatives of the Buyer (including, but not limited to, accountants, appraisers, attorneys, engineers, etc.) hired by the Buyer to assist in performing a due diligence investigation of the Company and the assets or Business of the Company relative to this Transaction (collectively, “Buyer’s Representatives”) to have full access to all premises, properties, personnel, books, records (including Tax records), Contracts, and documents of or pertaining to the Company and shall make the officers and employees of the Company available to the Buyer’s Representatives as the Buyer’s Representatives shall from time to time reasonably request, in each case to the extent that such access and disclosure would not obligate the Company to take any actions that would disrupt the normal course of its business or violate the terms of any agreement to which the Company is bound or any applicable Law or regulation. The Seller will deliver to the Buyer or the Buyer’s Representatives correct and complete copies of the Certificate of Incorporation, Bylaws, and minutes and actions of the Company’s Board of Directors, Shareholders, and all committees of each thereof, and will also cause the Transfer Agent to deliver a recent complete and accurate list of all of the Company’s stockholders reasonably acceptable to the Buyer. The Buyer’s Representatives will not use any of the Confidential Information received from the Company except in connection with this Agreement, and, if this Agreement is terminated for any reason whatsoever, the Buyer’s Representatives will return to the Company all tangible embodiments (and all summaries and copies, including electronically stored information) of the Confidential Information that they receive from the Company which are in its possession and will only use such Confidential Information in the defense of any litigation related to this Agreement; provided, however , that the Buyer’s Representatives shall not be responsible for the confidentiality of any information (i) which, at the time of disclosure, is available publicly, through no fault of the Buyer (ii) which, after disclosure, becomes available publicly through no fault of the Buyer’s Representatives, or (iii) which the Buyer’s Representatives knew or to which the Buyer’s Representatives had access prior to disclosure.

 

SECTION 5.5. Exclusivity. Until Closing, the Seller will not (and the Seller will not cause or permit the Company to: (i) solicit, initiate, or encourage the submission of any proposal or offer from any Person relating to the acquisition of any capital stock or other voting securities, or any substantial portion of the assets, of the Company (including any acquisition structured as a merger, consolidation, or share exchange) or (ii) participate in any discussions or negotiations regarding, furnish any information with respect to, assist or participate in, or facilitate in any other manner any effort or attempt by any Person to do or seek any of the foregoing. The Seller will not any such acquisition structured as a merger, consolidation, or share exchange. The Seller will notify the Buyer immediately if any Person makes any proposal, offer, inquiry, or contact with respect to any of the foregoing.

 

SECTION 5.6. Efforts.

 

(a) Subject to the terms and conditions hereof, each party hereto shall use all reasonable efforts to consummate this Transaction as promptly as practicable. An undertaking of a Person under this Agreement to use such Person’s commercially reasonable efforts shall not require such Person to incur unreasonable expenses or obligations in order to satisfy such undertaking.

 

(b) The Seller and the Buyer will, and the Seller shall cause the Company, to, as promptly as practicable (i) make the required filings with, and use their respective best efforts to obtain all required authorizations, approvals, consents and other actions of, governmental Authorities and (ii) use their respective commercially reasonable efforts to obtain all other required consents of other Persons, with respect to this Transaction.

 

  20  
 

 

(c) The Buyer will use commercially reasonable efforts to obtain the financing necessary to consummate this Transaction.

 

SECTION 5.7. Maintenance of Insurance. Not Applicable

 

SECTION 5.8. Notice and Supplemental Information. The Seller and the Buyer shall each give prompt notice to the other parties of any material adverse development causing a breach of any of their respective representations and warranties in Articles III and IV respectively, and of their respective covenants contained in this Article V. In addition, the Seller will, from time to time, as necessary, within a reasonable period of time preceding the Closing, by notice in accordance with the terms of this Agreement, supplement or amend the Schedules, including one or more supplements or amendments to correct any matter which would constitute a breach of any representation, warranty, agreement or covenant contained herein. If the Seller supplements or amends the Schedules with facts or circumstances that would reasonably be expected to have a Material Adverse Effect on the Company, the sole remedy of the Buyer under this Section 5.8 shall be termination of the Agreement as provided for in Section 10.1(e).

 

SECTION 5.9. Press Releases and Public Announcements. No party shall issue any press release or make any public announcement relating to the subject matter of this Agreement without the prior written approval of the Buyer and the Seller, such approval not to be unreasonably withheld or delayed; provided, however , that any party may make any public disclosure it believes in good faith is required by applicable Law or any listing or trading agreement concerning its publicly-traded securities (in which case the disclosing party will use its best efforts to advise the other parties prior to making the disclosure).

 

SECTION 5.10. Consistent Tax Reporting. The Seller and the Buyer shall treat and report this Transaction in all respects consistently for purposes of any federal, state, local or foreign Tax. The parties hereto shall not take any actions or positions inconsistent with the obligations set forth herein.

 

SECTION 5.11. Resignation of Officers and Directors. The Seller shall cause each officer of the Company to tender his or her resignation from such position, and shall appoint Buyer’s nominee(s) as officers effective as of the Closing. The Seller shall cause each director of the Company to tender his or her resignation from such position effective as of the Closing. Seller shall cause the appointment of the Buyer’s nominee (s) as Director of the Company effective as of the Closing. Current Director’s will resign concurrently with the H&H Vend Out.

 

SECTION 5.12. Transition. The Seller will not take any action, and the Seller will cause the Company not to take any action, that is designed or intended to have the effect of discouraging any lessor, licensor, customer, supplier, or other business associate of the Company from maintaining the same business relationships with the Company after the Closing as it maintained with the Company prior to the Closing.

 

SECTION 5.13. Post-Closing Covenants. The Seller and the Buyer agree as follows with respect to the period following the Closing:

 

(a) In case at any time after the Closing any further action is necessary or desirable to carry out the purposes of this Agreement, each of the parties will take such further action (including the execution and delivery of such further instruments and documents) as any other party hereto reasonably may request, all at the sole cost and expense of the requesting party (unless the requesting party is entitled to indemnification therefor under Article VIII). From and after the Closing the Buyer will be entitled to access all documents, books, records, agreements, and financial data of any sort relating to the Company that was not received by the Buyer at the Closing.

 

  21  
 

 

(b) In the event and for so long as any party hereto actively is contesting or defending against any charge, complaint, action, suit, proceeding, hearing, investigation, claim, or demand in connection with (i) this Transaction or (ii) any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing Date involving the Company, each of the other parties hereto will cooperate with him or it and his or its counsel in the contest or defense, make available their personnel, and provide such testimony and access to their books and records as shall be necessary in connection with the contest or defense, all at the sole cost and expense of the contesting or defending party (unless the contesting or defending party is entitled to indemnification therefor under Article VIII).

 

ARTICLE VI
CONDITIONS TO OBLIGATION OF THE BUYER

 

The obligation of the Buyer to consummate this Transaction is subject to satisfaction of the following conditions:

 

 

SECTION 6.1. Representations and Warranties True as of Closing Date. The representations and warranties set forth in Article III shall have been accurate, true and correct on and as of the date of this Agreement, and shall also be accurate, true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date.

 

SECTION 6.2. Compliance with Covenants. The Seller shall have performed and complied with all of the covenants hereunder in all material respects through the Closing.

 

SECTION 6.3. Actions or Proceedings. No action, suit, or proceeding shall be pending before any court or quasi-judicial or administrative agency of any federal, state, local, or foreign jurisdiction wherein an unfavorable injunction, judgment, order, decree, ruling, or charge would (a) prevent consummation of this Transaction or (b) cause this Transaction to be rescinded following consummation (and no such injunction, judgment, order, decree, ruling, or charge shall be in effect).

 

SECTION 6.4. Certificate. The Seller shall have delivered to the Buyer a certificate to the effect that each of the conditions specified above in Sections 6.1, 6.2, 6.3 and 6.6 has been satisfied in all respects.

 

SECTION 6.5. Closing of Other Transactions. Simultaneously with the Closing, (a) the Buyer shall cause the China Acquisition and (b) the H&H Vend-Out.

 

SECTION 6.6. Name Change. The Company shall have taken all requisite corporate action, including without limitation, approval by the Company’s board of directors and requisite shareholders, to change the name of the Company to be determined (the “Name Change”) and the Company shall have prepared the requisite amendment to the Company’s Articles of Incorporation to effectuate the Name Change (the “Amendment”) and shall have delivered the Amendment, fully executed and ready for filing in Nevada, to Buyer so that Buyer can file the Amendment immediately after Closing. It is understood that name change may require the filing of a proxy, and that in addition, a corporate action usually takes approximately 30 days to process and receive FINRA authorization.

 

SECTION 6.7. Consent and Releases. The Seller shall have delivered to Buyer copies of the fully executed releases between the Company and each of officer, director, H&H Glass,

 

  22  
 

 

SECTION 6.8. Documents. All actions to be taken by the Seller in connection with the consummation of this Transaction and all certificates, instruments, and other documents required to effect this Transaction will be reasonably satisfactory in form and substance to the Buyer.

 

ARTICLE VII
CONDITIONS TO OBLIGATION OF THE SELLER

 

The obligation of the Seller to consummate this Transaction is subject to satisfaction of the following conditions:

 

SECTION 7.1. Representations and Warranties True as of Closing. The representations and warranties set forth in Article IV shall have been accurate, true and correct on and as of the date of this Agreement, and shall also be accurate, true and correct on and as of the Closing Date with the same force and effect as though made on and as of the Closing Date.

 

SECTION 7.2. Compliance with Covenants. The Buyer shall have performed and complied with all of its covenants hereunder in all material respects through the Closing.

 

SECTION 7.3. Actions or Proceedings. No action, suit, or proceeding shall be pending before any court or quasi judicial or administrative agency of any federal, state, local, or foreign jurisdiction wherein an unfavorable injunction, judgment, order, decree, ruling, or charge would (A) prevent consummation of this Transaction or (B) cause this Transaction to be rescinded following consummation (and no such injunction, judgment, order, decree, ruling, or charge shall be in effect).

 

SECTION 7.4. Certificate. The Buyer shall have delivered to the Seller a certificate to the effect that each of the conditions specified above in Sections 7.1 - 7.3 is satisfied in all respects.

 

SECTION 7.5. Documents. All actions to be taken by the Buyer in connection with the consummation of this Transaction and all certificates, instruments, and other documents required to effect this Transaction will be reasonably satisfactory in form and substance to the Seller.

 

ARTICLE VIII
SURVIVAL AND REMEDY; INDEMNIFICATION

 

SECTION 8.1. Survival of Representations and Warranties. All of the terms and conditions of this Agreement, together with the warranties, representations, agreements and covenants contained herein or in any instrument or document delivered or to be delivered pursuant to this Agreement, shall survive the execution of this Agreement and the Closing Date, notwithstanding any investigation heretofore or hereafter made by or on behalf of any party hereto; provided, however , that unless otherwise stated, the agreements and covenants set forth in this Agreement shall survive and continue until June 30, 2019 (the “Indemnification Period”) and any claim for indemnification under this Article VIII must be made before the end of the indemnification period.

 

SECTION 8.2. Indemnification by the Seller.

 

(a) In the event that, during the Indemnification Period there is (i) a material breach (or an alleged breach) of any of the representations or warranties made by, or any material breach of or material failure to perform any covenant, agreement or obligation of, the Seller in this Agreement or any other material document contemplated hereby, or in any material document relating hereto or thereto or contained in any exhibit or Schedule to this Agreement, (ii) any Liabilities, Adverse Consequences or remediation, clean-up or similar obligations or costs under Environmental Laws and relating to the Business and activities or the ownership, operation or lease by the Company of facilities in respect of any periods prior to the Closing, or (iii) any demands, assessments, judgments, costs and reasonable legal and other expenses or other Adverse Consequences arising from, or in connection with, any investigation, action, suit, proceeding or other claim incident to the Liability or any of the foregoing and, if there is an applicable survival period pursuant to Section 8.1, then, in each case, provided that the Buyer made a written claim for indemnification and provided that Buyer incurs an aggregate of Two Hundred Dollars ($200.00) in out-of-pocket expenses and costs in connection with any of the foregoing (the “Threshold Amount”), then thereafter the Seller agrees (subject to the limitations set forth in this Section 8.2) to indemnify the Buyer and its Affiliates, including without limitation, the Company, and the Company’s directors, officers and employees (collectively, the “Buyer Indemnified Parties”) from and against the entirety of any material Adverse Consequences the Buyer Indemnified Parties may suffer through and after the date of the claim for indemnification resulting from, arising out of, relating to, in the nature of, or caused by any material breach (or alleged breach) of the foregoing.

 

  23  
 

 

(b) Subject to the provisions of Section 8.2(a), the Seller agrees to indemnify the Buyer Indemnified Parties from and against any loss, liability or damage Buyer Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by any Liability of the Company for any Taxes of the Company.

 

(c) Subject to the provisions of Section 8.2(a), the Seller agrees to indemnify the Buyer Indemnified Parties from and against any Adverse Consequences Buyer Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by any unknown, undisclosed, or contingent debts or obligations (including, but not limited to, environmental, legal and employee benefit Liability exposures) of the Company to the extent such debts or obligations relate to any time periods prior to the Closing Date or after the Closing Date.

 

SECTION 8.3. Indemnification by the Buyer. Provided that the Seller makes a written claim for indemnification against the Buyer within the survival period set forth in Section 8.1 and that the amount sought by the Seller, together with amounts previously sought by Seller pursuant to this Section 8.3, is in excess of the Threshold Amount, the Buyer agrees to indemnify the Seller against, and agrees to hold him harmless from, any and all Adverse Consequences up to the Limit Amount the Seller may suffer through and after the date of the claim for indemnification (including any Adverse Consequences the Seller may suffer through and after the end of the applicable survival period) resulting from, arising out of, relating to, in the nature of, or caused by (i) any breach of or any inaccuracy in any representation or warranty made by the Buyer pursuant to this Agreement, any agreement, or instrument contemplated hereby, any document relating hereto or thereto or contained in any exhibit or Schedule to this Agreement; (ii) any breach of or failure by the Buyer to perform any agreement, covenant or obligation of the Buyer set out in this Agreement, any agreement, or instrument contemplated hereby, any document relating hereto or thereto or contained in any exhibit or Schedule to this Agreement; and (iii) any obligations and Liabilities in respect of the Company from and after the Closing Date, other than any such obligations or Liabilities that are related to any breach of a representation or warranty or covenant or agreement of Seller.

 

  24  
 

 

SECTION 8.4. Third-Party Claims.

 

(a) If any third party shall notify any party (the “Indemnified Party”) with respect to any matter (a “Third Party Claim”) which may give rise to a claim for indemnification against any other party (the “Indemnifying Party”) under this Article VIII, then the Indemnified Party shall promptly notify each Indemnifying Party thereof in writing; provided, however , that no delay on the part of the Indemnified Party in notifying any Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then solely to the extent) the Indemnifying Party thereby is prejudiced.

 

(b) Any Indemnifying Party will have the right to defend the Indemnified Party against the Third Party Claim with counsel of its choice reasonably satisfactory to the Indemnified Party so long as (A) the Indemnifying Party notifies the Indemnified Party in writing within forty-five (45) days after the Indemnified Party has given notice of the Third Party Claim that the Indemnifying Party will indemnify the Indemnified Parry from and against the entirety of any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third Party Claim, (B) the Indemnifying Party provides the Indemnified Party with evidence reasonably acceptable to the Indemnified Party that the Indemnifying Party will have the financial resources to defend against the Third Party Claim and fulfill its indemnification obligations hereunder, (C) the Third Party Claim involves only money damages and does not seek an injunction or other equitable relief, (D) settlement of, or an adverse judgment with respect to, the Third Party Claim is not, in the good faith judgment of the Indemnified Party, likely to establish a precedential custom or practice materially adverse to the continuing business interests of the Indemnified Party, and (E) the Indemnifying Party conducts the defense of the Third Party Claim actively and diligently.

 

(c) So long as the Indemnifying Party is conducting the defense of the Third Party Claim in accordance with Section 8.4(b) above, (A) the Indemnified Party may retain separate co-counsel at its sole cost and expense and participate in the defense of the Third Party Claim, (B) the Indemnified Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior written consent of the Indemnifying Party (not to be withheld unreasonably), and (C) the Indemnifying Party will not consent to the entry of any judgment or enter into any settlement with respect to the Third Party Claim without the prior written consent of the Indemnified Party (not to be withheld unreasonably).

 

(d) In the event any of the conditions in Section 8.4(b) above is or becomes unsatisfied in the reasonable judgment of the Indemnified Party, however, (A) the Indemnified Party may defend against, and consent to the entry of any judgment or enter into any settlement with respect to, the Third Party Claim in any manner it reasonably may deem appropriate (and the Indemnified Party need not consult with, or obtain any consent from, any Indemnifying Party in connection therewith), (B) the Indemnifying Party will reimburse the Indemnified Party promptly and periodically for the reasonable costs of defending against the Third Party Claim (including attorneys’ fees and expenses), and (C) the Indemnifying Party will remain responsible for any Adverse Consequences the Indemnified Party may suffer resulting from, arising out of, relating to, in the nature of, or caused by the Third Party Claim to the fullest extent provided in this Article IX.

 

SECTION 8.5. Intentionally Left Blank

 

  25  
 

 

ARTICLE IX
TAX MATTERS

 

SECTION 9.1. Tax Matters. The following provisions shall govern the allocation of responsibility as between the Buyer and the Seller for certain tax matters following the Closing Date:

 

SECTION 9.2. Tax Periods Ending on or Before the Closing Date. The Seller shall prepare or cause to be prepared and file or cause to be filed all Tax Returns for the Company for all periods ending on or prior to the Closing Date (December 31, 2015 federal returns).

 

SECTION 9.3. Tax Periods Beginning Before and Ending after the Closing Date. The Buyer shall prepare or cause to be prepared and file or cause to be filed any Tax Returns of the Company for Tax periods which begin before the Closing Date and end after the Closing Date. The Buyer shall permit the Seller to review and comment on each such Tax Return described in the preceding sentence prior to filing. The Buyer and the Seller shall attempt in good faith to resolve any disagreements regarding such Tax Returns; provided, however , that the final decision regarding any such Tax Return shall rest with the Buyer. For purposes of this Section, in the case of any Taxes that are imposed on a periodic basis and are payable for a Tax period that includes (but does not end on) the Closing Date, the portion of such Tax which relates to the portion of such Tax period ending on the Closing Date shall (x) in the case of any Taxes other than Taxes based upon or related to income or receipts, be deemed to be the amount of such Tax for the entire Tax period multiplied by a fraction the numerator of which is the number of days in the Tax period ending on the Closing Date and the denominator of which is the number of days in the entire Tax period, and (y) in the case of any Tax based upon or related to income or receipts be deemed equal to the amount which would be payable if the relevant Tax period ended on the Closing Date. Any credits relating to a Tax period that begins before and ends after the Closing Date shall be taken into account as though the relevant Tax period ended on the Closing Date. All determinations necessary to give effect to the foregoing allocations shall be made in a manner consistent with prior practice of the Company. The intent of this paragraph is that taxes related to H&H when vended out be paid by H&H.

 

SECTION 9.4. Cooperation on Tax Matters.

 

(a) The Buyer and the Seller shall cooperate fully, as and to the extent reasonably requested by the other party, in connection with the filing of Tax Returns pursuant to this Article IX and any audit, litigation or other proceeding with respect to Taxes. Such cooperation shall include the retention and (upon the other party’s request) the provision of records and information which are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. The Seller agrees (A) to retain all books and records with respect to Tax matters pertinent to the Company, as the case may be, relating to any taxable period beginning before the Closing Date until the expiration of the statute of limitations (and, to the extent notified by the Buyer or the Seller, any extensions thereof) of the respective taxable periods, and to abide by all record retention agreements entered into with any taxing Authority, and (B) to give the other party reasonable written notice prior to transferring, destroying or discarding any such books and records and, if the other party so requests, the Buyer or the Seller, as the case may be, shall allow the other party to take possession of such books and records.

 

(b) The Buyer and the Seller further agree, upon request, to use their reasonable efforts to obtain any certificate or other document from any governmental Authority or any other Person as may be necessary to mitigate, reduce or eliminate any Tax that could be imposed (including, but not limited to, with respect to this Transaction); provided, however , that no party shall be required to take any action which would reasonably be expected to have an adverse effect on such party.

 

  26  
 

 

(c) The Buyer and the Seller further agree, upon request, to provide the other party with all information that either party may be required to report pursuant to Section 6043 of the Code and all Treasury Department Regulations promulgated thereunder.

 

SECTION 9.5. Certain Taxes. All transfer, documentary, sales, use, stamp, registration and other such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement, shall be paid by the Seller when due; and the Seller will, at its own expense, file all necessary Tax Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp, registration and other Taxes and fees, and, if required by applicable Law, the Buyer will, and will cause its affiliates to, join in the execution of any such Tax Returns and other documentation.

 

ARTICLE X
TERMINATION

 

SECTION 10.1. Termination of Agreement. Certain of the parties may terminate this Agreement as provided below:

 

(a) the Buyer and the Seller may terminate this Agreement by mutual written consent at any time prior to the Closing;

 

(b) the Buyer may terminate this Agreement by giving written notice to the Seller on or before the fifth (5th) day following the date of this Agreement, but prior to the Closing, if the Buyer is not satisfied with the results of its continuing business, legal, environmental, and accounting due diligence regarding the Company;

 

(c) the Buyer may terminate this Agreement by giving written notice to the Seller at any time prior to the Closing (A) in the event the Seller has breached any material representation, warranty, or covenant contained in this Agreement in any material respect, the Buyer has notified the Seller of the breach, and the breach has continued without cure for a period of ten (10) days after the notice of breach, or (B) if the Closing shall not have occurred on or before July 31, 2016 by reason of the failure of any condition precedent under Article VI hereof (unless the failure results primarily from the Buyer itself breaching any representation, warranty, or covenant contained in this Agreement);

 

(d) the Seller may terminate this Agreement by giving written notice to the Buyer at any time prior to the Closing (A) in the event that the Buyer has breached any material representation, warranty, or covenant contained in this Agreement in any material respect, the Seller have notified the Buyer of the breach, and the breach has continued without cure for a period of ten (10) days after the notice of breach or (B) if the Closing shall not have occurred on or before July 31, 2016, by reason of the failure of any condition precedent under Article VII hereof (unless the failure results primarily from the Seller breaching any representation, warranty, or covenant contained in this Agreement;

 

(e) the Buyer may terminate this Agreement by giving written notice to the Seller at any time prior to the Closing in the event: (x) the Seller supplements or amends the Schedules with facts or circumstances that would reasonably be expected to have a Material Adverse Effect on the Company, or (y) the Company does anything outside of the Ordinary Course of Business to affect the working capital of the Company between the date hereof and the Closing Date; and

 

SECTION 10.2. Effect of Termination. If the Seller terminates this Agreement, the Seller shall return the Deposit to the Buyer. If Buyer terminates the Agreement the $100,000 deposit paid to the Seller pursuant to the LOI and the Amended LOI dated February 16, 2016 is non-refundable, without any Liability of any party to any other party (except for any Liability of any party then in breach). If there has been no terminations pursuant to this section, the $100,000 deposit will also become non-refundable on July 1, 2016 concurrent with the closing date of this agreement.

 

  27  
 

 

ARTICLE XI
MISCELLANEOUS

 

SECTION 11.1. Expenses. The Buyer shall bear his costs and expenses and the Seller shall bear his and the Company’s costs and expenses (including, but not limited to, legal fees and expenses) incurred in connection with this Agreement and this Transaction.

 

SECTION 11.2. No Third-Party Beneficiaries. Subject to the provisions of Section 11.5, this Agreement shall not confer any rights or remedies upon any Person other than the parties and their respective successors and permitted assigns.

 

SECTION 11.3. Entire Agreement. This Agreement (including the documents referred to herein) constitutes the entire agreement among the parties and supersedes any prior understandings, agreements, or representations by or among the parties, written or oral, to the extent they related in any way to the subject matter hereof.

 

SECTION 11.4. Succession and Assignment. This Agreement shall be binding upon and inure to the benefit of the parties named herein and their respective successors and permitted assigns. No party may assign either this Agreement or any of his or its rights, interests, or obligations hereunder without the prior written approval of the Buyer and the Seller; provided, however , that the Buyer may, upon prior written notice (i) assign any or all of its rights and interests hereunder to one or more of its Affiliates, (ii) designate one or more of his Affiliates to perform his obligations hereunder (in any or all of which cases the Buyer nonetheless shall remain responsible for the performance of all of his obligations hereunder) and (iii) grant a security interest in respect of its rights hereunder to his lenders.

 

SECTION 11.5 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument.

 

SECTION 11.6. Headings. The section headings contained in this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement.

 

SECTION 11.7. Notices. All notices, requests, demands, claims, and other communications hereunder will be in writing and a copy shall be sent by email. Any notice, request, demand, claim, or other communication hereunder shall be deemed duly given if (and then two (2) business days after) it is sent by registered or certified mail, return receipt requested, postage prepaid, and addressed to the intended recipient as set forth below:

 

(a) If to the Seller, addressed as follows:

 

 

  28  
 

 

(b) If to the Buyer, addressed as follows:

 

Any party may send any notice, request, demand, claim, or other communication hereunder to the intended recipient at the address set forth above using any other means (including personal delivery, expedited courier, messenger service, telecopy, ordinary mail, or electronic mail), but no such notice, request, demand, claim, or other communication shall be deemed to have been duly given unless and until it actually is received by the intended recipient. Any party may change the address to which notices, requests, demands, claims, and other communications hereunder are to be delivered by giving the other parties notice in the manner herein set forth.

 

SECTION 11.8. Governing Law. This Agreement shall be governed by and construed in accordance with the domestic Laws of the State of Nevada as if this Agreement were fully performed and all obligations recited herein were undertaken solely within the State of Nevada without giving effect to any choice or conflict of Law provision or rule (whether of the State of Nevada or any other jurisdiction) that would cause the application of the Laws of any jurisdiction other than the State of Nevada. Any dispute or claims made under this Agreement or any attempt to enforce the terms of this Agreement shall be resolved in Orange County California, pursuant to Section 11.9 of this Agreement.

 

SECTION 11.9. Arbitration. Any dispute or claim arising to or in any way related to this Agreement shall be settled by arbitration in Orange County, California . All arbitration shall be conducted in accordance with the rules and regulations of the American Arbitration Association ("AAA"). AAA shall designate an arbitrator from an approved list of arbitrators following both parties' review and deletion of those arbitrators on the approved list having a conflict of interest with either party. Each party shall pay its own expenses associated with such arbitration. A demand for arbitration shall be made within a reasonable time after the claim, dispute or other matter has arisen and in no event shall such demand be made after the date when institution of legal or equitable proceedings based on such claim, dispute or other matter in question would be barred by the applicable statutes of limitations. The decision of the arbitrators shall be rendered within 60 days of submission of any claim or dispute, shall be in writing and mailed to all the parties included in the arbitration. The decision of the arbitrator shall be binding upon the parties and judgment in accordance with that decision may be entered in any court having jurisdiction thereof.

 

SECTION 11.10. Amendments and Waivers. No amendment of any provision of this Agreement shall be valid unless the same shall be in writing and signed by the Buyer and the Seller. No waiver by any party of any default, misrepresentation, or breach of warranty or covenant hereunder, whether intentional or not, shall be deemed to extend to any prior or subsequent default, misrepresentation, or breach of warranty or covenant hereunder or affect in any way any rights arising by virtue of any prior or subsequent such occurrence.

 

SECTION 11.11. Severability. Any term or provision of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability of the remaining terms and provisions hereof or the validity or enforceability of the offending term or provision in any other situation or in any other jurisdiction.

 

SECTION 11.12. Construction. The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state, local, or foreign statute or Law shall be deemed also to refer to all rules and regulations promulgated thereunder, unless the context requires otherwise. The word “including” shall mean including without limitation.

 

  29  
 

 

SECTION 11.13. Incorporation of Exhibits, Annexes, and Schedules. The Exhibits and Schedules identified in this Agreement are incorporated herein by reference and made a part hereof.

 

SECTION 11.14. Language. If there is a conflict between English and Chinese language in the agreement the English version shall be the binding language.

 

SECTION 11.15 Boxes in Storage. Upon Closing, IPLO will deliver the twelve boxes of Company records in storage as directed by the Buyers. The cost of such delivery will be paid by the Buyers.

 

 

 

 

  30  
 

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

 

 

“Buyer”

 

Xiuhua Song

 

 

By: ___/s/ Xiuhua Song_____________

Name: Xiuhua Song

 

 

 

TBD China Company

 

 

By: ___/s/ Xiuhua Song ___________________

Name: Xiuhau Song - Owner

 

 

 

“Seller”

 

International Packaging and Logistics Group, Inc.

 

 

By: ____/s/ Owen Naccarato__________

Name: Owen Naccarato

Its: Director, President, CFO and Secretary

 

 

 

Standard Resources Ltd.

 

 

By: ___/s/ Allen Lin__________________

Name: Allen Lin - Owner

 

 

 

[SIGNATURE PAGE TO STOCK PURCHASE AGREEMENT]

 

 

 

 

 

  31  

EXHIBIT 10.2

 

STOCK PURCHASE AGREEMENT

 

This is an Agreement, entered into on July 1, 2016 (the “Effective Date”), by and between Standard Resources Ltd. a Hong Kong company, Allen Lin , and H&H Glass, Inc., an Illinois corporation, collectively the (“Buyer”), International Packaging and Logistics Group Inc. (“IPL” or “Seller”), a corporation organized under the laws of Nevada with principle executive offices located at 7700 Irvine Center Dr., Suite 870, Irvine, California 92618 (the “Seller”), Allen Lin founder and CEO of H&H Glass, Inc. (“Lin”) and H&H Glass, Inc. (“H&H”).

 

Background

 

A. The Buyer owns 3,915,000 shares of the (87%) of IPL’s Common Stock.

 

B. Buyer desires to purchase 100% of the equity of H&H held by the Seller.

 

C. Seller has agreed to sell to Buyer, and Buyer has agreed to purchase from Seller, such 100% interest in H&H.

 

NOW, THEREFORE , intending to be legally bound, the parties agree as follows:

 

1.0 Acquires of 100% Interest .

 

Acquired Shares of Stock . Upon the terms and conditions of this Agreement, Seller hereby sells, transfers, assigns, conveys and delivers to Buyers, and Buyer hereby purchases, accepts and acquires from Seller, free and clear of any and all liens or encumbrances of any kind whatsoever, one hundred percent (100%) of the H&H Shares (the “Acquired Shares”):

 

2.0 Purchase Price and Payment .

 

    Common Shares. The purchase price for the Acquired shares shall be paid 3,915,000 common shares of IPL (the “ Common Shares ”) as of the Effective Date. Such Common Shares shall be returned to IPL’s treasury.

 

3.0 Closing .

 

Time and Place of Closing . The closing of the transactions described in this Agreement (“Closing”) shall take place upon the issuance of the audited financial statements of Shandong Confucian Biologics Co. Ltd by a PCAOB auditor or at such other time as the parties may mutually agree (the “Closing Date”).

 

4.0 Seller’s Representations and Warranties . Seller hereby makes the following representations and warranties to Buyer, each of which shall survive the Closing:

 

4.1 Corporate Organization . Seller is duly organized, validly existing, and in good standing under the laws of the State of Nevada and has qualified to do business in each jurisdiction where such qualification is required. Seller has all requisite corporate power and authority and all necessary licenses and permits to conduct its business as now conducted and to own, lease, and operate the assets and properties now owned, leased, or operated by it.

 

4.2 Compliance with Laws . Seller has complied with all applicable laws in the operation of its business and has not received any notice of violation of any law, ordinance, rule, regulation, or order which has a material adverse effect on or, so far as any of them can now reasonably foresee, could reasonably be expected to in the future to have a material adverse effect on the Acquired Assets.

 

5.0 Buyer’s Representations and Warranties . Buyer hereby makes the following representations and warranties to Seller, each of which shall survive the Closing:

 

5.1 Enforceable Agreement - this Agreement has been duly executed and delivered by the Buyer and constitutes a legal, valid and binding obligation of the Buyer, enforceable by the Seller against the Buyer in accordance with its terms, subject to the availability of equitable remedies and the enforcement of creditors' rights generally;

 

5.2 Bankruptcy and Insolvency Matters – No action or proceeding has been commenced or filed by or against the Buyer which seeks or may lead to bankruptcy or any other similar proceeding in respect of the Buyer. No such action or proceeding has been authorized or is being considered by or on behalf of the Buyer and no creditor or equity security holder of the Buyer has, to the knowledge of the Buyer, threatened to commence or advise that it may commence, any such action or proceeding;

 

 

  1  
 

 

5.3 Broker's Fees – The Buyer has not incurred any obligation or liability, contingent or otherwise for broker's or finder's fees in respect of the transaction herein provided for which the Vendor shall have any obligation and liability;

 

5.4 Consents – no approval, consent, order, authorization or other action by, or notice to or filing with, any governmental authority or regulatory or self-regulatory agency, or any other person or entity, and no lapse of a waiting period, is required in connection with the execution, delivery or performance by the Buyer of this Agreement; and

 

5.5 Litigation - there is no action, suit, proceeding or investigation pending or currently threatened against the Buyer its affiliates that questions the validity of this Agreement or the right of the Buyer to enter into this Agreement or to consummate, or cause to be consummated, the transactions contemplated hereby.

 

6.0 Indemnifications .

 

6.1 Indemnification By Buyer, H&H and Allen Lin . Buyer, H&H, and Allen Lin (collectively “Indemnifiers”) shall jointly and severally defend, hold harmless, and indemnify Seller and its employees, officers, and managers, and members against all liabilities, damages, losses, claims, judgments and expenses (including reasonable attorneys’ fees and related costs) arising from (i) the conduct of H&H business which is includes but not limited to any past, present or future liabilities of H&H; or (ii) a material breach by Buyer of any of the covenants, agreements, warranties or representations contained in this Agreement.

 

6.2 Additional Indemnification of Indemnifiers. Additionally Indemnifiers shall indemnify and hold Seller and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Seller (within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling person (each, a “ Seller Party ”) harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Seller Party may suffer or incur as a result of or relating to (a) any material breach of any of the representations, warranties, covenants or agreements made by the Buyer and H&H in this Agreement or (b) any action instituted against a Seller Party in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company or H&H who is not an Affiliate of such Seller Party related go this agreement. If any action shall be brought against any Seller Party in respect of which indemnity may be sought pursuant to this Agreement, such Seller Party shall promptly notify the Indemnifiers in writing, and the Indemnifiers shall have the right to assume the defense thereof with counsel of its own choosing reasonably acceptable to the Seller Party. Any Seller Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of such Seller Party except to the extent that (i) the employment thereof has been specifically authorized by the Indemnifiers in writing, (ii) the Indemnifiers has failed after a reasonable period of time to assume such defense and to employ counsel or (iii) in such action there is, in the reasonable opinion of such separate counsel, a material conflict on any material issue between the position of the Company and the position of such Seller Party, in which case the Indemnifiers shall be responsible for the reasonable fees and expenses of no more than one such separate counsel.

 

7.0Miscellaneous .

 

7.1 Amendments; Waivers . No amendment, modification, or waiver of any provision of this Agreement shall be binding unless in writing and signed by the party against whom the operation of such amendment, modification, or waiver is sought to be enforced. No delay in the exercise of any right shall be deemed a waiver thereof, nor shall the waiver of a right or remedy in a particular instance constitute a waiver of such right or remedy generally.

 

7.2 Notices . Any notice or document required or permitted to be given under this Agreement shall be deemed to be given on the date such notice is (i) deposited in the United States mail, postage prepaid, certified mail, return receipt requested, (ii) deposited with a commercial overnight delivery service with delivery fees paid, or (iii) transmitted by electronic mail with transmission acknowledgment, to the following addresses or such other address or addresses as the parties may designate from time to time by notice satisfactory under this section:

 

7.3 Governing Law . This Agreement shall be governed by the internal laws of Nevada without giving effect to the principles of conflicts of laws. Each party hereby consents to the personal jurisdiction of the state or California, and agrees that all disputes arising from this Agreement shall be prosecuted in such courts. Each party hereby agrees that any such court shall have in personam jurisdiction over such party and consents to service of process by notice sent by regular mail to the address set forth above and/or by any means authorized by Nevada law.

 

 

  2  
 

 

7.4 Language Construction . The language of this Agreement shall be construed in accordance with its fair meaning and not for or against any party. The parties acknowledge that each party and its counsel have reviewed and had the opportunity to participate in the drafting of this Agreement and, accordingly, that the rule of construction that would resolve ambiguities in favor of non-drafting parties shall not apply to the interpretation of this Agreement.

 

7.5 No Offer . The submission of this Agreement by any party for the review and/or execution by another party does not constitute an offer or reservation of rights for the benefit of any party. This Agreement shall become effective, and the parties shall become legally bound, only if and when all parties have executed this Agreement.

 

7.6 Payment of Fees . In the event of a dispute arising under this Agreement, the prevailing party shall be entitled to recover reasonable attorneys’ fees and costs, provided that if a party prevails only in part the court shall award fees and costs in accordance with the relative success of each party.

 

7.7 Signature in Counterparts . This Agreement may be signed in counterparts, each of which shall be deemed to be a fully-executed original.

 

7.8 Signature by Email . An original signature transmitted by email shall be deemed to be original for purposes of this Agreement.

 

7.9 Assignment . Neither party to this Agreement shall assign its rights or duties hereunder without the prior written consent of the other party. Any attempted assignment without such prior written consent shall be null and void.

 

7.10 No Third Party Beneficiaries . Except as otherwise specifically provided in this Agreement, this Agreement is made for the sole benefit of the parties. No other persons shall have any rights or remedies by reason of this Agreement against any of the parties or shall be considered to be third party beneficiaries of this Agreement in any way.

 

7.11 Binding Effect . This Agreement shall inure to the benefit of the respective heirs, legal representatives and permitted assigns of each party, and shall be binding upon the heirs, legal representatives, successors and assigns of each party.

 

7.12 Titles and Captions . All article, section and paragraph titles and captions contained in this Agreement are for convenience only and are not deemed a part of the context hereof.

 

7.13 Pronouns and Plurals . All pronouns and any variations thereof are deemed to refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons may require.

 

7.14 Entire Agreement . This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements and understandings.

 

  3  
 

 

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement, as of the date first written hereinabove.

 

 

 

INTERNATIONAL PACKAGING AND LOGISTICS GROUP INC.

 

The Seller

 

/s/ Owen Naccarato

By: Owen Naccarato

Its: Chief Executive Officer

 

 

 

STANDARD RESOURCES LTD. 

THE BUYER:

 

/s/ Allen Lin

By: Allen Lin

Its: Chief Executive Officer

 

Indemnifiers

 

H&H Glass, Inc.

 

/s/ Allen Lin

By: Allen Lin

Its: Chief Executive Officer

 

 

 

 

  4